



Morbidity and Mortality Weekly Report

www.cdc.gov/mmwr

Weekly

January 2, 2009 / Vol. 57 / No. 51 & 52

Reduced Hospitalizations for Acute Myocardial Infarction After Implementation of a Smoke-Free Ordinance — City of Pueblo, Colorado, 2002–2006

Exposure to secondhand smoke (SHS) has immediate adverse cardiovascular effects, and prolonged exposure can cause coronary heart disease (1). Nine studies have reported that laws making indoor workplaces and public places smoke-free were associated with rapid, sizeable reductions in hospitalizations for acute myocardial infarction (AMI) (2–7). However, most studies examined hospitalizations for 1 year or less after laws were implemented; thus, whether the observed effect was sustained over time was unknown. The Pueblo Heart Study examined the impact of a municipal smoke-free ordinance in the city of Pueblo, Colorado, that took effect on July 1, 2003 (3). The rate of AMI hospitalizations for city residents decreased 27%, from 257 per 100,000 person-years during the 18 months before the ordinance's implementation to 187 during the 18 months after it (the Phase I postimplementation period).* This report extends that analysis for an additional 18 months through June 30, 2006 (the Phase II post-implementation period). The rate of AMI hospitalizations among city residents continued to decrease to 152 per 100,000 person-years, a decline of 19% and 41% from the Phase I postimplementation and pre-implementation period, respectively. No significant changes were observed in two comparison areas. These findings suggest that smoke-free policies can result in reductions in AMI hospitalizations that are sustained over a 3-year period and that these policies are important in preventing morbidity and mortality associated with heart disease. This effect likely is mediated through reduced SHS exposure among

nonsmokers and reduced smoking, with the former making the larger contribution (4,6,7).

Two control sites were selected for comparison with the city of Pueblo: 1) the area of Pueblo County outside the city of Pueblo limits and 2) El Paso County, including Colorado Springs, the most populous city in this county. The city of Pueblo and Colorado Springs are located approximately 45 miles apart (Figure 1). Neither of the control sites had smokefree laws in place before or during the study periods. Based on data from the Behavioral Risk Factor Surveillance System, the adult smoking prevalence for Pueblo County (including the city of Pueblo) and El Paso County during 2002–2003 was 25.9% (95% confidence interval [CI] = 20.2%–31.6%) and 17.4% (CI = 14.5%–20.2%), respectively. The corresponding prevalences for 2004–2005 were 20.6% (CI = 15.4%–25.8%) and 22.3% (CI = 19.3%–25.4%). Separate smoking prevalence estimates were not available for the city of Pueblo.

Persons with recognized AMIs that occur in the city of Pueblo and Pueblo County receive care at two hospitals, Parkview

INSIDE



Recommended Immunization Schedules for Persons Aged 0 Through 18 Years — United States, 2009

1377 Campylobacter jejuni Infection Associated with Unpasteurized Milk and Cheese — Kansas, 2007

1379 Underground Coal Mining Disasters and Fatalities — United States, 1900–2006

1383 QuickStats

^{*}Some of the AMI hospitalization admission figures, AMI hospitalization admission rates, relative rates, and relative rate confidence intervals calculated for this analysis differ from those previously published (3) because of receipt of routinely amended coding data from the Colorado Hospital Association.

The MMWR series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2008;57:[inclusive page numbers].

Centers for Disease Control and Prevention Julie L. Gerberding, MD, MPH

Director

Tanja Popovic, MD, PhD

Chief Science Officer

James W. Stephens, PhD

Associate Director for Science

Steven L. Solomon, MD

Director, Coordinating Center for Health Information and Service

Jay M. Bernhardt, PhD, MPH

Director, National Center for Health Marketing

Katherine L. Daniel, PhD

Deputy Director, National Center for Health Marketing


Editorial and Production Staff

Frederic E. Shaw, MD, JD Editor, MMWR Series Susan F. Davis, MD (Acting) Assistant Editor, MMWR Series Robert A. Gunn, MD, MPH Associate Editor, MMWR Series Teresa F. Rutledge Managing Editor, MMWR Series Douglas W. Weatherwax Lead Technical Writer-Editor Donald G. Meadows, MA Jude C. Rutledge Writers-Editors Martha F. Boyd Lead Visual Information Specialist Malbea A. LaPete Stephen R. Spriggs Visual Information Specialists Kim L. Bright, MBA Quang M. Doan, MBA Phyllis H. King Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR William Schaffner, MD, Nashville, TN Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

FIGURE 1. Pueblo smoke-free area, comparison areas, and hospitals treating acute myocardial infarction patients — Pueblo Heart Study, January 2002–June 2006



Medical Center and St. Mary-Corwin Medical Center, both located within the city of Pueblo. Persons with recognized AMIs that occur in El Paso County receive care at two other hospitals, Penrose Hospital and Memorial Hospital, both located in Colorado Springs. Data on AMI hospitalizations were drawn from electronic Colorado Hospital Association administrative data. These data included admission date, primary diagnosis code (based on International Classification of Diseases, Ninth Revision codes 410.0-410.9), sex, age, postal code of residence, and hospital name. No other patient-level data, including smoking status, were available. U.S. Census Bureau population data for 2006 were used as denominators in calculating AMI hospitalization rates. A more extensive description of the study's methodology has been published previously (3). AMI hospitalization rates among residents of the city of Pueblo, the area of Pueblo County outside the city of Pueblo limits, and El Paso County were compared across three periods: 0–18 months before the smoke-free law took effect (pre-implementation period), 0-18 months after this date (Phase I, post-implementation period), and 19–36 months after this date (Phase II, post-implementation period), for a total of 54 months. Rates were compared between periods using a chi-square test. Relative rates (RRs) were calculated as the ratios of AMI rates between two periods. Data presented in this report were not adjusted for seasonality because a seasonadjusted analysis of Phase I versus the pre-implementation period found that the adjustment did not significantly change the findings (3).

During Phase II, AMI hospitalizations among residents of the city of Pueblo continued to decrease (Figure 2). AMI hospitalization rates differed significantly across all three periods within the city of Pueblo (p<0.001). The rate of AMI hospitalization among residents in the city of Pueblo in the

Phase II post-implementation period was 152 per 100,000 person-years, compared with 187 per 100,000 person-years in the Phase I post-implementation period, for an RR of 0.81 (CI = 0.67–0.96) (Table). In contrast, no significant change was observed for residents of the area of Pueblo County outside the city of Pueblo limits (139 per 100,000 person-years versus 115 per 100,000 person-years; RR = 1.21 [CI = 0.80-1.62]) or for residents of El Paso County (149 per 100,000 person-years versus 150 per 100,000 person-years; RR = 0.99 [CI = 0.91–1.08]) during the same period. The RR for AMI hospitalizations in the city of Pueblo in the Phase II post-implementation period compared with the pre-implementation period (rate = 257 per 100,000 person-years) was 0.59 (CI = 0.49-0.70). In contrast, RRs for the area of Pueblo County outside the city of Pueblo limits and for El Paso County for the same period were 1.03 (CI = 0.68-1.39) and 0.95 (CI = 0.87-1.03), respectively; the pre-implementation period rates were 135 per 100,000 person-years and 157 per 100,000 person-years, respectively. Within each site, the distribution of AMI patients by age and sex was unchanged over time.


To further examine whether the change in AMI rates could be attributed to pre-existing secular trends, AMI rates were examined for all three sites for three 18-month periods immediately preceding the pre-implementation phase. No statistically significant secular trend occurred in any of the three sites before July 1, 2003.

To ensure that the observed change in the city of Pueblo was not attributable to undercounting fatal AMIs post-implementation, the number of AMI deaths for the city of Pueblo were obtained from the Health Statistics Section of the Colorado Department of Public Health and Environment. After accounting for AMI deaths in a conservative manner (by assuming that all fatal AMIs occurred in patients who failed to reach the hospital) and adding these numbers to the hospital AMI admission data, the RR for the city of Pueblo remained statistically significant at 0.82 (CI = 0.64–0.97) from the Phase II to Phase I post-implementation periods and at 0.66 (CI = 0.55–0.77) from Phase II post-implementation to the pre-implementation period.

Reported by: RN Alsever, MD, Parkview Medical Center; WM Thomas, PhD, St. Mary-Corwin Medical Center; C Nevin-Woods, DO, R Beauvais, S Dennison, R Bueno, Pueblo City-County Health Dept; L Chang, PhD, Colorado State Univ-Pueblo; CE Bartecchi, MD, Univ of Colorado School of Medicine. S Babb, MPH, A Trosclair, MS, M Engstrom, MS, T Pechacek, PhD, R Kaufmann, PhD, Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Editorial Note: Evidence from animal and human studies indicates that SHS exposure can produce rapid adverse effects on the functioning of the heart, blood, and vascular systems that increase the risk for a cardiac event (1). Relevant mechanisms

FIGURE 2. Rate* of hospitalizations for acute myocardial infarction before and after smoking ordinance, by area and period — city of Pueblo, Pueblo County outside city of Pueblo limits, and El Paso County, Pueblo Heart Study, January 2002–June 2006†



- * Per 100,000 person-years. Based on U.S. Census Bureau population data for 2006.
- [†] Because of receipt of routinely amended coding data from the Colorado Hospital Association, certain data points for the pre-implementation and Phase I post-implementation periods differ from those published previously (Bartecchi C, Alsever RN, Nevin-Woods C, et al. Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation 2006;114:1490–6).
- § January 2002–June 2003.
- ¶ July 2003-December 2004.
- ** January 2005–June 2006.

include effects on platelet function, endothelial function, and inflammation. Epidemiologic and laboratory data indicate that the risk for heart disease and AMI increase rapidly with relatively small doses of tobacco smoke, such as those received from SHS, and then continue to increase more slowly with larger doses (1,8,9). Evidence also suggests that the acute effects of SHS exposure might be rapidly reversible (8,9).

Eliminating smoking in indoor spaces is the only way to fully protect nonsmokers from SHS (1). Previous studies have found that SHS exposure decreases substantially among nonsmoking employees of restaurants and bars and among nonsmoking adults in the general public after implementation of smoke-free laws (1,5,7,10). Compliance with smoke-free laws typically reaches high levels rapidly and then increases further over time (1,5). In addition, smoke-free laws are associated with increased adoption of no-smoking rules in private homes (1,10). Smoke-free policies have been found to prompt some smokers to quit smoking (1); because active smoking is a major risk factor for heart disease and AMI, this effect also would be expected to reduce heart disease and AMI rates at a population level. The continued decrease in AMI hospitalizations observed in this study might be a result of a combination of 1) the immediate reduction in SHS exposure among nonsmokers

TABLE. Number and rate* of hospitalizations for acute myocardial infarction (AMI) before and after smoking ordinance, by sex and area — city of Pueblo, Pueblo County outside city of Pueblo limits, and El Paso County, Pueblo Heart Study, January 2002–June 2006[†]

	implem	re- entation iod [§]	implem	e I post- entation riod¶	implem	II post- entation od**	Relative rate (RR) for AMI (Phase I vs. pre-implementation)	Relative rate for AMI (Phase II vs. Phase I)	Relative rate for AMI (Phase II vs. pre-implementation)
Area	No.	Rate	No.	Rate	No.	Rate	RR (95% CI ^{††})	RR (95% CI)	RR (95% CI)
City of Pue	blo (inter	vention a	rea)				,		
Male	233	150	175	113	157	101	0.75 (0.61-0.90)	0.90 (0.69-1.10)	0.67 (0.52-0.82)
Female	166	107	116	75	80	51	0.70 (0.53-0.87)	0.69 (0.51-0.87)	0.48 (0.36-0.60)
Total	399	257	291	187	237	152	0.73 (0.64-0.82)	0.81 (0.67-0.96)	0.59 (0.49-0.70)
Pueblo Cou	unty outsi	de city o	f Pueblo	limits (co	mpariso	n area)			
Male	55	83	55	83	63	95	1.00 (0.58-1.42)	1.15 (0.64-1.65)	1.15 (0.59-1.70)
Female	34	51	21	32	29	44	0.62 (0.28-0.95)	1.38 (0.70-2.06)	0.85 (0.38-1.32)
Total	89	135	76	115	92	139	0.85 (0.56-1.14)	1.21 (0.80-1.62)	1.03 (0.68-1.39)
El Paso Co	unty (con	nparison	area)						
Male	872	106	849	103	815	99	0.97 (0.87-1.08)	0.96 (0.84-1.08)	0.93 (0.84-1.03)
Female	427	52	392	47	415	50	0.92 (0.78–1.05)	1.06 (0.90–1.21)	0.97 (0.84–1.10)
Total	1,299	157	1,241	150	1,230	149	0.96 (0.87–1.04)	0.99 (0.91–1.08)	0.95 (0.87–1.03)

* Per 100,000 person-years. Based on U.S. Census Bureau population data for 2006.

that occurred when the city of Pueblo smoke-free ordinance was implemented, 2) further reductions in this exposure that occurred because of increased compliance with the ordinance and increased adoption of smoke-free home rules over time, and 3) increased quitting among smokers as a result of the ordinance and associated changes in social norms.

In addition to the previous study conducted in the city of Pueblo (3), eight other published studies have reported that smoke-free laws were associated with rapid, sizeable reductions in hospitalizations for AMI (2,4-7). The current study adds to the previous evidence by documenting this effect in a relatively large population and by demonstrating that the effect was sustained over an extended period. A meta-analysis of seven of the previous eight studies and one unpublished study yielded a pooled estimate of a 19% (CI = 14%-24%) reduction in AMI hospitalization rates after implementation of smoke-free laws (2). Three studies have suggested that these reductions are more pronounced among nonsmokers than among smokers (4,6,7). For example, one study that included objective confirmation of patients' smoking status reported reductions of 21%, 19%, and 14% in the number of hospitalizations for acute coronary syndrome among never smokers, former smokers, and current smokers, respectively, in the year after implementation of a comprehensive national smoke-free law, with the decrease in hospitalizations among nonsmokers accounting for 67% of the total decrease (7).

The findings in this report are subject to at least four limitations. First, because no data were available on whether study subjects were nonsmokers or smokers, determining what portion of the observed decrease in hospitalizations was attributable to reduced SHS exposure among nonsmokers and what portion was attributable to increased quitting among smokers was not possible. The prevalence of smoking decreased in Pueblo County as a whole, but the difference over time was not statistically significant. Second, the study did not directly document reductions in SHS exposure among nonsmokers after the city of Pueblo smoke-free law took effect, although studies elsewhere have reported such reductions (1,5,7,10). Third, individual residences were assigned based on postal codes, which might have resulted in a small amount of misclassification (3); however, misclassifying residents' exposure to the city of Pueblo smoke-free ordinance would result in underestimating the effect of this ordinance. In addition, residents of the area of Pueblo County outside the city of Pueblo limits might work in workplaces or patronize restaurants or bars in the city of Pueblo, or vice versa; again, this would bias findings toward the null. Finally, the ecologic nature of this study precludes definite conclusions about the extent to which the observed decline in AMI hospitalizations in the city of Pueblo was attributable to the smoke-free ordinance. To the extent that any unmeasured factors influenced rates, the findings described in this report might overestimate or underestimate the actual

[†] Because of receipt of routinely amended coding data from the Colorado Hospital Association, certain data points for the pre-implementation and Phase I post-implementation periods differ from those published previously (Bartecchi C, Alsever RN, Nevin-Woods C, et al. Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation 2006;114:1490–6).

[§] January 2002–June 2003.

[¶] July 2003–December 2004. ** January 2005–June 2006.

^{††} Confidence interval.

effect. AMI hospitalization rates initially were substantially higher in the city of Pueblo than in the two comparison areas, suggesting that these areas might not be fully comparable to the intervention site because of demographic and other differences. However, no significant changes in the manner in which AMI patients were diagnosed, treated, or transported occurred in the three study sites during the study period. Future studies could further expand the evidence base by including information on the smoking status of AMI patients and biomarkers (e.g., cotinine and troponin) for objective measurement of SHS exposure and case ascertainment, as was done in one recent study (7).

The Phase I study findings suggested that the city of Pueblo's smoke-free ordinance led to a rapid decrease in AMI hospitalizations. The findings described in this report suggest that the initial decrease in AMI hospitalizations observed immediately after the implementation of comprehensive smoke-free laws continued over time. These findings provide support for considering smoke-free policies an important component of interventions to prevent heart disease morbidity and mortality.

Acknowledgments

This report is based, in part, on contributions by MJ Krantz, MD, B Bucher Bartelson, PhD, and RO Estacio, MD, Colorado Prevention Center, Denver, Colorado.

References

- US Department of Health and Human Services. The health consequences
 of involuntary exposure to tobacco smoke: a report of the Surgeon
 General. Atlanta, GA: US Department of Health and Human Services,
 CDC; 2006. Available at http://www.surgeongeneral.gov/library/
 secondhandsmoke/report/fullreport.pdf.
- Glantz S. Meta-analysis of the effects of smokefree laws on acute myocardial infarction: an update. Prev Med 2008;47:452–3.
- Bartecchi C, Alsever RN, Nevin-Woods C, et al. Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation 2006;114:1490–6.
- Barone-Adesi F, Vizzini L, Merletti F, Richiardi L. Short-term effects of Italian smoking regulation on rates of hospital admission for acute myocardial infarction. Eur Heart J 2006;20:2468–72.
- Juster HR, Loomis BR, Hinman TM, et al. Declines in hospital admissions for acute myocardial infarction in New York State after implementation of a comprehensive smoking ban. Am J Public Health 2007;97:2035–9.
- Seo D-C, Torabi MR. Reduced admissions for acute myocardial infarction associated with a public smoking ban: matched controlled study. J Drug Educ 2007;37:217–26.
- 7. Pell JP, Haw S, Cobbe S, et al. Smoke-free legislation and hospitalizations for acute coronary syndrome. N Engl J Med 2008;359:482–91.
- 8. Pechacek TF, Babb S. Commentary: how acute and reversible are the cardiovascular risks of secondhand smoke? BMJ 2004;328:980–3.
- 9. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke nearly as large as smoking. Circulation 2005;111:2684–98.
- Haw SJ, Gruer L. Changes in exposure of adult non-smokers to secondhand smoke after implementation of smoke-free legislation in Scotland: national cross sectional survey. BMJ 2007;335:549

 –52.

Campylobacter jejuni Infection Associated with Unpasteurized Milk and Cheese — Kansas, 2007

On October 26, 2007, a family health clinic nurse informed the Kansas Department of Health and Environment (KDHE) that Campylobacter jejuni had been isolated from two ill persons from different families who were members of a closed community in a rural Kansas county. By October 29, 17 additional members of the community had reported gastrointestinal illness and visited the clinic within a week. All 19 persons reported consuming fresh cheese* on October 20 that was made the same day at a community fair from unpasteurized milk obtained from a local dairy. This report summarizes the findings of an investigation by KDHE and the local health department to determine the source and extent of the outbreak. Eating fresh cheese at the fair was the only exposure associated with illness (relative risk [RR] = 13.9). Of 101 persons who ate the cheese, 67 (66%) became ill. C. jejuni isolates from two ill persons had indistinguishable pulsed-field gel electrophoresis (PFGE) patterns, and the isolate from a third ill person was nearly identical to the other two. Although all samples of cheese tested negative for Campylobacter, results of the epidemiologic investigation found an association between illness and consumption of fresh cheese made from unpasteurized milk. To minimize the risk for illness associated with milkborne pathogens, unpasteurized milk and milk products should not be consumed.

The outbreak occurred in an insular religious community (population approximately 150) consisting nearly exclusively of agricultural workers who practice small-scale and traditional farming techniques. On October 20, 2007, members held a community fair celebrating their pioneer heritage. During the fair, unpasteurized cheese was made at an activity station by adding rennet extract to unpasteurized milk donated by a local dairy, producing soft cheese in 5–6 hours. Butter also was made, but from pasteurized milk. Adults and children were encouraged to participate in these activities. Hand-washing stations were available at the food preparation stations. The cheese was served at a banquet that evening. Foods made at other activity stations, including buffalo stew and chili, and potluck meals brought from community member homes also were served at the banquet.

As part of the investigation, a self-administered questionnaire was distributed at a community meeting on November 4, 2007, to collect information regarding demographics, illness status

^{*} Fresh cheeses, such as cottage cheese and Neufchâtel, are made by curdling milk and draining the whey, with little additional processing, and also are referred to as soft or unripened cheeses.

and characteristics, food history, and other possible exposures. A case was defined as diarrhea (three or more loose stools in a 24-hour period) in a member of the community, with onset during October 20–30, 2007. Of the 150 community members, 130 (87%) completed the questionnaire, and 68 (52%) persons met the case definition. Among ill persons, 66 (97%) reported watery diarrhea, 18 (27%) reported bloody diarrhea, and 16 (24%) reported vomiting and diarrhea. None of the respondents had diarrhea immediately before the fair; illness onset occurred during October 21–29 (Figure). Two patients were hospitalized for dehydration. One was released the next day; the other, a pregnant woman, remained in the hospital for 5 days. No deaths were reported. Median age of ill persons was 25 years (range: 1–75 years); 41 (60%) were aged ≤15 years, and 37 (54%) were female.

In a cohort analysis, consuming the fresh cheese was significantly associated with illness (RR = 13.9). Factors not significantly associated with illness included making cheese (RR = 1.3), making (RR = 1.2) or consuming butter made from pasteurized milk (RR = 1.4), and drinking well water (RR = 2.1) (Table). Of the 101 persons who reported consuming fresh cheese made from unpasteurized milk, 67 (66%) met the case definition. One apparent case of secondary transmission occurred in a person who did not consume the fresh cheese, but became ill on October 29, 6 days after her child became ill.


Stool specimens were collected from three persons who met the case definition and sent to the KDHE laboratory. *C. jejuni* was isolated from all three specimens. Isolates from two of the samples had indistinguishable PFGE patterns (PulseNet pattern number DBRS16.1150) and the third isolate differed by only two bands (PulseNet pattern number DBRS16.0024).

On November 3, KDHE collected six slabs of leftover cheese from the freezer of the community church for laboratory testing and advised community leaders to discard all other cheese remaining from the community fair. On November 6, the Kansas Department of Agriculture inspected the dairy floor, roof, and ceiling; milk tank; equipment; and animal housing for cleanliness and rodent control but did not find any regulatory violations. Milk samples also were examined for bacterial content, antibiotic residue, and presence of added water. Samples of fresh cheese remaining from the event and milk from the dairy were sent for laboratory analysis. *C. jejuni* was not isolated from the samples of leftover fresh cheese or unpasteurized milk.

Reported by: DC Hunt, MPH, MC Bañez Ocfemia, MPH, D Neises, MPH, G Hansen, DVM, Kansas Dept of Health and Environment. ST Aghoghovbia, MSc, EIS Officer, CDC.

Editorial Note: Unpasteurized milk products have been a documented source of infection with *Campylobacter, Salmonella, Escherichia coli* O157:H7, *Listeria, Brucella, Mycobacterium*

FIGURE. Number of cases of diarrheal illness (N = 68) among persons who attended a community fair, by day of illness onset — Kansas, October 2007



bovis, and other pathogens (1). Milk can become contaminated with Campylobacter from cow feces or colonized cow teats (2,3). This investigation produced evidence that unpasteurized cheese was the source of the outbreak of diarrheal illness among persons who attended a community fair in Kansas. However, investigators could not establish definitively when in the manufacturing process the cheese was contaminated. The cheese could have been contaminated at any point in its manufacture, including at the fair when community members directly participated in making the cheese. Although the causative organism was not found in dairy samples taken after the event, contamination of the milk during transit to the fair cannot be ruled out.

Although unpasteurized milk could not be identified definitively as the source of the outbreak described in this report, it has been the source of numerous other Campylobacter outbreaks. In 2006, unpasteurized milk or unpasteurized milk products were the vehicle of infection identified in six outbreaks of *Campylobacter spp.* in the United States. In those outbreaks, 95 persons were infected, and seven of those persons were hospitalized (CDC, unpublished data, 2008). Kansas has had previous outbreaks of campylobacteriosis associated with unpasteurized milk. In April 2002, KDHE and a local health department investigated a campylobacteriosis outbreak among 86 preschoolers and adults who visited a local dairy. Of the 86 persons, 65 (76%) reported consuming raw milk when they visited the dairy; no illness was reported among those who did not consume raw milk. C. jejuni isolates from six children had indistinguishable PFGE patterns. Laboratory tests of samples from the dairy's bulk tank were inconclusive. During August— December 2007, in a separate incident, KDHE and two local health departments identified 25 persons who had diarrheal

TABLE. Association between reported exposures and diarrheal illness among 130 respondents who attended a community fair — Kansas, October 2007

		Exposed	d	N	lot expos	ed		
Exposure	III	Total	III (%)	III	Total	III (%)	RR*	(95% CI†)
Drank well water	61	101	(60)	2	7	(29)	2.1	(0.6–6.9)
Made butter	24	38	(63)	41	79	(52)	1.2	(0.9-1.7)
Made cheese	21	31	(68)	42	83	(51)	1.3	(0.9–1.6)
Ate butter	37	55	(67)	29	61	(48)	1.4	(1.0–1.9)
Ate cheese	67	101	(66)	1	21	(5)	13.9	(2.0-94.8)
Ate chili	60	106	(57)	6	14	(43)	1.3	(0.7-2.4)
Ate biscuits	42	62	(68)	25	56	(45)	1.5	(1.0–2.1)
Shoed horses	26	42	(62)	39	74	(53)	1.2	(0.9–1.6)

^{*} Relative risk.

illness after consuming raw milk or products made with raw milk purchased from another local dairy. Seven (28%) patients had *C. jejuni* isolated from stool specimens; three of the isolates had indistinguishable PFGE patterns. *Campylobacter* was not isolated from any of the milk or cheese samples. Unpasteurized milk legally can be sold or donated at dairies in Kansas. Dairy farms in Kansas that sell unpasteurized milk on-site are not required to display notices regarding the potential hazards of consuming unpasteurized milk.[†]

When Scotland banned the sale of unpasteurized milk in 1983, milkborne infection decreased markedly in that country. Before the ban, an average of 14 outbreaks annually affected an average of 1,090 persons per year; after the ban, an average of eight outbreaks annually affected an average of 46 persons per year in dairy farming communities. None of the outbreaks in the postban period occurred in the general community (4).

Required permits and point-of-sale signage warning of the potential dangers of unpasteurized milk and unpasteurized milk products have not demonstrably decreased outbreaks of gastrointestinal illness in other states (5–7). Stricter laws prohibiting the sale or donation of unpasteurized milk might better protect the public, especially members of certain groups that are at increased risk for infection-related complications (e.g., young and elderly persons and pregnant women) (8). To prevent milkborne infections, unpasteurized milk and unpasteurized milk products should not be consumed.

Acknowledgments

This report is based, in part, on contributions by ME Vajnar, Kansas Department of Health and Environment; L Johnson and C Brehman, Minnesota Dept of Agriculture Laboratories; the Kansas Dept of Agriculture; local health department staff members, and K Bisgard, Office of Workforce and Career Development, CDC.

References

- Gillespie IA, Adak GK, O'Brien SJ, Bolton FJ. Milkborne general outbreaks of infectious intestinal disease, England and Wales, 1992–2000. Epidemiol Infect 2003;103:461–8.
- Warner DP, Bryner JH, Beran GW. Epidemiologic study of campylobacteriosis and the possible role of unpasteurized milk as a vehicle of infection. Am J Vet Res 1986;47:254–8.
- Hutchinson DN, Bolton FJ, Hinchliffe PM, et al. Evidence of udder excretion of *Campylobacter jejuni* as the cause of milk-borne *Campylobacter* outbreak. J Hyg 1985;94:205–15.
- Sharp JC, Patterson GM, Barrett NJ. Pasteurization and the control of milkborne infection in Britain. Br Med J 1985;291:463–4.
- CDC. Salmonella Typhimurium infection associated with raw milk and cheese consumption—Pennsylvania, 2007. MMWR 2007;56:1161–4.
- Potter ME, Blaser MJ, Sikes RK. Human Campylobacter infection associated with certified raw milk. Am J Epidemiol 1983;117:475

 –83.
- CDC. Multistate outbreak of Salmonella serotype Typhimurium infections associated with drinking unpasteurized milk—Illinois, Indiana, Ohio, and Tennessee, 2002–2003. MMWR 2003;52:613–5.
- 8. Allos BM. *Campylobacter jejuni* infections: update on emerging issues and trends. Clin Inf Dis 2001;32:1201–6.

Underground Coal Mining Disasters and Fatalities — United States, 1900–2006

During a 5-month period in 2006, three underground coal mining incidents in the United States resulted in the deaths of 19 miners. All three incidents received nationwide attention, particularly the Sago Mine disaster, which occurred on January 2 and resulted in the deaths of 12 miners. The other two incidents, which occurred at the Alma No. 1 Mine on January 19 and the Darby No. 1 Mine on May 20, resulted in the deaths of two miners and five miners, respectively. The occurrence of three fatal incidents in 5 months was a departure from recent trends in underground coal mining safety. Before 2006, the number of mining disasters had decreased from a high of 20 in 1909 to an average of one every 4 years during 1985–2005. Deaths resulting from the three incidents were the stimulus for

[†] Confidence interval.

[†] The Kansas Dairy Law. Kansas Statute K.S.A. 65-789 Ch. 65 Art. 7(d). Available at http://www.ksda.gov/includes/statute_regulations/dairy/06dairylaw.pdf.

the Mine Improvement and New Emergency Response Act of 2006 (MINER Act) (1), which amended the Mine Safety and Health Act of 1977 to improve safety, health, preparedness, and emergency response in U.S. mining. This report briefly describes the three 2006 mining incidents, reviews mining disasters in the United States during 1900–2006, and traces the effect of the disasters and the 2006 incidents on mining health and safety regulations.

Federal law mandates reporting of mining-related incidents that can result in loss of life, such as an explosion or fire in an underground coal mine. The Mine Safety and Health Administration (MSHA) determines whether investigation of such incidents is required and, if so, initiates the investigation within 24 hours. MSHA teams evaluate the scene, interview witnesses and experts, and with the aid of researchers from CDC's National Institute for Occupational Safety and Health (NIOSH) and other technical specialists, recreate specific conditions to measure and evaluate outcomes. The three 2006 incidents were investigated at both the state and federal level. Of the three incidents, two were classified by MSHA as disasters, which are defined as incidents with five or more fatalities (2–4).

To better understand the context of these events, NIOSH researchers reviewed mining fatality surveillance data from the period 1900–2006 published by MSHA (5–6) and the U.S. Bureau of Mines (7). Underground mine disasters are classified by cause as follows: 1) explosion, 2) fire, 3) haulage (i.e., transportation of personnel, material, or equipment), 4) ground fall/bump (i.e., fall of roof rock or outward bursting of walls in an underground work area), 5) inundation (i.e., usually an inrush of toxic gases or water from old mine workings), and 6) other (8). Using MSHA reports, NIOSH researchers collected additional data on the deaths and circumstances associated with the Sago, Alma, and Darby incidents. Researchers reviewed published materials and traced how events during these 2006 incidents led to the MINER Act.

2006 Mining Incidents

In 2006, a total of 14,885 mines were operating in the United States, representing every state and multiple mining commodities (e.g., coal, metal, nonmetal, stone, and sand and gravel). These mines included 2,113 active coal mines (1,438 surface mines and 675 underground mines). Most underground coal mines were concentrated in Kentucky, West Virginia, and Pennsylvania. In 2006, the two incidents in West Virginia and one in Kentucky resulted in the deaths of 19 workers, accounting for 26% of the 73 U.S. mine worker fatalities in that year.

Sago Mine. The first 2006 incident occurred on January 2 at the Sago Mine near Tallmansville, West Virginia. At approximately 6:30 a.m., 30 minutes after the 13 members of the No. 1 production crew entered the mine (2), a methane gas explosion occurred underground near a worked-out area approximately 2 miles from the mine entrance. MSHA investigators determined that lightning was the most likely ignition source for the explosion (2). The force of the explosion broke foam concrete block walls and propelled dust, dirt, and debris toward the mine entrance, killing one miner instantly and cutting communication wires. The other 12 miners in the No. 1 production crew, who had arrived at their work area approximately 1,000 feet beyond the site of the explosion, donned their 1-hour self-contained breathing apparatus and attempted to escape. After encountering smoke, dust, and debris, and with no information regarding the condition of the mine, the miners returned to their work area, erected a barricade, and awaited rescue. Eleven of the 12 died of carbon monoxide poisoning before rescuers reached them 41 hours later; the twelfth trapped miner survived. Because communications were cut off by the explosion, rescuers were unsure where the miners were located and whether any had survived. As a result, the trapped miners could not be told they were 700 feet from fresh air and could walk out of the mine. The deceased miners ranged in age from 28 to 61 years; average age was 49.4 years. They ranged in experience from 1.6 to 37 years and averaged 23.6 years of experience.

Alma No. 1 Mine. The second 2006 incident occurred on January 19 at the Alma No. 1 Mine near Stollings, West Virginia. A conveyor belt that removed coal from the mine caught on fire. A total of 29 miners were in the mine at the time, and two miners became separated when the others escaped in heavy smoke. Several unsuccessful attempts were made to locate the missing workers. After the fire had been extinguished, the two bodies were found by mine rescue teams 46 hours later (4).

Darby No. 1 Mine. The third 2006 incident occurred on May 20 at the Darby No. 1 Mine in Holmes Mill, Kentucky (3). At the end of the afternoon shift, the crew foreman and another miner had remained to finish some construction work when the four-member night shift crew entered the mine. An underground explosion destroyed several mine seals, which MSHA later attributed to improper construction of the seals and inappropriate use of cutting and welding equipment in an attempt to correct the deficient mine seal construction (3). The two miners who were finishing construction work died of blunt force trauma near one of the destroyed mine seals. Three other miners died of carbon monoxide poisoning while trying to escape from the mine through smoke and toxic gases.


The sixth miner was able to navigate part way out of the mine through smoke, rock, and debris by wearing his 1-hour breathing apparatus; he was found by mine rescue teams within 2 hours. The bodies of the five victims were removed from the mine 10 hours later.

Coal Mining Disasters, 1900–2006

During 1900–2006, a total of 11,606 underground coal mine workers died in 513 U.S. underground coal mining disasters* (Figure), with most disasters resulting from explosion or fire (Table). In 1907 alone, 692 miners died in four mine explosions in West Virginia, Pennsylvania, and Alabama (6). However, the frequency and severity of underground coal mining disasters and the number of deaths of miners decreased substantially during 1970–2005. Until the 2006 incidents, underground coal mine disasters with multiple fatalities were thought to be permanently on the decline.

Many of the disasters during 1900–2006 led to new legislation (Figure) (5,6). The 1907 explosions led to establishment in 1910 of the U.S. Bureau of Mines, an agency specifically authorized to conduct mine safety and health research. A 1968 explosion at the Farmington No. 9 Mine in West Virginia resulted in the deaths of 78 miners and led to 1) passage of the Federal Coal Mine Health and Safety Act of 1969 (1969 Act), the most sweeping mine safety and health legislation ever adopted in the United States, and 2) creation of the Mining Enforcement and Safety Administration (MESA), a separate agency from the Bureau of Mines, to enforce mine safety and health requirements. The 1969 Act strengthened numerous mine safety and health regulations, including those relating to explosion prevention, fire prevention and protection, and ventilation. In 1976, two explosions at the Scotia Mine in Kentucky resulted in the deaths of 26 miners and rescuers and led to passage of the Federal Mine Safety and Health Act of 1977 (1977 Act). This legislation strengthened provisions of the 1969 Act and also incorporated new mandates for all

FIGURE. Number of worker deaths in underground coal mining disasters* and key mining safety milestones — United States, 1900–2006



^{*} Disasters are defined by the Mine Safety and Health Administration as incidents resulting in five or more deaths.

^{*}Reliable data on fatalities in coal mining nondisasters (i.e., incidents with four or fewer deaths) are not available for the early 1900s.

TABLE. Number of worker deaths in underground coal mining disasters,* by causal classification — United States, 1900–2006

Causal classification	No. of diasters	No. of deaths
Explosion	420	10,390
Fire	35	727
Haulage [†]	21	145
Ground fall/Bump§	13	83
Inundation [¶]	7	62
Other	17	199
Total	513	11,606

- * Disasters are defined by the Mine Safety and Health Administration as incidents resulting in five or more deaths.
- † Transportation of personnel, material, or equipment.
- \S Fall of roof rock or outward bursting of walls in an underground work area.
- ¶Usually an inrush of toxic gases or water from old mine workings.

noncoal mines. The 1977 Act also renamed MESA as MSHA and moved the agency from the U.S. Department of the Interior to the U.S. Department of Labor.

The MINER Act of 2006

The 2006 coal mine disasters were the stimulus for the MINER Act (1). This legislation contains provisions to improve safety, health, preparedness, and emergency response in U.S. mines. After the explosion at the Sago Mine, delays occurred in incident reporting and emergency response. The MINER Act requires mine operators to develop and maintain a preparedness and response plan to reduce the delays and improve the quality of the response.

Under the MINER Act, mine operators must provide caches of self-contained breathing apparatus along escapeways; the breathing apparatus must supply at least 2 hours of oxygen per miner and must be spaced no more than 30 minutes travel time apart to enable miners to make their way through the entire escapeway. Before the Sago disaster, mines were only required to provide miners with a single self-contained breathing apparatus, providing 1 hour of oxygen. The sole survivor of the group of Sago miners told rescuers that some miners thought their self-contained breathing apparatus was not working properly. Regulators felt miners needed to be provided with sufficient quantities of breathing apparatus to give them at least 2 hours of protection in the event of a prolonged escape. The MINER Act also calls for installation and maintenance of directional lifelines[†] in escapeways, a direct response to NIOSH research findings (9). In addition, the inability of trapped miners to communicate with rescuers during the Sago disaster led to another feature in the MINER Act. By July 2009, mine operators must install wireless two-way communications and tracking systems that will link surface rescuers with underground workers. Congress subsequently passed an emergency supplemental appropriation to accelerate implementation of 1) emergency oxygen supplies, 2) refuge chambers, and 3) communications and tracking systems.

As a result of the three 2006 incidents, the National Mining Association created an independent commission of mining and safety experts, which concluded that more research was needed in rescue and escape training and communications, realistic training, professional emergency response and rescue capability, and development of a safety culture in mining organizations. These safety improvements will require more attention to human behavior and comprehensive risk management (10).

Coal mining disasters have decreased substantially in frequency and number of fatalities since 1900. The 2006 underground coal mine incidents and their 19 fatalities marked a reversal of that trend. However, the incidents also drew critical attention to mine safety in the United States, engaging the public, industry, and government and resulting in legislative and regulatory action.

Reported by: KM Kowalski-Trakofler, PhD, DW Alexander, PhD, MJ Brnich Jr, LJ McWilliams, MS, Office of Mine Safety and Health Research, Pittsburgh Research Laboratory; DB Reissman, MD, Office of the Director, National Institute for Occupational Safety and Health, CDC.

Acknowledgment

This report is based, in part, on contributions by A Podlesny and PJ Lenart, National Institute for Occupational Safety and Health, CDC

References

- Mine Improvement and New Emergency Response Act of 2006 (MINER Act), Pub. L. No. 109-236 (S 2803). Available at http://www.msha.gov/ mineract/mineractsinglesource.asp.
- 2. Gates RA, Phillips RL, Urosek JE, et al. Report of investigation: fatal underground coal mine explosion, January 2, 2006. Sago Mine, Wolf Run Mining Company, Tallmansville, Upshur County, West Virginia, ID No. 46-08791. Arlington, VA: US Department of Labor, Mine Safety and Health Administration; 2007. Available at http://www.msha.gov/sagomine/sagomine.asp.
- 3. Light TE, Herndon RC, Guley AR, et al. Report of investigation: fatal underground coal mine explosion, May 20, 2006. Darby No. 1 Mine, Kentucky Darby LLC, Holmes Mill, Harlan County, Kentucky. ID No. 15-18185. Arlington, VA: US Department of Labor, Mine Safety and Health Administration; 2007. Available at http://www.msha.gov/fatals/2006/darby/ftl06c2731.pdf.
- 4. Murray KA, Pogue CW, Stahlhut RW, et al. Report of investigation: fatal underground coal mine fire, January 19, 2006. Aracoma Alma Mine No. 1, Aracoma Coal Company, Inc., Stollings, Logan County, West Virginia. ID No. 46-08801. Arlington, VA: US Department of Labor, Mine Safety and Health Administration; 2007. Available at http://www.msha.gov/fatals/2006/aracoma/ftl06c1415.pdf.
- DeMarchi J. Historical mining disasters. Beckley, WV: US Department of Labor, Mine Safety and Health Administration, National Mine Health and Safety Academy; 1997:34

 –44.


[†] A rope with cones spaced at regular intervals along its length. If a miner's hand slides over the cone, the miner is going in the correct direction. If the hand is blocked by the cone, the miner is headed in the wrong direction.

- Mine Safety and Health Administration. Historical summary of mine disasters in the United States. Volume II: coal mines, 1959–1998. Beckley, West Virginia: US Department of Labor, Mine Safety and Health Administration, National Mine Health and Safety Academy; 1998.
- 7. Humphrey HB. Historical summary of coal-mine explosions in the United States, 1810–1958. Bulletin 586. Washington, DC: US Department of the Interior, Bureau of Mines; 1960.
- Mine Safety and Health Administration. Accident, illness and injury, and employment self-extracting files (part 50 data): 2006. Denver, CO: US Department of Labor, Mine Safety and Health Administration, Office of Injury and Employment Information. Available at http://www.msha. gov/stats/part50/p50y2k/p50y2k.htm.
- Conti R, Chasko L, Wiehagen W, Lazzara C. Fire response preparedness for underground mines. DHHS IC 9481. Washington, DC: US Department of Health and Human Services; 2005. Available at http://www.cdc.gov/niosh/mining/pubs/pdfs/2006-105.pdf.
- 10. Mine Safety Technology and Training Commission. Improving mine safety technology and training: establishing U.S. global leadership. Available at http://www.coalminingsafety.org/documents/msttc_report.pdf.

QuickStats

FROM THE NATIONAL CENTER FOR HEALTH STATISTICS

Mean Percentage Body Fat,* by Age Group and Sex — National Health and Nutrition Examination Survey, United States, 1999–2004[†]



- * Based on whole body, dual energy, x-ray absorptiometry (DXA) scans.
- [†] Estimates are based on DXA scans acquired from a sample (N = 22,010) of the civilian, noninstitutionalized U.S. population.

During 1999–2004, females had higher mean percentage body fat than males at all ages. Male/female differences were smallest at age 8–11 years (3.9 percentage points) but increased to 12.0 percentage points at age 16–19 years. In males, mean percentage body fat ranged from 22.9% at age 16–19 years to 30.9% at age 60–79 years. In females, mean percentage body fat ranged from 32.0% at age 8–11 years to 42.4% at age 60–79 years.

SOURCE: National Health and Nutrition Examination Survey, 1999–2004. Available at http://www.cdc.gov/nchs/nhanes.htm.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 20, 2008 (51st week)*


	Current	Cum	5-year weekly	repo	To orted fo	tal cas or prev		ears	
Disease	week	2008	average†	2007	2006	2005	2004	2003	States reporting cases during current week (No.)
Anthrax	_	_	_	1	1	_	_	_	
Botulism:									
foodborne	_	12	1	32	20	19	16	20	
infant	2	97	2	85	97	85	87	76	CT (1), AZ (1)
other (wound & unspecified)	_	22	1	27	48	31	30	33	
Brucellosis	1	84	3	131	121	120	114	104	NE (1)
Chancroid	_	31	1	23	33	17	30	54	
Cholera		2	0	7	9	8	6	2	110 (11)
Cyclosporiasis§	1	123	2	93	137	543	160	75	NC (1)
Diphtheria	_	_	_	_	_	_	_	1	
Domestic arboviral diseases§,¶:									
California serogroup	_	43	0	55	67	80	112	108	
eastern equine	_	2	0	4	8	21	6	14	
Powassan	_	1	_	7	1	1	1		
St. Louis	_	8	_	9	10	13	12	41	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis/Anaplasmosis [§] ,**:	4	005	10	000	F70	FOC	220	201	NIV (1) MNI (1) NIC (0)
Ehrlichia chaffeensis	4	835 9	19	828	578	506	338	321	NY (1), MN (1), NC (2)
Ehrlichia ewingii	10	456	30	834	646	786	537	362	NV (2) MN (7) NC (1)
Anaplasma phagocytophilum	10						59	362 44	NY (2), MN (7), NC (1)
undetermined Haemophilus influenzae,††	_	67	2	337	231	112	59	44	
invasive disease (age <5 yrs):									
() , ,	1	28	1	22	29	9	19	20	IN (1)
serotype b	1	163	4	199	175	135	135	32 117	FL (1)
nonserotype b unknown serotype	3	176	5	180	179	217	177	227	MO (1), FL (1), UT (1)
Hansen disease§	_	69	2	101	66	87	105	95	WIO (1), 1 L (1), O1 (1)
Hantavirus pulmonary syndrome§	_	14	1	32	40	26	24	26	
Hemolytic uremic syndrome, postdiarrheal§	_	222	7	292	288	221	200	178	
Hepatitis C viral, acute	5	788	26	849	766	652		1,102	PA (1), IN (1), MN (1), FL (2)
HIV infection, pediatric (age <13 years)§§	_	700	3	U43	700	380	436	504	1 A (1), IIV (1), IVIIV (1), 1 L (2)
Influenza-associated pediatric mortality ^{§,¶¶}	_	90	0	77	43	45		N	
Listeriosis	2	628	20	808	884	896	753	696	NY (1), NC (1)
Measles***	1	132	1	43	55	66	37	56	FL (1)
Meningococcal disease, invasive†††:		102	•	40	55	00	01	50	1 = (1)
A, C, Y, & W-135	1	262	8	325	318	297	_	_	PA (1)
serogroup B	1	147	6	167	193	156	_	_	MN (1)
other serogroup		30	1	35	32	27	_	_	(.)
unknown serogroup	3	584	20	550	651	765	_	_	MN (1), NC (1), KY (1)
Mumps	4	367	18		6,584	314	258	231	PA (1), IN (1), NE (1), CO (1)
Novel influenza A virus infections	_	1	_	4	N	N	N	N	(-), (-), (-)
Plague	_	1	0	7	17	8	3	1	
Poliomyelitis, paralytic	_	_	_	_	_	1	_	_	
Polio virus infection, nonparalytic§	_	_	_	_	N	N	N	N	
Psittacosis§	_	12	0	12	21	16	12	12	
Qfever total ^{§,§§§} :	_	112	3	171	169	136	70	71	
acute	_	100	_	_	_	_	_	_	
chronic	_	12	_	_	_	_	_	_	
Rabies, human	_	1	0	1	3	2	7	2	
Rubella 111	_	16	0	12	11	11	10	7	
Rubella, congenital syndrome	_	_	_	_	1	1	_	1	
SARS-CoV ^{§,****}	_	_	_	_	_	_	_	8	
Smallpox§	_	_	_	_	_	_	_	_	
Streptococcal toxic-shock syndrome§	_	125	4	132	125	129	132	161	
Syphilis, congenital (age <1 yr)	_	227	9	430	349	329	353	413	
Tetanus	_	15	1	28	41	27	34	20	
Toxic-shock syndrome (staphylococcal)§	1	67	3	92	101	90	95	133	IN (1)
Trichinellosis	_	7	0	5	15	16	5	6	
Tularemia	_	102	3	137	95	154	134	129	
Typhoid fever	_	371	8	434	353	324	322	356	
Vancomycin-intermediate Staphylococcus aureus§	_	33	0	37	6	2	_	Ν	
Vancomycin-resistant Staphylococcus aureus§	_	_	0	2	1	3	1	Ν	
Vibriosis (noncholera Vibrio species infections)§	5	435	5	447	Ν	N	Ν	Ν	NC (3), FL (2)
Yellow fever	_	_	_	_	_	_	_	_	

See Table I footnotes on next page.

TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 20, 2008 (51st week)*

- -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.
 - * Incidence data for reporting year 2008 are provisional, whereas data for 2003, 2004, 2005, 2006, and 2007 are finalized.
 - † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
 - Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 and 2008 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
 - Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
- ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to *E. chaffeensis*); Ehrlichiosis, human granulocytic (analogous to *Anaplasma phagocytophilum*), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of *E. ewingii*).
- †† Data for H. influenzae (all ages, all serotypes) are available in Table II.
- §§ Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
- III Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. There are no reports of confirmed influenza-associated pediatric deaths for the current 2008-09 season.
- *** The one measles case reported for the current week was imported.
- ††† Data for meningococcal disease (all serogroups) are available in Table II.
- §§§ In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases.
- 199 No rubella cases were reported for the current week.
- **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals December 20, 2008, with historical data



^{*} Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data Team

Patsy A. Hall

Deborah A. Adams
Willie J. Anderson
Lenee Blanton
Rosaline Dhara
Michael S. Wodajo
Pearl C. Sharp

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

			Chlamy	/dia [†]			Cocc	idiodom	ycosis			Cry	ptosporidi	osis	
		Prev						/ious					vious		
Donauting avec	Current			Cum	Cum	Current		reeks	Cum	Cum	Current		veek	Cum	Cum
Reporting area United States	week 6,382	Med 21,275	28 892	2008 1,051,977	2007 1,079,482	week 162	Med 122	Max 341	2008 6,897	2007 7,780	<u>week</u> 	Med 104	Max 430	2008 7,599	2007 10,919
New England Connecticut Maine [§] Massachusetts New Hampshire	933 340 — 520	707 202 51 327 41	1,516 1,093 72 624 64	36,365 10,983 2,484 16,979 2,039	34,913 10,361 2,508 15,880 2,029		0 0 0 0	1 0 0 0	1 N N N 1	2 N N N	1 - 1 -	5 0 0 1	40 38 6 9	297 38 45 91 56	334 42 56 131 47
Rhode Island [§] Vermont [§]	73 —	54 15	208 52	3,116 764	3,095 1,040	N	0	0 0		N	_	0 1	3 7	10 57	11 47
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1,105 579 — 526	2,773 394 532 1,006 808	4,969 535 2,177 3,412 1,050	142,205 19,378 26,901 55,354 40,572	141,359 21,253 27,798 50,693 41,615	N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	7 -5 - 2	13 0 4 2 5	34 2 17 6 15	703 26 263 102 312	1,345 67 242 102 934
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	907 — 680 227 —	3,507 1,067 375 832 812 322	4,373 1,711 710 1,226 1,261 615	169,544 48,599 19,808 43,320 41,578 16,239	177,548 54,334 20,558 36,788 46,546 19,322	2 N N 1 1	1 0 0 0 0	3 0 0 3 1	41 N N 30 11 N	36 N N 24 12 N	9 -5 -4 	25 2 3 5 6 8	124 12 41 13 59 46	2,001 176 185 268 682 690	1,863 198 108 208 564 785
W.N. Central lowa Kansas Minnesota Missouri Nebraska§ North Dakota South Dakota	289 180 — — — 109 —	1,260 173 181 264 479 77 32 55	1,696 240 529 373 566 244 58 85	62,296 8,964 8,827 12,245 23,519 4,299 1,625 2,817	62,273 8,506 8,143 13,305 22,983 5,022 1,748 2,566	N N - N N N	0 0 0 0 0 0	77 0 0 77 1 0 0	3 N N - 3 N N N	9 N N 9 N N N	2 1 — 1 — —	16 4 1 5 3 2 0 1	71 30 8 15 13 8 51	958 277 82 224 174 112 7 82	1,588 609 143 288 180 173 27 168
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	1,333 48 48 1,237 — — — —	3,578 69 127 1,363 179 439 0 465 621 59	7,609 150 207 1,571 1,338 696 4,783 3,045 1,059 101	183,834 3,675 6,580 67,838 19,110 22,158 5,901 25,537 30,035 3,000	210,326 3,445 5,970 56,771 41,808 22,762 25,828 26,243 24,376 3,123		0 0 0 0 0 0 0	1 0 0 0 1 0 0	4 1 N N 3 N N N	5 2 N N 3 N N N	9	18 0 0 7 4 1 0 1	46 2 2 35 13 4 16 4 3	975 11 11 463 230 45 77 49 68 21	1,264 20 3 661 235 36 125 84 89
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	773 — 266 — 507	1,557 440 239 390 534	2,302 561 373 1,048 791	79,535 20,126 11,989 20,101 27,319	80,800 24,906 8,558 20,768 26,568	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	_ _ _ _	3 1 0 0 1	9 6 4 2 6	159 66 34 17 42	614 124 248 102 140
W.S. Central Arkansas [§] Louisiana Oklahoma Texas [§]	409 156 253 —	2,793 276 388 168 1,948	4,426 455 775 392 3,923	137,469 13,362 20,626 7,668 95,813	123,205 9,827 19,106 12,409 81,863	N N N	0 0 0 0	1 0 1 0 0	3 N 3 N N	3 N 3 N N	_ _ _ _	5 0 1 1 3	154 6 5 16 139	1,601 38 54 132 1,377	450 62 63 120 205
Mountain Arizona Colorado Idaho§ Montana§ Nevada§ New Mexico§ Utah Wyoming§	555 256 — — 14 227 — 28 30	1,270 462 222 63 59 178 135 109 29	1,811 651 587 314 363 416 561 253 58	63,234 22,659 11,087 3,797 2,822 9,054 7,353 4,979 1,483	72,603 24,445 17,002 3,662 2,385 9,480 8,899 5,542 1,188	160 160 N N N 	86 86 0 0 0 1 0	165 161 0 0 0 6 3 3	4,560 4,476 N N N 45 28 9	4,903 4,741 N N N 71 23 65	4 2 2 — — — — —	8 1 1 1 1 0 1 0 0	37 9 12 5 6 1 23 6 4	520 90 110 65 41 1 150 46	2,912 53 211 463 69 36 125 1,899 56
Pacific Alaska California Hawaii Oregon [§] Washington	78 76 — 2 —	3,701 85 2,879 103 191 367	4,676 129 4,115 160 631 634	177,495 4,345 139,600 5,125 10,285 18,140	176,455 4,815 137,813 5,584 9,762 18,481	N N N N	32 0 32 0 0	217 0 217 0 0 0	2,285 N 2,285 N N N	2,822 N 2,822 N N N	1 - - - 1	8 0 5 0 1 2	29 1 14 1 4 16	385 3 234 2 52 94	549 4 290 6 126 123
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	81 —	0 4 117 12	20 — 24 333 23	73 — 124 6,726 502	95 — 813 7,797 150	N — N —	0 0 0 0	0 0 0 0	N — N —	N — N —	N — N —	0 0 0 0	0 0 0 0	N — N —	N — N —

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2008 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.

† Chlamydia refers to genital infections caused by Chlamydia trachomatis.

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

			Giardiasi	s				Gonorrhe	ea		———		s influen s, all ser	zae, invasi otypes [†]	ve
			/ious /eeks	_				vious veeks	_				ious eeks	_	
Reporting area	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007
United States	130	305	1,158	16,670	18,259	1,556	5,917	8,913	288,402	347,078	27	47	173	2,457	2,368
New England	3	24	49	1,210	1,447	117	97	227	5,076	5,517	1	3	12	146	176
Connecticut Maine [§]	3	6 3	11 12	291 182	366 192	61 —	50 2	199 6	2,483 92	2,128 118	1	0 0	9 2	42 17	45 13
Massachusetts	_	9	17	343	602	55	38	69	2,076	2,673	_	1	5	57	87
New Hampshire Rhode Island [§]	_	2 1	11 8	142 87	33 83	1	2 6	6 13	97 297	137 398	_	0	1 7	9 13	18 9
Vermont§	_	3	13	165	171		0	3	31	63	_	0	3	8	4
Mid. Atlantic	33	60	131	3,101	3,152	267	616	1,028	31,459	35,451	9	9	31	485	460
New Jersey New York (Upstate)	 19	7 22	14 111	302 1,183	401 1,164	117	91 118	167 545	4,676 5,883	6,000 6,844	4	1 3	7 22	71 151	68 131
New York City	5	15	29	792	837	_	180	633	10,225	10,295	1	1	6	86	101
Pennsylvania	9	15	46	824	750	150	214	394	10,675	12,312	4	4	8	177	160
E.N. Central Illinois	21	47 11	86 31	2,502 599	2,827 855	268	1,223 362	1,648 589	60,238 16,779	71,595 20,332	5	7 2	28 7	362 111	373 120
Indiana	N	0	0	N	N		148	284	7,857	8,741	3	1	20	71	58
Michigan Ohio	2 19	11 16	22 31	582 880	611 811	203 65	327 288	657 531	16,448 14,770	15,154 20,686	_	0 2	2 6	21 132	31 106
Wisconsin	_	8	19	441	550	_	88	176	4,384	6,682	_	0	2	27	58
W.N. Central	10	30	621	1,944	1,616	45	314	425	15,762	19,111	3	3	24	190	137
Iowa Kansas	2	6 3	18 11	313 157	299 183	15 —	29 41	48 130	1,553 2,210	1,890 2,273	_	0	1 3	2 16	1 11
Minnesota	_	0	575	666	338	_	55	92	2,648	3,422	1	0	21	58	61
Missouri Nebraska [§]	4 4	8 4	22 10	451 207	513 156	30	148 24	199 47	7,591 1,299	9,745 1,413	1 1	1 0	6 2	72 29	40 18
North Dakota	_	0	36	23	24	_	2	6	113	114		Ö	3	13	6
South Dakota	_	2	10	127	103	_	7	15	348	254	_	0	0	_	_
S. Atlantic Delaware	46	54 1	87 3	2,786 40	3,018 41	421 12	1,188 19	3,072 44	61,732 1,001	82,715 1,284	6	12 0	29 2	650 7	591 8
District of Columbia	_	1	5	56	74	40	48	101	2,575	2,349	_	Ö	2	11	3
Florida	39	24 9	57 27	1,336	1,252 676	369	448 97	522 560	22,419	22,994	4	3 2	10	186 135	164 120
Georgia Maryland [§]	6	5	12	557 250	263	_	116	206	7,301 5,990	17,312 6,666	_	2	9 6	91	85
North Carolina	N	0	0	N	N	_	0	1,949	2,638	14,717	2	1	9	76	54
South Carolina§ Virginia§	1	2 8	6 39	130 361	120 543		180 182	830 486	9,103 10,009	10,228 6,248	_	1 1	7 6	49 74	54 75
West Virginia	_	1	5	56	49	_	14	26	696	917	_	Ö	3	21	28
E.S. Central	1	8	21	447	567	206	552	837	28,146	31,536	1	3	8	128	135
Alabama [§] Kentucky	 N	5 0	12 0	248 N	268 N	— 89	172 90	250 153	7,967 4,494	10,750 3,359	_	0 0	2 1	21 2	28 10
Mississippi	N	0	0	N	N	_	133	401	7,090	7,967	_	0	2	13	10
Tennessee§	1	4	13	199	299	117	164	297	8,595	9,460	1	2	6	92	87
W.S. Central Arkansas§	1	7 3	41 8	413 134	428 152	139 45	946 86	1,355 167	46,531 4,313	50,850 4.098	_	2	29 3	100 10	102 9
Louisiana	_	2	10	120	139	94	166	317	8,760	11,000	_	0	2	8	12
Oklahoma Texas§	 N	2	35 0	159 N	137 N	_	57 633	124 1,102	2,903 30,555	4,781 30,971	_	1 0	21 3	72 10	70 11
Mountain	11	27	62	1,497	1,840	84	208	338	10,203	13,611	2	5	14	280	253
Arizona	 8	2 10	8 27	136 540	189 577	34	63 58	93 100	3,176 2,956	4,972 3,328	_	2 1	11 4	108 54	89 56
Colorado Idaho [§]	_	3	27 14	191	216	_	3	13	2,956	266	_	0	4	12	8
Montana [§]	_	1	9	84	109	1	2	10	106	112	_	0	1	4	2
Nevada [§] New Mexico [§]	_	1 1	8 7	90 85	142 117	49 —	39 24	130 104	2,051 1,200	2,350 1,692	_	0 1	2 4	14 39	12 41
Utah	3	6	22	344	444	_	10	20	426	811	2	1	5	45	39
Wyoming§	_	0	3	27	46	_	2	9	115	80	_	0	2	4	6
Pacific Alaska	4 3	54 2	185 10	2,770 102	3,364 79	9 8	600 10	759 24	29,255 502	36,692 569	_	2 0	7 2	116 16	141 15
California	_	35	91	1,792	2,245	_	500	657	24,320	30,637	_	0	3	24	47
Hawaii Oregon [§]	_	1 8	4 18	41 434	77 455	1	11 23	22 48	550 1,196	652 1,230	_	0 1	2 4	20 53	11 65
Washington	1	8	87	401	508	_	54	90	2,687	3,604	_	Ö	3	3	3
American Samoa	_	0	0	_	_	_	0	1	3	3	_	0	0	_	_
C.N.M.I. Guam	_			_	_	_	_ 1	 15	— 73	137	_			_	_ 1
Puerto Rico	_	2	13	151	366	1	5	25	269	318	_	Ö	0	_	2
U.S. Virgin Islands	_	0	0	_	_	_	2	6	93	39	N	0	0	N	N

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Med: * Incidence data for reporting year 2008 are provisional.

† Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

(51St Week)"				Hepat	itis (viral,	acute), by	type†								
			Α					В					egionellos	sis	
			rious reeks	•				rious reeks	•				ious eeks		
Reporting area	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007
United States	11	48	171	2,300	2,808	28	67	259	3,340	4,260	31	43	144	2,702	2,599
New England	_	2	7 4	101 26	131 26	2	1 0	7 7	62 23	124 38	1	2	16 5	140	162
Connecticut Maine [§]	_	0	2	11	5		0	2	13	18	1	0	2	46 9	41 9
Massachusetts New Hampshire	_	0	5 2	38 12	66 12	_	0	1 2	9 11	42 5	_	0 0	3 5	13 27	50 8
Rhode Island [§] Vermont [§]	_	0	2 1	12	14	_	0	1	4 2	16 5	_	0	14 1	40 5	45 9
Mid. Atlantic	 5	6	12	294	446	4	8	14	412	554	 12	13	58	899	824
New Jersey New York (Upstate)		1	4 6	57 64	123 73	_ 1	2 1	7 4	111 64	160 87	 8	1 4	7 19	79 325	115 225
New York City	_	2	6	104	155	_	2	6	90	120	_	1	12	112	183
Pennsylvania E.N. Central	2 1	1 6	6 16	69 315	95 336	3 3	2 8	8 13	147 403	187 446	4 5	6 10	33 40	383 564	301 591
Illinois		2	10	98	117	_	2	6	112	128	_	1	8	73	110
Indiana Michigan	_	0 2	4 7	21 116	28 94		1 2	6 6	49 125	58 119	_	1 2	7 16	52 156	64 169
Ohio Wisconsin	1	1 0	4 2	50 30	67 30	1	2	8 1	111 6	121 20	5	4 0	18 3	265 18	211 37
W.N. Central	1	4	29	243	172	5	2	9	103	112	1	2	9	135	113
Iowa Kansas	_	1 0	7 3	105 14	45 11	_	0 0	2 3	17 7	25 9	_	0	2 1	17 2	11 10
Minnesota Missouri	1	0	23 3	37 43	70 22	4 1	0	5 4	14 55	20 38	<u>_</u>	0	4 7	23 69	28 45
Nebraska§	_	Ö	5	43	18		Ö	2	9	12		Ö	4	21	45 15
North Dakota South Dakota	_	0	2 1	4	<u> </u>	_	0 0	1 0	1	1 7	_	0 0	2 1	3	4
S. Atlantic	3	7	15	368	470	11	17	60	864	979	8	8	28	459	436
Delaware District of Columbia	U	0	1 0	7 U	8 U	U	0 0	3 0	10 U	15 U	_	0	2 2	13 15	11 16
Florida Georgia	2	2 1	8 4	145 45	149 67	8	6 3	12 6	334 131	333 153	6	3 0	7 4	148 32	148 42
Maryland [§] North Carolina	1	1	3	40 61	72 63	1 2	2	4 17	80 80	111 124	1	2	10 7	121 37	84 44
South Carolina§	_	0	3	19	18	_	1	6	60	63	1	0	2	13	17
Virginia [§] West Virginia	_	1 0	5 2	46 5	84 9	_	2 1	16 30	105 64	128 52	_	1 0	6 3	59 21	55 19
E.S. Central	1	1	9	78	107	1	7	13	364	378	2	2	10	110	99
Alabama [§] Kentucky	_	0	2	12 29	24 20	_	2 2	6 5	97 91	128 76		0 1	2 4	15 55	11 49
Mississippi Tennessee [§]	_ 1	0	2 6	5 32	8 55	_ 1	1 3	3 8	44 132	37 137	_	0	1 5	1 39	— 39
W.S. Central	_	4	55	186	264	_	12	131	592	934	1	1	23	86	130
Arkansas [§] Louisiana	_	0	1 1	5 10	13 28	_	0 1	4 4	30 73	71 99	_	0	2 2	11 9	15 6
Oklahoma	_	0	3	7	12	_	2	22	111	130	_	Ö	6	10	6
Texas [§] Mountain	_	3 4	53 12	164 200	211 228	_ 1	7 4	107 12	378 188	634 211	1 1	1 2	18 8	56 88	103 110
Arizona	_	2 0	11	105	150	<u>i</u>	i 0	5 3	69 30	81	<u>i</u>	0	3 2	23 10	39
Colorado Idaho [§]	_	0	3 3	35 18	26 8	_	0	2	8	35 14	_	Ö	1	3	21 6
Montana [§] Nevada [§]	_	0	1 3	1 9	9 12	_	0 1	1 3	2 33	1 48	_	0 0	1 2	4 10	3 9
New Mexico [§] Utah	_	0	3 2	17 12	12 8	_	0	2	11 31	13 14	_	0	1 2	7 31	10 19
Wyoming§	_	0	1	3	3	_	0	1	4	5	=	0	0	_	3
Pacific Alaska	_	10 0	51 1	515 3	654 4	1	7 0	30 2	352 9	522 9	_	4 0	18 1	221 3	134
California	_	7	42	424	561	_	5	19	252	383	_	3	14	177	98
Hawaii Oregon [§]	_	0 0	2 3	17 25	7 30	_	0 1	1 3	7 39	17 57	_	0 0	1 2	8 16	2 13
Washington	_	1	7	46	52	1	1	9	45	56		0	3	17 N	21
American Samoa C.N.M.I.	_	0	0	_	_	_	0	0	_	14	N —	0	0	N —	N —
Guam Puerto Rico	_	0	0 2	 17	<u> </u>	_	0	1 5	 39	2 88	_	0	0 1		4
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	_	_	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable.

* Incidence data for reporting year 2008 are provisional.

† Data for acute hepatitis C, viral are available in Table I.

[§] Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

			yme disea	ise				Malaria				Α	II serotyp	ise, invasi es	ve [†]
	Current		vious veeks	Cum	Cum	Current		rious eeks	Cum	Cum	Current		rious reeks	Cum	Cum
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007	week	Med	Max	2008	2007
United States	391	405	1,447	25,998	26,069	11	21	136	1,038	1,272	5	20	53	1,023	1,024
New England	19	43 0	259 8	3,637	7,771 3,054	1	0	35 27	36 11	59 3	_	0	3 1	22	43 6
Connecticut Maine§	16	2	72	860	528	_	0	1	1	8	_	0	1	1 6	7
Massachusetts	_	12	114	1,039	2,982	_	0	2	14	34	_	0	3	15	20
New Hampshire Rhode Island§	_	11 0	139 0	1,381	893 177	_	0 0	1 8	4 1	9	_	0	0	_	3 3
Vermont§	3	3	40	357	137	1	Ō	1	5	5	_	0	1	_	4
Mid. Atlantic	331	235	1,003	15,247	10,793	2	4	14	240	392	1	2	6	117	123
New Jersey New York (Upstate)	303	31 89	209 453	2,743 5,590	3,119 3,295		0 0	1 7	32	71 71	_	0 0	2	10 31	18 35
New York City	_	0	4	51	416	_	3	10	169	207		0	2	27	21
Pennsylvania	28	81	531	6,863	3,963	_	1	3	39	43	1	1	5	49	49
E.N. Central Illinois	1	10 0	143 11	1,344 95	2,094 149	_	3 1	7 6	138 68	136 62	_	3 1	9 4	173 62	160 59
Indiana	_	0	8	41	52	_	0	2	5	10	_	0	4	27	28
Michigan Ohio	1	1	10 5	96 49	51 33	_	0 0	2 3	18 29	20 27	_	0 1	3 4	30 40	26 35
Wisconsin	_	8	127	1,063	1,809	_	Ö	3	18	17	_	Ö	2	14	12
W.N. Central	27	7	740	1,305	658	_	1	10	68	56	2	2	8	94	69
Iowa Kansas	_	1 0	8 1	95 5	123 8	_	0 0	3 2	9 9	3 4	_	0	3 1	19 5	15 5
Minnesota	27	2	731	1,179	507	_	0	8	28	29	2	0	7	26	22
Missouri Nebraska [§]	_	0 0	1 2	8 14	10 7	_	0 0	3 2	14 8	8 7	_	0 0	3 1	26 12	17 5
North Dakota	_	0	9	1	3	_	0	1	_	4	_	0	1	3	2
South Dakota	_	0	1	3	_	_	0	0	_	1	_	0	1	3	3
S. Atlantic Delaware	13	67 12	215 37	4,020 746	4,479 710	7	5 0	15 1	266 3	260 4	1	2	10 1	148 2	175 1
District of Columbia	_	2	11	158	116	_	0	2	4	3	_	Ö	Ö	_	_
Florida Georgia	1	2	10 3	113 23	30 11	4	1 1	7 5	62 51	55 37	_	1 0	3 2	50 16	66 24
Maryland [§]	11	30	156	2,055	2,562	1	i	6	67	74	_	0	4	17	21
North Carolina	1	0	7 2	51 24	50 30	2	0	7 1	30 9	21 7	1	0	3 3	14 22	22 16
South Carolina§ Virginia§	_	11	68	776	891	_	1	7	40	58	_	0	2	22	23
West Virginia	_	0	11	74	79	_	0	0	_	1	_	0	1	5	2
E.S. Central Alabama§	_	0	5 3	46 10	51 13	_	0	2 1	21 4	39 7	1	1 0	6 2	53 10	52 9
Kentucky	_	Ö	2	5	6	_	Ö	i	5	9	1	ő	2	10	13
Mississippi Tennessee§	_	0	1 3	1 30	1 31	_	0	1 2	1 11	2 21	_	0 0	2	12 21	12 18
W.S. Central	_	2	3 11	98	80	_	1	64	76	92	_	2	13	110	102
Arkansas§	_	0	0	_	1	_	Ö	0	_	2	_	0	2	14	9
Louisiana Oklahoma	_	0 0	1 1	3	2	_	0 0	1 4	3 4	14 6	_	0 0	3 5	22 18	28 17
Texas§	_	2	10	95	77	_	1	60	69	70	_	1	7	56	48
Mountain	_	0	4	46	45	_	1	3	32	65	_	1	4	55	67
Arizona Colorado	_	0 0	2 2	8 7	2	_	0	2 1	14 4	12 23	_	0	2 1	9 15	13 21
Idaho§	_	0	2	9	9	_	0	1	3	6	_	0	i	4	8
Montana [§] Nevada [§]	_	0	1 2	4 5	4 15	_	0	0 3	_ 3	3	_	0	1 1	5 4	2 6
New Mexico§	_	0	2	6	5	_	0	1	3	5	_	0	1	7	3
Utah Wuaming ⁸	_	0	1	4	7	_	0	1	5	13	_	0	3	9	12
Wyoming§ Pacific	_	0 5	1 10	3 255	3 98	_ 1	0 2	0 10	— 161	— 173	_	0 5	1 19	2 251	2 233
Alaska	_	0	2	5	10		0	2	6	2	_	0	2	5	2
California Hawaii	 N	3	10 0	195 N	72 N	_	2	8 1	120 3	123 2	_	3 0	19 1	179 5	167 10
Oregon§		1	4	1N 44	N 6	_	0	2	4	18	_	1	3	38	31
Washington	_	Ö	4	11	10	1	0	3	28	28	_	0	5	24	23
American Samoa	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_
C.N.M.I. Guam	_	0	0	_	_	_	0		3	1	_	0	0	_	_
Puerto Rico	N	0	0	N	N	_	0	1	1	3	_	0	1	3	8
U.S. Virgin Islands	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_

C.N.M.I.: Confinonwealth of Not most seed.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Nieu. Nieu.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

			Pertussis				Ra	abies, anir	nal		F	Rocky Mo	untain sp	otted feve	-
			rious					vious		_			ious		
Reporting area	Current week	Med Med	eeks Max	Cum 2008	Cum 2007	Current week	Med Med	reeks Max	Cum 2008	Cum 2007	Current week	52 w Med	Max	Cum 2008	Cum 2007
United States	158	181	849	9,239	9,605	19	102	164	4,816	5,870	18	41	195	2,238	2,026
New England	1	12	49	608	1,503	9	7	20	361	513	_	0	2	4	10
Connecticut Maine [†]	_ 1	0	4 5	34 45	88 81	7 2	4 1	17 5	199 60	212 86	N	0	0	N	N
Massachusetts	<u>.</u>	9	32	420	1,161	N	0	0	N	N	_	0	1	1	9
New Hampshire Rhode Island [†]	_	0 1	4 25	38 59	80 34	N	0	3 0	35 N	53 N	_	0	1 2	1 2	1
Vermont†	_	0	4	12	59	_	1	6	67	162	_	0	0	_	_
Mid. Atlantic New Jersey	37	18 1	43 9	1,011 54	1,271 220	3	28 0	63 0	1,528	988	_	1 0	5 2	80 12	84 32
New York (Upstate)	7	7	24	420	526	3	9	20	492	507	_	0	2	17	6
New York City Pennsylvania	30	0 9	5 25	46 491	148 377	_	0 18	2 48	19 1,017	44 437	_	0	2 2	24 27	28 18
E.N. Central	46	29	189	1,724	1,473	_	3	28	247	411	_	1	15	147	59
Illinois Indiana	9	6 1	32 15	437 112	196 56	_	1 0	21 2	103 10	113 12	_	1 0	10 3	102 8	39 5
Michigan	3	5	14	281	290	_	1	8	73	202	_	0	1	3	4
Ohio Wisconsin	34	9 2	176 7	782 112	604 327	N	1 0	7 0	61 N	84 N	_	0 0	4 1	33 1	10 1
W.N. Central lowa	26	17 1	142 12	1,194 104	767 149	_	4	12 5	195 29	264 31	1	4	32 2	453 7	364 17
Kansas	_	1	13	66	104	_	0	7	_	107	_	0	0	_	12
Minnesota Missouri	 13	2 5	131 49	224 485	262 115	_	0 1	10 8	65 65	39 38	_ 1	0 3	4 31	423	2 314
Nebraska [†]	13	2	35	271	69	_	Ô	0	_	_	_	0	4	20	14
North Dakota South Dakota	_	0 0	5 5	1 43	9 59	_	0 0	8 2	24 12	22 27	_	0 0	0 1	3	<u></u>
S. Atlantic	19	16	50	883	928	7	36	101	1,962	2,153	13	12	71	908	987
Delaware District of Columbia	_	0	3 1	18 7	11 9	_	0 0	0 0	_	_	_	0	5 2	32 8	17 3
Florida	11	5 1	20	302	208	_	0	77	139	128	_	0	3	18	19
Georgia Maryland [†]	7	2	6 8	77 126	37 117	_	5 8	42 17	298 409	292 429	_	1 1	8 7	73 71	60 63
North Carolina South Carolina [†]	_ 1	0 2	38 8	79 122	292 100	7	9	16 0	448	470 46	13	3 1	55 9	499 54	637 64
Virginia [†]	_	3	10	143	124	_	11	24	591	711	_	2	15	146	119
West Virginia E.S. Central	_ 8	0 7	2 25	9 378	30 458	_	1 3	9 7	77 165	77 155	_	0 3	1 23	7 314	5 274
Alabama†	_	1	5	54	90	_	0	0	_	_	_	1	8	88	95
Kentucky Mississippi	2	1 2	11 5	130 89	32 255	_	0	4 1	45 2	21 3	_	0	1 1	1 6	5 20
Tennessee [†]	6	1	14	105	81	_	2	6	118	131	_	2	19	219	154
W.S. Central Arkansas†	_	26 1	198 18	1,465 82	1,105 162	_	1 0	40 6	92 48	1,046 32	3 3	2	153 14	285 68	208 109
Louisiana	_	1	7	70	21	_	0	0	_	6	_	0	1	5	4
Oklahoma Texas [†]	_	0 22	21 179	53 1,260	50 872	_	0	32 12	42 2	46 962	_	0 1	132 8	170 42	54 41
Mountain	6	15	37	775	1,100	_	1	8	77	97	1	1	3	43	37
Arizona Colorado	3	3 3	10 8	189 148	209 302	N —	0	0 0	N	N	1	0	2 1	17 1	10 3
Idaho†	_	0	5	35	45	_	0	0	_	12	_	0	į	1	4
Montana [⊤] Nevada [†]	_	0	11 7	83 19	49 37	_	0 0	2 4	9 5	21 13	_	0	2	3 2	1
New Mexico [†] Utah	 3	1 4	8 27	61 224	74 360	_	0	3 6	25 14	15 16	_	0	1 1	2 7	6
Wyoming [†]	_	0	2	16	24	_	0	3	24	20	_	0	2	10	13
Pacific Alaska	15 8	23 3	303 21	1,201 246	1,000 88	_	3	13 4	189 14	243 45		0	1 0	4 N	3 N
California	_	7	129	382	461	_	3	12	161	186	_	0	1	1	1
Hawaii Oregon [†]	_	0 3	2 10	16 164	18 120	_	0	0 4	 14	_ 12	N	0	0 1	N 3	N 2
Washington	7	5	169	393	313	_	0	0	_	_	N	Ö	0	Ň	N
American Samoa C.N.M.I.	_	0	0	_	_	N	0	0	N	N	N	0	0	N	<u>N</u>
Guam	_	0	0	=	_	_	0	0	_	_	N	0	0	N	N
Puerto Rico U.S. Virgin Islands	_	0 0	0 0	_	_	 N	1 0	5 0	59 N	47 N	N N	0 0	0 0	N N	N N
J.J. VIIGITISIATUS		U				IN	U			11/	111	U			- 11

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Incidence data for reporting year 2008 are provisional.

† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

		S	almonello	sis		Shig	a toxin-pı	roducing	E. coli (ST	EC)†			Shigellosi	s	
			vious					ious					vious		
Reporting area	Current week	Med	veeks Max	Cum 2008	Cum 2007	Current week	Med	eeks Max	Cum 2008	Cum 2007	Current week	Med Med	weeks Max	Cum 2008	Cum 2007
United States	366	813	2,110	43,921	45,885	30	82	250	5,018	4,706	264	436	1,227	19,712	18,531
New England	1	19	506	1,688	2,227	1	3	47	218	311	_	2	39	157	246
Connecticut Maine§	_ 1	0 2	477 8	477 146	431 136	_ 1	0	44 3	44 24	71 40	_	0	38 6	38 21	44 14
Massachusetts		14	52	741	1,301		1	11	80	143	_	1	5	78	153
New Hampshire Rhode Island [§]	_	2	10 8	138 106	170 109	_	0	3 3	34 9	35 7	_	0	1 1	3 12	7 24
Vermont§	_	1	8 7	80	80	_	0	3	9 27	15	_	0	2	5	4
Mid. Atlantic	29	89	177	4,987	5,820	2	6	192	581	521	8	44	96	2,270	914
New Jersey New York (Upstate)	 15	13 26	30 73	636 1,417	1,215 1,403		0 3	3 188	26 406	116 201	4	12 11	38 35	754 567	184 165
New York City	2	23	53	1,240	1,285	_	1	5	58	50	1	13	35	699	280
Pennsylvania E.N. Central	12 47	27 88	78 192	1,694 4.860	1,917 5.849	— 10	1 11	8 74	91 906	154 736	3 83	3 75	21 145	250 3,884	285 3,041
Illinois	_	25	72	1,273	1,936	_	1	9	109	131	_	18	32	845	752
Indiana Michigan	18 2	9 17	53 38	597 901	655 960	_	1 2	14 43	93 230	102 124	9 5	10 3	83 20	591 196	213 82
Ohio	27	25	65	1,324	1,311	10	3	17	198	154	69	30	80	1,833	1,239
Wisconsin W.N. Central	— 16	15 49	50 151	765 2,720	987 2,791	 5	4 13	20 58	276 798	225 753	<u> </u>	8 16	32 39	419 886	755 1,786
Iowa	1	8	16	407	467	1	2	22	199	174	1	3	11	176	108
Kansas Minnesota	_	7 13	31 70	452 691	404 674	_	0 3	7 21	51 201	52 227	_	1 5	5 25	62 299	26 230
Missouri	12	13	48	748	755	2	2	11	147	151	3	4	14	221	1,266
Nebraska [§] North Dakota	3	4 0	13 35	234 45	272 46	2	2	29 20	148 3	93 9	_	0 0	3 15	15 37	28 6
South Dakota	_	2	9	143	173	_	1	4	49	47	_	0	9	76	122
S. Atlantic Delaware	184	248 2	457 9	12,038 143	12,221 138	<u>5</u>	13 0	50 2	766 12	688 16	45	58 0	149 1	3,020 11	4,628 11
District of Columbia	_	1	4	52	64	_	0	1	12	_	_	0	3	19	18
Florida Georgia	100	100 38	174 86	5,169 2,171	4,948 2,004	1	2 1	11 7	143 87	162 93	11	15 21	68 48	791 1,063	2,258 1,608
Maryland [§]	12	13	36	770	896	2	2	10	119	84	8	2	7	110	116
North Carolina South Carolina§	65 7	22 18	228 55	1,526 1,088	1,616 1,149	2	1 1	12 4	121 40	142 14	23 3	3 8	27 32	267 521	105 214
Virginia [§]	_	18	49	962	1,200	_	3	25	203	158	_	4	13	222	187
West Virginia E.S. Central	_ 11	3 57	25 138	157 3,293	206 3,437	_ 1	0 5	3 21	29 276	19 317	— 16	0 38	61 77	16 1,840	111 2,993
Alabama§	_	15	47	909	969	_	1	17	58	67	_	7	20	381	733
Kentucky Mississippi	3	9 13	18 57	473 1,027	568 1,041	_	1 0	7 2	99 6	123 7	1	4 5	24 23	258 288	501 1,400
Tennessee§	8	14	57	884	859	1	2	7	113	120	15	18	43	913	359
W.S. Central	47	108	894	5,850	5,171	_	6	27	317	275	91	92	748	4,782	2,369
Arkansas [§] Louisiana	7	11 13	40 49	762 916	826 971	_	1 0	3 1	43 2	43 12	6	11 10	27 25	564 549	94 490
Oklahoma Texas [§]	<u> </u>	15 54	72 794	784 3,388	634 2,740	_	1 4	19 10	52 220	19 201	— 85	3 62	32 702	171 3,498	129 1,656
Mountain	24	58	110	3,136	2,707	3	10	38	587	583	16	18	53	1,159	971
Arizona	8	19	45	1,098	991	1	1	5	68	106	14	9	34	622	551
Colorado Idaho [§]	12 —	12 3	43 14	679 184	559 154	1	3 2	17 15	188 144	153 132	2	2 0	11 2	135 14	120 13
Montana§	_	2	10	121	111	_	0	3	35	_	_	0	1	8	27
Nevada [§] New Mexico [§]	_	3 6	9 33	171 476	258 286	_	0 1	2 6	10 49	31 40	_	4 1	13 10	216 118	77 108
Utah Wyoming§	3 1	6 1	19 4	356 51	276 72	1	1 0	9 1	88 5	99 22	_	1 0	4 1	39 7	42 33
Pacific	7	108	399	5,349	5,662	3	8	49	569	522	1	29	82	1,714	1,583
Alaska	1	1	4	56	87	_	0	1	7	5	_	0	1	1	8
California Hawaii	_	78 5	286 15	3,914 250	4,285 307	_	5 0	39 2	305 13	271 37	_	27 1	74 3	1,481 41	1,278 70
Oregon [§] Washington	<u> </u>	7 12	20 103	409 720	326 657	 3	1 2	8 16	65 179	77 132	_ 1	1 2	10 13	90 101	81 146
American Samoa	_	0	103	720 2	057	<u> </u>	0	0		- 132	_	0	13	101	5
C.N.M.I.	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_
Guam Puerto Rico		0 10	2 41	13 522	20 908	_	0	0 1		<u> </u>	_	0	3 4	15 19	19 24
U.S. Virgin Islands	-	0	0	_	_		0	0	_	_		0	0	_	-

U: Unavailable. — No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2008 are provisional.

† Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

United States			Streptococcal	diseases, inv	asive, group A		Streptococc	us pneumonia	ae, invasive di Age <5 years	isease, nondru	g resistant†
United States		Current	52 w	eeks			Current	52 w	eeks		
New England	Reporting area		Med	Max	2008	2007	week	Med	Max	2008	2007
Connecificut 1 0 26 101 1139 — 0 11 111 13 13 14 14 13 14 15 15 14 14 15 15 15 15 15 15 15 15 15 15 15 15 15	United States						22				
Maines		2	6								
Massachusets											
Ribode Islandis	Massachusetts	_	2	8	138	185		0	5	39	87
Vermont [§] - 0 2 112 18 - 0 1 1 1 2 Vermont [§] - 0 2 112 18 - 0 1 1 1 2 Vermont [§] - 0 1 1 1 2 Vermont [§] - 0 1 1 1 38 3 168 3 - 1 1 6 62 Vers Versey		_									
Mid. Alantact 10	Vermont§										
New Jersey — 2 11 138 168 — 1 6 62 72 New York (Upstate) 5 6 177 321 278 278 2 14 101 New York (Upstate) 5 5 6 177 321 278 278 2 2 14 101 New York (Upstate) 5 6 177 16 330 266 N 0 0 8 14 11 128 New York (Upstate) 5 7 16 330 266 N 0 0 8 14 11 128 New York (Upstate) 5 7 16 330 266 N 0 0 8 14 11 128 New York (Upstate) 5 7 16 330 266 N 0 0 8 14 11 128 New York (Upstate) 5 7 16 330 266 N 0 0 8 14 11 128 New York (Upstate) 5 7 16 330 266 N 0 0 8 14 11 128 New York (Upstate) 5 7 16 320 268 N 0 0 8 14 10 128 New York (Upstate) 5 7 16 320 268 N 0 0 8 14 10 128 New York (Upstate) 5 7 18 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Mid. Atlantic	10					2		19	203	
New York City	New Jersey	_	2	11	138	168	_	1	6	62	72
Pennsylvania 5 7 16 330 246 N 0 0 N N N N N Pennsylvania 5 7 16 330 246 N 0 0 N N N N N Pennsylvania 5 7 16 330 246 N 0 0 N N N N N N N N N N											
EM. Central 5											
Illinois	•										
Michigan 1 3 10 168 199 — 1 5 77 82 Dinio 1 5 14 254 230 2 1 5 61 64 Wisconsin — 1 10 107 122 — 1 4 37 59 Wisconsin — 1 10 107 122 — 1 4 37 59 Wisconsin — 1 1 0 107 122 — 1 4 37 59 Wisconsin — 1 1 0 107 122 — 1 4 37 59 Wisconsin — 1 1 10 107 122 — 1 4 37 59 Wisconsin — 1 1 10 107 122 — 1 1 4 37 59 Wisconsin — 1 1 10 107 122 — 1 1 4 37 59 Wisconsin — 1 1 10 107 122 — 1 1 4 37 59 Wisconsin — 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Illinois	_	4						5		
Dho	Indiana										
Wisconsin											
M.N. Control	Wisconsin										
owa		8	5				4	2	16		
Minnesolat	Iowa	_	0	0	_	_	_	0	0	_	_
Missouri — 2 10 89 84 2 1 2 37 26 North Dakotas — 0 5 12 19 — 0 2 8 1 North Dakota — 0 5 12 19 — 0 2 8 1 North Dakota — 0 5 12 19 — 0 2 8 1 S. Atlantic 9 21 37 1,068 1,230 4 6 6 16 292 388 Delaware — 0 2 9 10 — 0 1 2 3 District of Columbia — 0 4 23 17 — 0 1 2 3 District of Columbia — 0 4 23 17 — 0 1 2 3 District of Columbia — 1 5 66 83 Georgia — 4 14 230 253 — 1 5 66 83 Aurylandid 2 4 8 175 207 — 1 5 66 83 Aurylandid 2 3 10 136 161 N 0 0 N N North Carolina	Kansas										
Nebraskå											
North Dakota	Nebraska [§]										
S. Atlantic 9 21 37 1,068 1,230 4 6 16 292 338 Delaware — 0 4 23 10 — 0 1 2 3 Delictrot Columbia 4 5 10 263 304 3 1 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	North Dakota	_		5	12	19			2		1
Delaware — 0 2 9 9 10 — 0 0 1 2 3 3 15											
District of Columbia — 0 4 23 17 — 0 1 2 3 6 6 6 6 6 6 6 6 8 3 3 4 3 1 4 6 6 8 6 9 6 8 3 3 4 3 1 4 5 6 6 8 3 3 4 3 1 4 5 6 6 8 3 3 4 3 1 4 5 6 6 8 3 3 4 5 7 5 6 6 8 3 3 4 7 7 — 1 5 5 6 6 8 3 4 8 175 207 — 1 5 5 6 6 8 3 4 8 175 207 — 1 5 5 5 8 7 0 8 4 1 1 1 5 5 8 7 3 10 1 3 6 16 1 N 0 0 N N N O O N N N N O O N N N N O O N N N N O O N N N N O O N N N N O O N N N N O O N N N N N O O N N N N N O O N N N N N O O N N N N N O O N	S. Atlantic	9								292	338
Florida		_									3
Marylands 2 4 8 175 207 — 1 5 58 70 North Carolina 2 3 10 136 161 N 0 0 0 N N South Carolinas 1 1 1 5 73 101 1 1 1 4 51 55 Virginias — 3 12 126 150 — 0 1 1 8 8 8 E.S. Central 3 3 3 9 171 208 1 2 11 98 108 Alabamas N 0 0 N N N N 0 0 0 N N N N Kentucky 2 1 1 3 41 39 N 0 0 0 N N N N Kentucky 2 1 1 3 41 39 N 0 0 0 N N N N 1 1 1 9 78 97 W.S. Central 5 9 85 462 316 7 5 66 271 284 Arkansas 5 — 0 2 5 188 — 0 2 10 38 20 11 2 10 38 20 11 2 2 10 38 20 11 2 2 10 38 20 2 10 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Florida	4						1			
Norfh Carolina 2 3 10 136 161 N 0 0 N N N South Carolina 5 1 1 1 5 73 101 1 1 1 4 51 55 South Carolina 6 1 1 1 5 73 101 1 1 1 4 51 55 South Carolina 6 1 1 1 5 73 101 1 1 1 4 51 55 South Carolina 6 1 1 1 5 73 101 1 1 1 1 4 51 55 South Carolina 6 1 1 1 98 108 Rest Virginia	Georgia	_						1			
South Carolinas								1			
Virginias											
E.S. Central 3 3 3 9 171 208 1 2 11 98 108 Alabama\$ N 0 0 0 N N N N 0 0 0 N N N N Sentucky 2 1 3 4 1 39 N 0 0 0 N N N Sentucky 2 1 3 4 1 39 N 0 0 0 N N N Sentucky 2 1 3 4 1 39 N 0 0 0 N N N Sentucky 2 1 1 3 4 1 39 N 0 0 0 N N N Sentucky 2 1 1 3 4 1 39 N 0 0 0 N N N Sentucky 3 2 1 1 3 6 130 169 1 1 9 78 97 8 97 8 97 8 97 8 97 8 97 8	Virginia [§]	_		12	126	150			6		50
Alabama§ N 0 0 N N N N 0 0 0 N N N N Centlucky 2 1 1 3 41 39 N 0 0 0 N N N N Centlucky 2 1 1 3 41 39 N 0 0 0 N N N M Sissispipi N 0 0 0 N N N N	West Virginia	_							-		
Kentucky 2 1 3 41 39 N 0 0 0 N N N S N 16 Start Sippi N 0 0 0 N N N N N N N N N N N N N N N											
Mississippi N 0 0 N N — 0 3 20 11 1 9 78 97 Ennessee\$ 1 1 3 6 130 169 1 1 1 9 78 97 897 M.S. Central 5 9 85 462 316 7 5 66 271 284 Arkansas\$ — 0 2 5 18 — 0 2 7 19 19 10 38 Oklahoma — 2 19 114 66 — 1 7 7 61 58 193 169 169 17 7 3 58 193 169 169 17 1 1 3 25 252 10 1 38 Mountain 4 10 22 535 558 2 4 13 225 252 Arizona 1 3 8 145 140 1 1 1 4 58 51 20 10 20 10 1 5 2 2 8 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1											
W.S. Central	Mississippi										
Arkansas\$ — 0 2 5 18 — 0 2 7 19 19 10 38 Oklahoma — 0 2 16 16 — 0 2 10 38 Oklahoma — 0 2 19 114 66 — 1 7 61 58 Texas\$ 5 6 6 65 327 216 7 3 58 193 169 Texas\$ 5 6 6 65 327 216 7 3 58 193 169 Texas\$ 6 7 3 7 8 11 11 123 Colorado 1 3 9 191 205 1 2 8 111 123 Colorado 1 3 8 145 140 1 1 4 58 111 123 Colorado 1 1 3 8 145 140 1 1 1 4 58 51 Colorado 1 1 3 8 145 140 1 1 1 4 58 51 Colorado 1 1 5 2 2 15 18 — 0 1 1 5 2 2 15 Colorado 1 1 5 2 2 15 18 — 0 1 1 5 2 2 15 Colorado 1 1 5 2 2 15 18 — 0 1 1 5 2 2 15 Colorado 1 1 5 2 2 15 18 18 — 0 1 1 5 2 2 15 Colorado 1 1 5 2 2 15 18 18 — 0 1 1 5 2 2 15 Colorado 1 1 5 2 2 15 18 18 — 0 1 1 5 2 2 15 Colorado 1 1 5 2 2 15 18 18 — 0 1 1 5 2 2 15 Colorado 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Tennessee§	1	3	6	130	169	1	1	9	78	97
Louisiana — 0 2 19 114 66 — 0 2 10 38 Oklahoma — 2 19 114 66 — 1 7 61 58 Fexas 5 5 6 65 327 216 7 3 58 193 169 Mountain 4 10 22 535 558 2 4 13 225 252 Arizona 1 3 9 191 205 1 2 8 111 123 Colorado 1 3 8 145 140 1 1 4 58 51 Colorado 1 3 8 145 140 1 1 4 58 51 Colorado 1 3 8 145 140 1 1 4 58 51 Colorado 1 1 3 8 145 140 1 1 4 58 51 Colorado 1 1 3 8 145 140 1 1 4 58 51 Colorado 1 1 3 8 145 140 1 1 1 4 58 51 Colorado 1 1 1 2 2 1 15 18 — 0 1 1 5 2 Colorado 1 1 2 2 8 111 123 Colorado 1 1 2 2 8 14 11 123 Colorado 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	W.S. Central	5					7				
Oklahoma — 2 19 114 66 — 1 7 61 58 Texas§ 5 6 65 327 216 7 3 58 193 169 Montain 4 10 22 535 558 2 4 13 225 252 Arizona 1 3 8 145 140 1 1 4 58 51 Colorado 1 3 8 145 140 1 1 4 58 51 Iddaho§ — 0 2 15 18 — 0 1 5 2 Montana§ N 0 0 N N — 0 1 4 58 51 Montana§ N 0 0 N N — 0 1 4 58 51 Montana§ 1 2 8		_									
Texas [§] 5 6 65 327 216 7 3 58 193 169 Mountain 4 10 22 535 558 2 4 13 225 252 Arizona 1 3 9 191 205 1 2 8 111 123 Colorado 1 3 8 145 140 1 1 4 58 51 daho§ — 0 2 15 18 — 0 1 5 2 Nontana§ N 0 0 N N N — 0 1 4 1 Newada§ — 0 1 1 12 2 N 0 0 N N N New Mexico§ 1 2 8 97 104 — 0 3 18 43 Hyoming§ — 0 2 7 5 — 0 4 28 32 Wyoming§ — 0 2 7 5 — 0 1 1 1 — 0 Pacific 1 3 8 168 147 — 0 2 19 13 Alaska — 1 4 4 40 25 N 0 0 N N N Hawaii 1 2 8 128 122 — 0 2 19 13 Oregon§ N 0 0 N N N American Samoa — 0 12 30 4 N 0 0 N N American Samoa — 0 12 30 4 N 0 0 N N American Samoa — 0 12 30 4 N 0 0 N N American Samoa — 0 0 12 30 4 N 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 — 14 — 0 0 0 N N American Samoa — 0 0 0 N N N American Samoa — 0 0 N N N American Samoa — 0 0 N N N American Samoa — 0 0 0 N N N American Samoa — 0 0 N N N American Samoa — 0 0 N N N Bo D D D N N N Bo D D D N N N Bo D D N N N Bo D D D D N N N Bo D D D D N N N Bo D D D D D D D D D D D D D D D D D D D	Oklahoma	_									
Arizona 1 3 9 191 205 1 2 8 111 123 Colorado 1 3 8 145 140 1 1 1 4 58 51 61 61 61 61 61 61 61 61 61 61 61 61 61	Texas [§]	5					7	3			
Colorado 1 3 8 145 140 1 1 4 58 51 Idaho§ — 0 2 15 18 — 0 1 5 2 Montana§ N 0 0 N N N — 0 1 4 1 New dad§ — 0 1 12 2 N 0 0 N N New Mexico§ 1 2 8 97 104 — 0 3 18 43 Utah 1 1 5 68 84 — 0 4 28 32 Wyoming§ — 0 2 7 5 — 0 1 1 — Pacific 1 3 8 168 147 — 0 2 19 13 Alaska — 1 4 40 25<	Mountain										
Idaho\$		•									
Montana [§] N 0 0 N N — 0 1 4 1 Nevada [§] — 0 1 12 2 N 0 0 N N New Mexico§ 1 2 8 97 104 — 0 3 18 43 Utah 1 1 5 68 84 — 0 4 28 32 Wyoming§ — 0 2 7 5 — 0 1 1 — Pacific 1 3 8 168 147 — 0 2 19 13 Alaska — 1 4 40 25 N 0 0 N N California — 0 0 — — N 0 0 N N Hawaii 1 2 8 128 122									1		
New Mexico§ 1 2 8 97 104 — 0 3 18 43 Utah 1 1 5 68 84 — 0 4 28 32 Wyoming§ — 0 2 7 5 — 0 1 1 1 — Pacific 1 3 8 168 147 — 0 2 19 13 Alaska — 1 4 40 25 N 0 0 N N N California — 0 0 0 — N N N Hawaii 1 2 8 128 122 — 0 2 19 13 Oregon§ N 0 0 N N N N 0 0 N N N Washington N 0 0 N N N N 0 0 N N N American Samoa — 0 12 30 4 N 0 0 N N American Samoa — 0 12 30 4 N 0 0 N N California — 0 0 0 — 14 — 0 0 0 — — Puerto Rico N 0 0 N N N N N 0 0 0 N N N	Montana [§]	N	0		N	N	_	0		4	1
Utah 1 1 5 68 84 — 0 4 28 32 Wyoming§ — 0 2 7 5 — 0 1 1 — Pacific 1 3 8 168 147 — 0 2 19 13 Alaska — 1 4 40 25 N 0 0 N N California — 0 0 — — N 0 0 N N Hawaii 1 2 8 128 122 — 0 2 19 13 Oregon§ N 0 0 N N N N 0 0 N N Washington N 0 0 N N N N 0 0 N N American Samoa — 0 12 30<		_									
Wyoming§ — 0 2 7 5 — 0 1 1 — Pacific 1 3 8 168 147 — 0 2 19 13 Alaska — 1 4 40 25 N 0 0 N N N California — 0 0 — — N 0 0 N N N Hawaii 1 2 8 128 122 — 0 2 19 13 Oregon§ N 0 0 N N N N 0 0 N N Washington N 0 0 N N N N 0 0 N N American Samoa — 0 12 30 4 N 0 0 N N C.N.M.I. — —<							_				
Alaska — 1 4 40 25 N 0 0 N N California — 0 0 — — N 0 0 N N Hawaii 1 2 8 128 122 — 0 2 19 13 Oregon§ N 0 0 N N N 0 0 N N Washington N 0 0 N N N 0 0 N N American Samoa — 0 12 30 4 N 0 0 N N C.N.M.I. — N N N N	Wyoming§	<u>.</u>					_				_
Alaska — 1 4 40 25 N 0 0 N N California — 0 0 — — N 0 0 N N Hawaii 1 2 8 128 122 — 0 2 19 13 Oregon§ N 0 0 N N N 0 0 N N Washington N 0 0 N N N 0 0 N N American Samoa — 0 12 30 4 N 0 0 N N C.N.M.I. — N N N N	Pacific	1				147		0	2	19	13
Hawaii 1 2 8 128 122 — 0 2 19 13 Oregon§ N 0 0 N N N N 0 0 0 N N N Washington N 0 0 N N N N 0 0 N N N American Samoa — 0 12 30 4 N 0 0 N N C.N.M.I. — — — — — — — — — — — — — — — — — —	Alaska	_	1	4					0	N	N
Oregon\$ N 0 0 N N N 0 0 N N Washington N 0 0 N N N 0 0 N N American Samoa — 0 12 30 4 N 0 0 N N C.N.M.I. —					129	122					
Washington N 0 0 N N N 0 0 N N American Samoa — 0 12 30 4 N 0 0 N N C.N.M.I. —											
C.N.M.I. — — — — — — — — — — — — — — — — — —	Washington										
C.N.M.I. — — — — — — — — — — — — — — — — — —	American Samoa	_	0	12	30	4	N	0	0	N	N
Puerto Rico N 0 0 N N N 0 0 N N	C.N.M.I.	_	_	_	_		_	_	_	_	_
		 NI								NI	 NI
	U.S. Virgin Islands		0	0			N	0	0	N	N

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2008 are provisional.

† Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available (NNDSS event code 11717).

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

(51St week)"		S	Streptococ	cus pneui	noniae, ir	vasive dis	ease, dru	g resistan	t [†]						1
			All ages				Αç	ged <5 yea	ırs		Sy	philis, pr	imary an	d seconda	ıry
			ious					ious					ious		
Reporting area	Current week	Med Med	eeks Max	Cum 2008	Cum 2007	Current week	Med	eeks Max	Cum 2008	Cum 2007	Current week	Med Med	eeks Max	Cum 2008	Cum 2007
United States	48	56	307	2,853	3,022	8	8	43	428	520	44	238	351	11,611	11,115
New England	1	1	49	102	107	_	0	8	13	13	2	5	13	290	268
Connecticut Maine [§]	_	0	48 2	55 17	55 12	_	0	7 1	5 2	4 2	_	0 0	6 2	31 10	33 9
Massachusetts	_	0	0	_	2	_	0	0	_	2	2	4	11	210	153
New Hampshire Rhode Island [§]	_	0	0 3	 16	 21	_	0	0 1	4	3	_	0 0	2 5	19 13	29 35
Vermont§	1	ŏ	2	14	17	_	ő	i	2	2	_	ő	5	7	9
Mid. Atlantic New Jersey	3	4 0	13 0	232	159	_	0	2 0	22	29	3	33 4	51 10	1,620 195	1,524 220
New York (Upstate)	1	1	6	62	52	_	Ō	2	7	10	1	3	13	136	142
New York City Pennsylvania	_	1 2	6 9	71 99	107	_	0 0	0 2	 15	— 19	_	20 5	36 12	1,029 260	900 262
E.N. Central	13	12	64	679	783	_	1	14	90	125	13	20	34	1,005	890
Illinois	_	0	17	71	208	_	0	3	14	47	_	5	14	251	459
Indiana Michigan	6	2 0	39 3	205 17	164 3	_	0 0	11 1	21 2	25 2	2	2 3	10 21	132 227	53 122
Ohio Wisconsin	7	8 0	17 0	386	408	_	1 0	4 0	53 —	51 —	11 —	6 1	15 4	339 56	192 64
W.N. Central	_	3	115	151	245	_	0	9	10	44	_	8	14	372	354
Iowa	_	0	0	_	_	_	0	0	_	_	_	0	2	15	21
Kansas Minnesota	=	0 0	5 114	59 —	90 72	_	0 0	1 9	4	10 26	_	0 2	5 5	30 100	28 57
Missouri Nebraska [§]	_	1 0	8 0	85 —	64 2	_	0	1 0	3	3	_	4 0	10 1	218 8	236 4
North Dakota	_	0	0	_	_	_	0	0	_	_	_	0	0	_	1
South Dakota	_	0	2	7	17	_	0	1	3	5	_	0	1	1	7
S. Atlantic Delaware	25 —	22 0	53 1	1,223 3	1,305 11	6	4 0	12 0	217	242 2	13	52 0	215 4	2,656 15	2,569 17
District of Columbia Florida	 25	0 14	3 30	19 746	21 710	<u> </u>	0 3	1	1 149	1 130	1 3	2 19	9 37	135 980	176 905
Georgia	_	7	23	360	490	_	1	12 5	56	101	_	12	175	581	505
Maryland [§] North Carolina	 N	0	2 0	6 N	1 N	 N	0	1 0	1 N	 N	9	6 5	14 19	320 278	337 305
South Carolina§	_	0	0	_	_	_	0	0	_	_	_	2	6	87	91
Virginia§ West Virginia	N —	0 1	0 9	N 89	N 72	N —	0 0	0 2	N 10	N 8	_	5 0	17 1	258 2	227 6
E.S. Central	4	5	15	264	267	2	1	4	44	37	7	21	37	1,083	912
Alabama [§] Kentucky	N	0 1	0 6	N 73	N 28	N —	0 0	0 2	N 11	N 3	_ 1	8 1	17 7	424 81	376 56
Mississippi	_	0	2	4	59	_	0	1	1	_	_	3	19	170	118
Tennessee§ W.S. Central	4	3 2	13 7	187 87	180 92	2	0	3 2	32 14	34 13	6 4	8 41	19 60	408 2,088	362 1,863
Arkansas§	_	0	4	20	6	_	0	1	4	2	3	2	19	167	121
Louisiana Oklahoma	_ N	1 0	6 0	66 N	86 N	 N	0	2 0	9 N	11 N	1	10 1	30 5	531 54	530 65
Texas§	_	Ö	1	1		_	Ő	1	1	_	_	26	47	1,336	1,147
Mountain Arizona	2	2	15 0	113	61	_	0	4	16	14	2	8 4	16 12	415 200	533 291
Colorado	-	0	0	-		-	0	0	-	-	_	2	7	92	57
Idaho§ Montana§	N	0 0	0 1	N 1	N	N	0 0	0 0	N —	N	_	0	2 0	6	1 8
Nevada§	N	0	0	N	N	N	0	0	N	N	2	1	6	73	108
New Mexico [§] Utah		0 1	1 14	2 106	<u> </u>	_	0	0 4	 16	11	_	1 0	4 2	40 1	46 18
Wyoming§	_	0	1	4	17	_	0	0	_	3	_	0	1	3	4
Pacific Alaska	 N	0	1 0	2 N	3 N	 N	0	1 0	2 N	3 N	_	44 0	64 1	2,082 1	2,202 7
California	N	0	0	N	N	N	0	0	N	N	_	38	58	1,877	2,017
Hawaii Oregon [§]	 N	0	1 0	2 N	3 N	 N	0 0	1 0	2 N	3 N	_	0 0	2	20 24	9 18
Washington	N	0	0	N	N	N	0	0	N	N	_	3	9	160	151
American Samoa C.N.M.I.	N	0	0	N	N	N	0	0	N	N	_	0	0	_	4
Guam	_	0	0	=	=	_	0	0	_	_	_	0	0	_	_
Puerto Rico U.S. Virgin Islands	_	0 0	0 0	_	_	_	0 0	0	_	_	5	3 0	11 0	163	159
O.S. Virgin Islands		U	U				U					U	U		

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Max* Incidence data for reporting year 2008 are provisional.

† Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720).

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 20, 2008, and December 22, 2007 (51st week)*

									W	est Nile v	irus diseas				
		Varice	ella (chick	enpox)				uroinvasi	ive			Noni	neuroinva	sive§	
			vious				Prev						ious		
Reporting area	Current week	Med Med	veeks Max	Cum 2008	Cum 2007	Current week	Med Med	eeks Max	Cum 2008	Cum 2007	Current week	Med Med	eeks Max	Cum 2008	Cum 2007
United States	348	501	1,660	26,295	38,486	- Week	1	80	639	1,227	- Week	2	82	717	2,402
New England	3	11	51	512	2,505	_	0	2	6	5	_	0	1	3	6
Connecticut	_	0	28	_	1,412	_	0	2	5	2	_	0	1	3	2
Maine [¶] Massachusetts	_	0	9 1	_ 1	356	_	0 0	0 0	_	3	_	0	0 0	_	3
New Hampshire	_	5	13	238	366	_	Ö	Ö	_	_	_	Ö	Ö	_	_
Rhode Island¶	_	0	0		074	_	0	1	1	_	_	0	0	_	1
Vermont [¶] Mid. Atlantic	3 39	6 45	17 81	273 2,209	371 4,632	_	0 0	0 8	46	 22	_	0 0	0 5	— 19	— 11
New Jersey	N	0	0	2,209 N	4,032 N	_	0	1	3	1	_	0	1	4	
New York (Upstate)	N	0	0	N	N	_	0	5	23	3	_	0	2	7	1
New York City Pennsylvania	N 39	0 45	0 81	N 2,209	N 4,632	_	0 0	2 2	8 12	13 5	_	0	2 1	6 2	5 5
E.N. Central	76	141	336	6,887	10,973	_	0	8	41	113	_	0	3	20	65
Illinois	1	22	63	1,324	1,089	_	0	4	11	63	_	0	2	8	38
Indiana Michigan	29	0 58	222 116	2,740	222 4,150	_	0 0	1 4	2 11	14 16	_	0 0	1 2	1 6	10 1
Ohio	46	47	106	2,339	4,492	_	0	3	14	13	_	0	1	1	10
Wisconsin	_	4	50	484	1,020	_	0	1	3	7	_	0	1	4	6
W.N. Central lowa	7 N	22 0	145 0	1,269 N	1,588 N	_	0	6 2	43 3	249 12	_	0 0	22 1	161 3	739 18
Kansas	_	6	40	444	585	_	Ö	2	8	14	_	ő	4	30	26
Minnesota		0	0	756	010	_	0	2 3	2	44	_	0	4	8	57
Missouri Nebraska [¶]	, N	11 0	51 0	756 N	919 N	_	0 0	ა 1	12 5	61 21	_	0 0	1 8	7 44	16 142
North Dakota	_	0	140	49	_	_	0	2	2	49	_	0	12	41	320
South Dakota	_	0	5	20	84	_	0	5	11	48	_	0	6	28	160
S. Atlantic Delaware	82	89 1	173 5	4,540 44	5,173 49	_	0 0	3 0	14	43 1	_	0 0	3 1	14 1	39
District of Columbia	-	0	3	23	31	_	0	0	_	_	_	0	Ô	_	_
Florida Georgia	68 N	29 0	87 0	1,687 N	1,297 N	_	0 0	2 1	2 4	3 23	_	0	0 1	4	 27
Maryland [¶]	N	Ö	0	N	N		0	2	7	6	_	0	2	7	4
North Carolina	N	0	0	N	N	_	0	0	_	4	_	0	0	_	4
South Carolina [¶] Virginia [¶]	14	14 21	67 81	833 1,295	1,093 1,509	_	0	0 0	_	3 3	_	0 0	1 1	1 1	2 2
West Virginia	_	12	36	658	1,194	_	Ö	1	1	_	_	Ö	Ö		_
E.S. Central	_	18	101	1,089	697	_	0	9	56	76	_	0	12	84	99
Alabama ¹ Kentucky	N	18 0	101 0	1,076 N	695 N	_	0 0	3 1	11 3	17 4	_	0 0	3 0	10	7
Mississippi	_	Ö	2	13	2	_	Ö	6	32	50	_	Ö	10	67	86
Tennessee [¶]	N	0	0	N	N	_	0	1	10	5	_	0	3	7	6
W.S. Central Arkansas ¹	90	110 8	886 38	7,530 514	10,106 776	_	0	7 1	56 7	269 13	_	0 0	8 1	58 2	158 7
Louisiana		1	10	69	121	_	Ö	2	9	27	_	0	6	27	13
Oklahoma	N	0	0	N	N	_	0	1	2	59	_	0	1	5	48
Texas [¶]	90	98 40	852	6,947	9,209 2,733	_	0 0	6 13	38 103	170 289	_	0 0	4 24	24 198	90 1,040
Mountain Arizona	49 —	0	90 0	2,121	2,733	_	0	10	62	289 50	_	0	24 8	47	47
Colorado	26	14	43	837	1,086	_	0	4	17	99	_	0	13	78	477
Idaho [¶] Montana [¶]	N 2	0 5	0 27	N 328	N 417	_	0 0	1 0	3	11 37	_	0 0	6 2	30 5	120 165
Nevada [¶]	N	0	0	N	N	_	Ö	2	9	2	_	Ö	3	7	10
New Mexico [¶]		3	18	207	422	_	0	2	6	39	_	0	1	3	21
Utah Wyoming [¶]	21 —	13 0	55 4	739 10	774 34	_	0	2 0	6	28 23	_	0 0	5 2	20 8	42 158
Pacific	2	2	8	138	79	_	0	38	274	161	_	0	24	160	245
Alaska	2	1	6	74	42	_	0	0	270	154	_	0	0	146	_
California Hawaii	_	0 1	0 6	64	37	_	0 0	38 0	270	154	_	0 0	19 0	146	226
Oregon [¶]	N	Ö	0	N	N	_	0	2	3	7	_	0	4	13	19
Washington	N	0	0	N	N	_	0	1	1	_	_	0	1	1	_
American Samoa C.N.M.I.	<u>N</u>	0	0	_N	_N	_	0	0	=	=	_	0	0	_	=
Guam	_	1	17	63	236	_	0	0	_	_	_	0	0	_	_
Puerto Rico	_	7	20	402	712	_	0	0	_	_	_	0	0	_	_
U.S. Virgin Islands		0	0				0	0				0	0		

U: Unavailable. —: No reported cases. N: Not notifiable.

* Incidence data for reporting year 2008 are provisional. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

[†] Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

[§] Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.

¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE III. Deaths in 122 U.S. cities.* week ending December 20, 2008 (51st week)

		All cau	ises, by a	ige (year	s)					All cau	ses, by a	age (yea	rs)		-
Reporting area	All Ages	≥65	45–64	25–44	1–24	<1	P&I [†] Total	Reporting area	All Ages	≥65	45–64	25–44	1–24	<1	P&I [†] Total
New England	479	336	97	28	7	11	50	S. Atlantic	1,181	744	262	111	31	32	73
Boston, MA	122	76	32	11	1	2	13	Atlanta, GA	136	83	30	19	3	1	_
Bridgeport, CT	42	31	7	2	2	_	4	Baltimore, MD	175	101	43	20	6	5	16
Cambridge, MA	14	13	1	_	_	_	6	Charlotte, NC	112	65	26	13	3	5	10
Fall River, MA	28	22 39	6 11	4	2	2	2 6	Jacksonville, FL	199 U	133 U	36 U	21 U	4 U	5 U	19 U
Hartford, CT Lowell, MA	58 17	10	4	1	_	2	-	Miami, FL Norfolk, VA	48	33	10	_	_	5	2
Lynn, MA	7	6	1		_	_	2	Richmond, VA	83	47	25	5	3	3	4
New Bedford, MA	19	18		_	1	_	2	Savannah, GA	48	33	5	4	1	5	5
New Haven, CT	Ü	Ü	U	U	Ú	U	Ū	St. Petersburg, FL	58	33	14	8	_	2	5
Providence, RI	46	33	8	3	1	1	2	Tampa, FL	212	155	42	9	6	_	9
Somerville, MA	1	_	1	_	_	_	_	Washington, D.C.	100	57	27	11	4	1	3
Springfield, MA	39	22	13	2	_	2	4	Wilmington, DE	10	4	4	1	1	_	_
Waterbury, CT	24	18	5	1	_	_	1	E.S. Central	948	646	211	64	14	13	56
Worcester, MA	62	48	8	4	_	2	8	Birmingham, AL	161	113	33	10	_	5	9
Mid. Atlantic	2,269	1,568	496	122	42	41	119	Chattanooga, TN	89	73	15	_	1	_	3
Albany, NY	62	48	9	3	_	2	2	Knoxville, TN	157	101	41 17	12	2	1	10
Allentown, PA Buffalo, NY	39 85	32 63	5 17	1 2	1	3	3 8	Lexington, KY Memphis, TN	84 140	55 93	17 33	8 11	3 2	1 1	6 9
Camden, NJ	22	17	2	2	_	ა 1	1	Mobile, AL	93	58	26	6	2	1	6
Elizabeth, NJ	23	15	6	2	_		2	Montgomery, AL	43	36	5	2	_		4
Erie, PA	54	40	12	1	1		5	Nashville, TN	181	117	41	15	4	4	9
Jersey City, NJ	28	19	7	i	i	_	1	W.S. Central	1,438	899	382	105	32	20	85
New York City, NY	1,083	746	242	52	23	20	39	Austin, TX	98	66	25	7	_	_	10
Newark, NJ	32	18	8	4	1	1	6	Baton Rouge, LA	U	U	U	U	U	U	U
Paterson, NJ	18	8	5	2	_	3	2	Corpus Christi, TX	U	U	U	U	U	U	U
Philadelphia, PA	381	217	112	37	9	6	15	Dallas, TX	169	95	49	15	7	3	8
Pittsburgh, PA§	31	23	7	1	_	_	3	El Paso, TX	127	84	30	6	1	6	4
Reading, PA	41	29	11	1	_	_	6	Fort Worth, TX	143	91	40	11	1	_	10
Rochester, NY	128	97	20	6	2	3	10	Houston, TX	438	255	124	37	12	10	22
Schenectady, NY	28	24	4	_	_	_	3	Little Rock, AR	U	U	U	U	U	U	U
Scranton, PA	35	30	3	_	2	_	2	New Orleans, LA¶	U	U	U	U	U	U	U
Syracuse, NY	112	85	18	5	2	2	5	San Antonio, TX	285	186	74	18	7	1	21
Trenton, NJ Utica, NY	32 17	25 16	6 1	1	_	_	1 3	Shreveport, LA Tulsa, OK	61 117	46 76	12 28	2 9	<u> </u>		5 5
Yonkers, NY	18	16	i	1	_	_	2	Mountain	1,021	678	233	62	27	21	69
E.N. Central	1,923	1,334	430	92	31	35	133	Albuquerque, NM	1,021 U	U	233 U	U	Ü	Ü	Ü
Akron, OH	58	44	13	_	1	_	3	Boise, ID	69	54	6	5	2	2	6
Canton, OH	48	35	7	4	_	2	3	Colorado Springs, CO	90	61	22	5	1	1	4
Chicago, IL	269	164	76	15	5	8	17	Denver, CO	78	48	17	6	3	4	7
Cincinnati, OH	93	58	21	4	6	4	5	Las Vegas, NV	245	167	57	14	1	6	19
Cleveland, OH	264	179	64	11	4	6	8	Ogden, UT	23	15	7	_	_	1	5
Columbus, OH	218	133	67	14	1	3	18	Phoenix, AZ	229	144	57	16	8	4	17
Dayton, OH	129	101	22	4	2		11	Pueblo, CO	29	19	8	2	_	_	1
Detroit, MI	U	U	ñ	U	U	U	U	Salt Lake City, UT	99	66	21	6	4	2	4
Evansville, IN	59	52	5	2	_	_	13	Tucson, AZ	159	104	38	8	8	1	6
Fort Wayne, IN Gary, IN	74 15	54 8	14 5	4	1	2	1 1	Pacific Berkeley, CA	1,564 16	1,099 10	322 4	88 1	28	27 1	150 2
Grand Rapids, MI	63	48	13	1		1	6	Fresno, CA	144	96	36	8	3	1	15
Indianapolis, IN	214	144	51	13	4	2	11	Glendale, CA	32	27	5	_	_		8
Lansing, MI	47	36	10	_	1	_	6	Honolulu, HI	77	59	13	2	1	2	6
Milwaukee, WI	70	43	18	8	_	1	5	Long Beach, CA	62	40	16	4	1	1	9
Peoria, IL	50	34	7	5	1	3	4	Los Angeles, CA	222	145	45	17	10	5	19
Rockford, IL	51	41	7	_	1	2	6	Pasadena, CA	25	19	6	_	_	_	4
South Bend, IN	54	43	6	4	1	_	3	Portland, OR	128	93	28	6	1	_	6
Toledo, OH	88	71	13	2	2	_	7	Sacramento, CA	202	140	38	15	2	7	18
Youngstown, OH	59	46	11	1	1	_	5	San Diego, CA	181	123	34	13	6	5	17
W.N. Central	722	464	185	44	12	17	56	San Francisco, CA	120	79	31	8	1	1	12
Des Moines, IA	119	90	23	4	2	_	13	San Jose, CA	186	149	27	7	1	2	20
Duluth, MN	44	29	11	4	_	_	3	Santa Cruz, CA	27	17	10	-	-		6
Kansas City, KS	28	11	10	6	_	1	2	Seattle, WA	U	U	U	U	Ų	Ų	ñ
Kansas City, MO	99	54	33	8	3	1	5	Spokane, WA	48	37	8	1	1	1	5
Lincoln, NE	48	37	9	2	_	_	4	Tacoma, WA	94	65	21	6	1	1	3
Minneapolis, MN	73	44	17	4	1	7	6	Total**	11,545	7,768	2,618	716	224	217	791
Omaha, NE	96	70	19	6	1	7	12	I							
St. Louis, MO St. Paul, MN	99 57	46 45	36 10	7 2	3		5 2	1							
Wichita, KS	57 59	45 38	17	1	2	1	4	1							
vvicilia, NO	29	30	17			- 1	4	L							

U: Unavailable. —:No reported cases.

* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

[§] Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

¹¹ Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted.

** Total includes unknown ages.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 27, 2008 (52nd week)*


	Current	Cum	5-year weekly	repo	To orted fo	tal cas or prev		ears_	
Disease	week	2008	average†	2007	2006	2005	2004	2003	States reporting cases during current week (No.)
Anthrax	_	_	_	1	1	_	_		
Botulism:									
foodborne	_	12	0	32	20	19	16	20	
infant	_	97	2	85	97	85	87	76	
other (wound & unspecified)	_	22	1	27	48	31	30	33	-
Brucellosis	1	86	3	131	121	120	114	104	FL (1)
Chancroid	_	31	0	23	33	17	30	54	
Cholera	_	2	0	7	9	8	6	2	FL (0)
Cyclosporiasis [§] Diohtheria	3	126	2	93	137	543	160	75	FL (3)
Diprimena Domestic arboviral diseases ^{§,¶} :	_	_	_	_	_	_	_	1	
California serogroup	_	40	0	55	67	80	112	108	
eastern equine	_	2	_	4	8	21	6	14	
Powassan	_	1	_	7	1	1	1		
St. Louis	_	8	_	9	10	13	12	41	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis/Anaplasmosis§,**:									
Ehrlichia chaffeensis	2	837	17	828	578	506	338	321	FL (2)
Ehrlichia ewingii	_	9	_	_	_	_	_	_	• •
Anaplasma phagocytophilum	6	462	27	834	646	786	537	362	NY (5), FL (1)
undetermined	1	69	2	337	231	112	59	44	NY (1)
Haemophilus influenzae,††									
invasive disease (age <5 yrs):									
serotype b	_	28	1	22	29	9	19	32	
nonserotype b	1	167	4	199	175	135	135	117	FL (1)
unknown serotype	1	177	5	180	179	217	177	227	GA (1)
Hansen disease§	_	69	2	101	66	87	105	95	
Hantavirus pulmonary syndrome§	_	14	1	32	40	26	24	26	TAL (4)
Hemolytic uremic syndrome, postdiarrheal§	1	226	7	292	288	221	200	178	TN (1)
Hepatitis C viral, acute	3	806	25	849	766	652		1,102	MI (1), WA (2)
HIV infection, pediatric (age <13 years)§§	_	_	3		40	380	436	504	MANI (4)
Influenza-associated pediatric mortality ^{§,¶¶} Listeriosis	1 5	91 636	1 19	77 808	43 884	45 896	— 753	N 696	MN (1) NN (1) BA (1) EL (1) MA (2)
Measles***	_	132	1	43	55	66	37	56	NY (1), PA (1), FL (1), WA (2)
Meningococcal disease, invasive ^{†††} :	_	132	'	43	55	00	37	50	
A, C, Y, & W-135	2	269	7	325	318	297	_	_	CO (1), WA (1)
serogroup B	_	149	6	167	193	156	_	_	33 (1), 1111 (1)
other serogroup	_	30	1	35	32	27	_	_	
unknown serogroup	1	581	22	550	651	765	_	_	ID (1)
Mumps	2	376	17		6,584	314	258	231	WÀ (2)
Novel influenza A virus infections	_	1	_	4	N	N	N	N	()
Plague	_	1	0	7	17	8	3	1	
Poliomyelitis, paralytic	_	_	_	_	_	1	_	_	
Polio virus infection, nonparalytic§	_	_	_	_	N	Ν	Ν	Ν	
Psittacosis§	_	12	0	12	21	16	12	12	
Qfever total ^{§,§§§} :	_	114	3	171	169	136	70	71	
acute	_	102	_	_	_	_	_	_	
chronic	_	12	_	_	_	_	_	_	
Rabies, human	_	. 1	0	. 1	3	2	7	2	
Rubella ^{¶¶¶}	1	17	0	12	11	11	10	7	WA (1)
Rubella, congenital syndrome	_	_	_	_	1	1	_	1	
SARS-CoV [§] ,****	_	_	_	_	_	_	_	8	
Smallpox§	_		_	100	105	100	100	_	011(4)
Streptococcal toxic-shock syndrome§	1	126	4 9	132 430	125	129	132	161	OH (1)
Syphilis, congenital (age <1 yr)	_	227			349	329	353	413	
Tetanus Toxic-shock syndrome (stanbylococcal)§	_	15 67	1 3	28 92	41 101	27	34	20 133	
Toxic-shock syndrome (staphylococcal)§ Trichinellosis	_	67 7	0	92 5	15	90 16	95 5	133	
Trichinellosis Tularemia	1	104	3	137	95	154	134	129	WA (1)
Tularemia Typhoid fever	1	376	8	434	353	324	322	356	WA (1) WA (1)
Typhold level Vancomycin-intermediate <i>Staphylococcus aureus</i> §		33	0	37	6	2	322	336 N	ma (i)
Vancomycin-intermediate <i>Staphylococcus aureus</i> § Vancomycin-resistant <i>Staphylococcus aureus</i> §	_		0	2	1	3	1	N	
Vibriosis (noncholera <i>Vibrio</i> species infections)§	4	442	5	447	N	N	N	N	FL (4)
Yellow fever	_	442	_	771	1.4	1.4	1.4	11	. – (' /

See Table I footnotes on next page.

TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 27, 2008 (52nd week)*

- -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.
 - * Incidence data for reporting year 2008 are provisional, whereas data for 2003, 2004, 2005, 2006, and 2007 are finalized.
 - † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
 - Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 and 2008 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
 - Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
- ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to *E. chaffeensis*); Ehrlichiosis, human granulocytic (analogous to *Anaplasma phagocytophilum*), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of *E. ewingii*).
- †† Data for H. influenzae (all ages, all serotypes) are available in Table II.
- §§ Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
- 11 Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. One influenza-associated pediatric death was reported for the current 2008-09 season.
- *** No measles cases were reported for the current week.
- ††† Data for meningococcal disease (all serogroups) are available in Table II.
- §§§ In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases.
- 111 The one rubella case reported for the current week was unknown.
- **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals December 27, 2008, with historical data



^{*} Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data Team

Patsy A. Hall

Deborah A. Adams
Willie J. Anderson
Lenee Blanton
Rosaline Dhara
Michael S. Wodajo
Pearl C. Sharp

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007 (52nd week)*

(52nd week)*			Chlamy	rdia [†]			Cocc	idiodomy	cosis			Cryp	otosporidi	osis	
		Prev	rious		-		Prev	/ious				Prev			
Danieline ere	Current		eeks	Cum	Cum	Current		eeks	Cum	Cum	Current	52 W		Cum	Cum
Reporting area United States	week 4,487	Med 21,410	28 892	2008 1,066,132	2007 1 108 374	week 96	Med 122	Max 341	2008 7,022	2007 8,121	week 34	Med 104	Max 429	2008 7,659	2007 11,170
New England Connecticut Maine Massachusetts New Hampshire Rhode Island Vermont	638 221 — 325 20 60 12	707 202 51 329 41 55	1,516 1,093 72 623 64 208 52	37,041 11,204 2,484 17,276 2,083 3,176 818	36,429 11,454 2,541 16,145 2,055 3,177 1,057	N N N N	0 0 0 0 0 0	1 0 0 0 1	1 N N N 1 —	2 N N N 2 — N	- - - - - -	5 0 0 1 1 0	40 38 6 9 4 3	300 38 45 91 56 10	335 42 56 132 47 11 47
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	852 139 391 — 322	2,752 442 532 993 811	5,069 576 2,177 3,412 1,054	145,326 21,651 27,288 55,354 41,033	144,722 21,536 29,975 50,742 42,469	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	5 -2 - 3	12 0 4 2 5	34 2 17 6 15	709 26 262 102 319	1,365 67 254 105 939
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	657 9 226 383 34 5	3,469 1,067 377 841 812 317	4,283 1,328 713 1,226 1,261 615	172,777 49,405 20,525 44,011 42,301 16,535	180,524 55,470 20,712 37,353 47,434 19,555	N N — N	1 0 0 0 0	3 0 0 3 1	42 N N 31 11	36 N N 24 12 N	3 — 1 — 2	25 2 3 5 6 9	124 13 41 13 59 46	2,016 178 185 270 682 701	1,921 201 149 211 570 790
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	528 57 179 — 214 78 —	1,260 174 178 264 490 78 31 54	1,696 240 529 373 566 244 58 85	63,637 9,057 9,128 12,245 24,379 4,386 1,625 2,817	63,085 8,643 8,180 13,413 23,308 5,132 1,789 2,620	N N — — N N	0 0 0 0 0 0	77 0 0 77 1 0 0	3 N N - 3 N N N	86 N N 77 9 N N	1 - - - 1 -	16 4 1 4 3 2 0 1	71 30 8 15 13 8 51	961 279 82 224 174 113 7 82	1,659 610 144 302 182 174 78 169
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	766 61 523 — — — — 182	3,578 67 125 1,367 205 433 0 465 621 59	7,609 150 207 1,571 1,301 696 4,783 3,045 1,059 101	185,663 3,736 6,580 68,565 19,914 22,158 5,901 25,537 30,272 3,000	217,935 3,479 6,029 57,575 42,913 23,150 30,611 26,431 24,579 3,168	 	0 0 0 0 0 0	1 1 0 0 0 1 0 0 0	4 1 N N 3 N N N	5 2 N 3 N N N	18 — 15 2 — — 1	17 0 0 7 4 1 0 1	46 2 2 35 13 4 16 4 4 3	994 11 11 478 233 45 77 49 69 21	1,287 20 3 667 239 36 132 88 90
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	203 — — — 203	1,575 456 242 399 534	2,302 561 373 1,048 791	82,392 22,240 11,989 20,614 27,549	82,503 25,153 8,798 21,686 26,866	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	1 1 —	3 1 0 0 1	9 6 4 2 6	163 67 35 17 44	616 125 249 102 140
W.S. Central Arkansas [§] Louisiana Oklahoma Texas [§]	174 128 — 46 —	2,793 276 388 165 1,948	4,426 455 775 392 3,923	137,756 13,501 20,626 7,816 95,813	127,631 9,954 19,362 12,529 85,786	N N N	0 0 0 0	1 0 1 0 0	3 N 3 N N	3 N 3 N N	1 1 — —	5 0 1 1 2	154 6 5 16 139	1,609 39 61 132 1,377	487 63 64 127 233
Mountain Arizona Colorado Idaho [§] Montana [§] Nevada [§] New Mexico [§] Utah Wyoming [§]	344 133 200 — — — — — — — 11	1,265 458 212 61 59 178 132 107 30	1,811 651 587 314 363 416 561 253 58	63,701 22,792 11,405 3,797 2,822 9,054 7,353 4,979 1,499	74,414 24,866 17,186 3,722 2,748 9,514 9,460 5,721 1,197	96 96 N N N	86 86 0 0 0 0	186 186 0 0 0 6 3 3	4,684 4,600 N N N 45 28 9	4,998 4,832 N N N 72 23 68	1 - 1 - - -	8 1 1 1 1 0 1 0	37 9 12 5 6 1 23 6 4	521 90 110 66 41 1 150 46	2,922 53 211 464 75 37 125 1,901 56
Pacific Alaska California Hawaii Oregon§ Washington	325 55 — — 167 103	3,684 85 2,880 103 188 356	4,676 129 4,115 160 631 634	177,839 4,419 139,600 5,125 10,452 18,243	181,131 4,911 141,928 5,659 9,849 18,784	N N N N	31 0 31 0 0	217 0 217 0 0 0	2,285 N 2,285 N N N	2,991 N 2,991 N N N	4 4	8 0 5 0 1	29 1 14 1 4 16	386 3 234 2 52 95	578 4 303 6 126 139
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands		0 4 116 12	20 — 24 333 23	73 124 6,726 502	95 822 7,909 150	N — N —	0 0 0 0	0 0 0 0	N — N —	N — N —	N — N —	0 0 0 0	0 0 0 0	N — N —	N — N —

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2008 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.

† Chlamydia refers to genital infections caused by *Chlamydia trachomatis*.

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007 (52nd week)*

			Giardiasi	s				Gonorrhe	ea				es, all ser	zae, invas otypes†	ive
	_		/ious /eeks	_	_	_		vious veeks	_		_		ious eeks	_	
Reporting area	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007
United States	99	303	1,158	16,843	19,417	1,068	5,920	8,913	292,509	355,991	12	46	173	2,486	2,541
New England	2	24	49	1,217	1,461	83	97	227	5,159	5,744	_	3	12	146	188
Connecticut Maine [§]		6 3	11 12	291 184	370 197	39	50 2	199 6	2,522 92	2,327 118	_	0 0	9 2	42 17	54 13
Massachusetts	_	9	17	343	605	40	39	69	2,113	2,695	_	1	5	57	89
New Hampshire Rhode Island§	_	2 1	11 8	142 87	33 85	4	2 6	6 13	98 301	138 402	_	0	1 7	9 13	18 10
Vermont§	_	3	13	170	171	_	0	3	33	64		0	3	8	4
Mid. Atlantic	21	60	131	3,141	3,283	181	621	1,028	32,143	36,479	5	10	31	496	491
New Jersey New York (Upstate)	 12	7 21	14 111	302 1,195	403 1,275	21 93	100 117	167 545	5,152 5,976	6,076 7,389	_ 1	1 3	7 22	71 152	70 153
New York City	1	15	29	804	847	-	178	633	10,225	10,308		2	6	88	103
Pennsylvania	8	15	46	840	758	67	214	394	10,790	12,706	4	4	8	185	165
E.N. Central	19	48	86 31	2,531	2,867	271	1,211	1,648	61,459	72,903	_	7	28 7	364	401 124
Illinois Indiana	 N	11 0	0	604 N	866 N	1 86	360 147	481 284	17,102 8,130	20,813 8,790	_	2 1	20	113 71	78
Michigan	2	11	22	588	620	176	327	657	16,728	15,482	_	0	2	21	31
Ohio Wisconsin	12 5	17 8	31 19	892 447	826 555	4 4	283 86	531 176	15,013 4,486	21,066 6,752	_	2	6 2	132 27	108 60
W.N. Central	2	28	621	1,951	2,237	107	314	425	16,113	19,356		3	24	190	161
Iowa	_	6	18	318	301	10	29	48	1,571	1,928	_	0	1	2	1
Kansas Minnesota	_	3 0	11 575	157 666	184 913	31 —	40 55	130 92	2,269 2.648	2,282 3,459	_	0	3 21	16 58	11 82
Missouri	_	8	22	451	515	47	149	199	7,845	9,876	_	1	6	72	42
Nebraska [§]	2	4	10	209	160	19	25	47	1,319	1,434	_	0	2	29	19
North Dakota South Dakota	_	0 2	36 10	23 127	60 104	_	2 7	6 15	113 348	116 261	_	0 0	3 0	13	6
S. Atlantic	27	54	87	2,823	3,088	226	1,177	3,072	62,303	85,787	5	12	29	657	620
Delaware	_	1	3	40	41	21	19	44	1,022	1,293	_	0	2	7	8
District of Columbia Florida	<u> </u>	1 24	5 57	56 1,357	74 1,268	143	48 447	101 522	2,575 22,620	2,373 23,327	3	0 3	2 9	11 189	3 168
Georgia	_	9	27	557	681	_	111	523	7,579	17,835	2	2	9	138	127
Maryland [§] North Carolina	2 N	5 0	12 0	254 N	269 N	_	116 0	206 1,949	5,990 2,638	6,768 16,666	_	2 1	6 9	92 76	88 59
South Carolina§		2	6	130	121	_	180	830	9,103	10,326	_	i	7	49	59 57
Virginia [§]	4	7	39	373	582	62	182	486	10,080	6,269	_	1	6	74	80
West Virginia	_	1	5	56	52		13	26	696	930	_	0	3	21	30
E.S. Central Alabama§	3	8 5	21 12	453 250	576 273	49 —	558 172	837 250	29,136 8,756	32,212 10,885	_	3 0	8 2	129 21	140 29
Kentucky	N	0	0	N	N	_	90	153	4,494	3,449	_	0	1	2	10
Mississippi Tennessee§	N 3	0 3	0 13	N 203	N 303	49	134 162	401 297	7,241 8,645	8,314 9,564	_	0 2	2 6	13 93	10 91
W.S. Central	2	8	41	434	469	53	947	1,355	46,625	52,205	_	2	29	103	131
Arkansas [§]	2	2	8	136	158	39	86	167	4,355	4,168	_	0	3	10	12
Louisiana Oklahoma	_	2 3	10 35	136 162	139 172	 14	166 56	317 124	8,760 2,955	11,137 4,827	_	0 1	2 21	10 73	14 91
Texas§	N	0	0	N	N	_	629	1,102	30,555	32,073	_	ó	3	10	14
Mountain	11	26	62	1,511	1,887	65	207	338	10,278	13,884	1	5	14	283	261
Arizona	 8	2	8 27	139 548	192 580	12 53	62 57	93 100	3,188	5,062	_ 1	2	11 4	109	91 58
Colorado Idaho [§]	1	10 3	14	192	223	_	3	13	3,017 173	3,376 269	_	1 0	4	55 12	8
Montana [§]	_	1	9	84	112	_	2	10	106	122	_	Ö	1	4	2
Nevada [§] New Mexico [§]	_	1 1	8 7	90 85	146 119	_	39 24	130 104	2,051 1,200	2,357 1,796	_	0 0	2 4	14 40	12 43
Utah	2	6	22	346	466	_	10	20	426	821	_	1	5	45	41
Wyoming§	_	0	3	27	49	_	2	9	117	81	_	0	2	4	6
Pacific Alaska	12	53 2	185 10	2,782 102	3,549 79	33 8	599 10	759 17	29,293 515	37,421 579	1	2 0	7 2	118 17	148 15
California	_	35	91	1,792	2,336	_	499	657	24,320	31,294	_	0	3	24	48
Hawaii	_	1	4	41	77	_	11	22	550	659	1	0	2	21	12
Oregon [§] Washington	 12	8 8	18 87	434 413	462 595	9 16	23 53	48 90	1,205 2,703	1,236 3,653	_	1 0	4 3	53 3	67 6
American Samoa	_	0	0	_	_	_	0	1	3	3	_	0	0	_	_
C.N.M.I.	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_
Guam Puerto Rico	_	0 2	0 13	 151	2 371	_	1 5	15 25	73 269	142 323	_	0 0	0	_	1 2
	_	~	10	101	3/1	_	5	20	209	323	_	U	U	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Med: * Incidence data for reporting year 2008 are provisional.

† Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007 (52nd week)*

(52nd week)"				Hepat	itis (viral,	acute), by	type†								
			Α					В					egionellos	sis	
			rious reeks		•			rious reeks	•				rious reeks		•
Reporting area	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007
United States	7	47	171	2,315	2,979	22	66	259	3,383	4,519	15	43	145	2,750	2,716
New England	_	2	7 4	101 26	131 26	_	1 0	7 7	62 23	125 38	_	2	16 5	140	165 44
Connecticut Maine [§]	_	0	2	11	5	_	0	2	13	19	_	0	2	46 9	9
Massachusetts New Hampshire	_	0	5 2	38 12	66 12	_	0	1 2	9 11	42 5	_	0 0	2 5	13 27	50 8
Rhode Island [§] Vermont [§]	_	0	2 1	12	14	_	0	1	4 2	16 5	=	0	14 1	40 5	45 9
Mid. Atlantic	2	6	12	300	455	3	9	14	421	561	9	13	59	937	842
New Jersey New York (Upstate)	_	1	4 6	59 64	124 79	_ 1	2 1	7 4	115 65	162 89	<u> </u>	1 5	8 19	103 329	116 234
New York City	1	2	6	108	156	_	2	6	92	122	_	1	12	116	184
Pennsylvania E.N. Central	1 1	1 6	6 16	69 317	96 343	2 1	3 8	8 13	149 406	188 457	5 2	6 10	33 40	389 568	308 608
Illinois		1	10	98	118	_	2	6	112	129	_	1	8	73	111
Indiana Michigan	_	0 2	4 7	21 116	28 97	_	1 2	6 6	49 127	64 120	_	1 2	7 16	52 158	71 172
Ohio Wisconsin	1	1 0	4 2	51 31	68 32	1	2	8 1	112 6	124 20	2	4 0	18 3	267 18	215 39
W.N. Central	_	4	29	243	201	_	2	9	103	121	_	2	9	136	118
Iowa Kansas	_	1 0	7 3	105 14	48 11	_	0 0	2 3	17 7	26 9	_	0	2 1	18 2	11 10
Minnesota	_	0	23	37	93	_	0	5	14	25	_	0	4 7	23	30
Missouri Nebraska [§]	_	1 0	3 5	43 40	22 19	_	1 0	4 2	55 9	39 13	_	1 0	4	69 21	46 15
North Dakota South Dakota	_	0	2 1	<u> </u>	2	_	0 0	1 0	1	2 7	_	0	2 1		2 4
S. Atlantic	1	7	15	370	485	11	17	60	878	1,039	3	8	28	463	464
Delaware District of Columbia		0	1 0	7 U	9 U	 U	0 0	3 0	11 U	15 U	_	0	2 2	13 15	12 17
Florida Georgia	1	2 1	8 4	146 45	152 67	9 1	6 3	12 6	340 133	337 155	1	3	7 4	149 32	153 43
Maryland§	_	1	3	40	73	_	2	4	80	113	2	2	10	123	89
North Carolina South Carolina§	_	0 0	9 3	61 19	66 18	_	0 1	17 6	80 60	128 65	_	0 0	7 2	37 13	51 17
Virginia [§] West Virginia	_	1 0	5 2	47 5	89 11	1	2 1	16 30	110 64	144 82	_	1 0	6 3	60 21	61 21
E.S. Central	1	1	9	79	109	1	7	13	368	385	_	2	10	111	102
Alabama [§] Kentucky	_	0	2	12 29	24 20	_ 1	2 2	6 5	99 92	128 76	_	0 1	2 4	15 56	12 50
Mississippi	<u> </u>	0	2 6	5 33	8 57	_	1 3	3 8	44	37 144	_	0 0	1	1 39	— 40
Tennessee§ W.S. Central		0 4	55	33 187	319	_ 3	3 12	131	133 601	1,065	_	1	5 23	39 86	153
Arkansas§	_	0	1	5	14 28		0	4	30 79	72 100	_	0 0	2 2	11 9	17
Louisiana Oklahoma	_	0	3	11 7	13	3	2	22	114	152	_	Ö	6	10	6 9
Texas [§] Mountain	_ 1	3 4	53 12	164 202	264 231	_	7 4	107 12	378 189	741 214	_ 1	1 2	18 7	56 88	121 112
Arizona	i	2	11	107	152	_	1	5	69	81	i	0	2	23	40
Colorado Idaho§	_	0 0	3 3	35 18	26 8	_	0 0	3 2	30 9	35 15	_	0	2 1	10 3	21 6
Montana [§] Nevada [§]	_	0	1 3	1 9	9 12	_	0 1	1 3	2 33	1 49	_	0	1 2	4 10	3 9
New Mexico§	_	0	3	17	12	_	0	2	11	13	_	0	1	7	10
Utah Wyoming [§]	_	0 0	2 1	12 3	9	_	0 0	3 1	31 4	15 5	_	0 0	2 0	31 —	20 3
Pacific	1	10	51	516	705	3	7	30	355	552	_	4	18	221	152
Alaska California	_	0 7	1 42	3 424	5 603	_	0 5	2 19	9 252	9 402	_	0 3	1 14	3 177	112
Hawaii Oregon [§]	_	0	2	17 25	7 31	_	0 1	1 3	7 39	17 59	_	0	1 2	8 16	2 14
Washington	1	1	7	47	59	3	1	9	48	65	_	0	3	17	24
American Samoa C.N.M.I.	_	0	0	_	_	_	0	0	_	14	N —	0	0	<u>N</u>	N —
Guam Puerto Rico	_	0	0 2	 17	— 64	_	0	1 5	— 39	3 93	_	0	0 1	_	<u> </u>
U.S. Virgin Islands	_	0	0		64 —	_	0	0	- -	93	_	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable.

* Incidence data for reporting year 2008 are provisional.

† Data for acute hepatitis C, viral are available in Table I.

[§] Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007 (52nd week)*

			yme disea	ise				Malaria			Me	Α	II serotyp	ise, invasi es	ve
	Current		vious veeks	Cum	Cum	Current		rious eeks	Cum	Cum	Current		rious reeks	Cum	Cum
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007	week	Med	Max	2008	2007
United States	186	412	1,448	26,327	27,444	9	21	136	1,059	1,408	3	20	53	1,029	1,077
New England	_	43 0	259 4	3,638	7,786	_	0	35 27	36	94 30	_	0	3 1	22	45 6
Connecticut Maine§	_	2	72	860	3,058 529	_	0 0	1	11 1	8	_	0	1	1 6	8
Massachusetts	_	12	114	1,039	2,988	_	0	2	14	34	_	0	3	15 —	20
New Hampshire Rhode Island§	_	11 0	139 0	1,381	896 177	_	0 0	1 8	4 1	9 8	_	0 0	0	_	3 3
Vermont§	_	3	40	358	138	_	0	1	5	5	_	0	1	_	5
Mid. Atlantic New Jersey	171	241 31	1,003 211	15,503 2,801	11,293 3,134	_2	4 0	14 1	244	403 72	_	2	6 2	117 10	128 18
New York (Upstate)	145	99	453	5,735	3,748	2	0	7	34	72 78	_	0	3	31	38
New York City	 26	0 83	4 531	51	417 3,994	_	3	10 3	170 40	209 44	_	0	2 5	27 49	22 50
Pennsylvania E.N. Central	3	10	143	6,916 1,365	2.102	_	1 3	3 7	138	139	_	1 3	9	173	167
Illinois	_	0	11	95	149	_	1	6	68	63	=	1	4	62	61
Indiana Michigan	_	0 1	8 10	41 97	55 51	_	0	2	5 18	11 20	_	0	4 3	27 30	31 28
Ohio	_	i	5	49	33	_	0	3	29	28	_	1	4	40	35
Wisconsin	3	8	127	1,083	1,814	_	0	3	18	17	_	0	2	14	12
W.N. Central lowa	_	8 1	740 8	1,311 101	1,398 123	_	1 0	10 3	71 12	57 3	_	2	8 3	94 19	73 15
Kansas	_	Ô	1	5	8	_	Ö	2	9	4	_	Ö	1	5	5
Minnesota Missouri	_	3 0	731 1	1,179 8	1,238 10	_	0	8 3	28 14	29 8	_	0 0	7 3	26 26	26 17
Nebraska§	_	0	2	14	7	_	0	2	8	7	_	0	1	12	5
North Dakota South Dakota	_	0 0	9 1	1 3	12	_	0 0	1 0	_	5 1	_	0 0	1 1	3 3	2 3
S. Atlantic	11	68	216	4,061	4,575	2	5	15	 271	273	_	2	10	149	177
Delaware	-	12	37	755	715	_	0	1	3	4	_	0	1	2	1 1
District of Columbia Florida		2 1	11 10	158 115	116 30		0 1	2 7	4 64	3 56	_	0 1	0 3	— 50	— 67
Georgia	_	0	3	23	11	_	1	5	51	39	_	0	2	17	24
Maryland§ North Carolina	4	29 0	157 7	2,059 51	2,576 53	_	1 0	6 7	68 30	76 22	_	0	4 3	17 14	21 22
South Carolina§	_	0	2	24	31	_	Ö	1	9	7	_	0	3	22	16
Virginia [§] West Virginia	5 —	11 0	68 11	802 74	959 84	_	1 0	7 0	42	65 1	_	0	2	22 5	23 3
E.S. Central	1	0	5	47	51	1	0	2	23	39	_	1	6	53	54
Alabama§	<u>.</u>	0	3	10	13	_	0	1	4	7	_	Ö	2	10	9
Kentucky Mississippi	_	0 0	2 1	5 1	6 1	_	0 0	1 1	6 1	9 2	_	0 0	2 2	10 12	13 12
Tennessee§	1	ő	3	31	31	1	ő	2	12	21	_	ő	3	21	20
W.S. Central	_	2	11	101	91	3	1	64	82	156	_	2	13	112	115
Arkansas§ Louisiana	_	0	0 1	3	1 2	_	0	0 1	4	2 14	_	0	2	14 24	9 29
Oklahoma	_	0	1	_	1	_	0	4	4	10	_	0	5	18	22
Texas§ Mountain	_	2 0	10 4	98 46	87 45	3	1 0	60 3	74 32	130 65	_	1	7 4	56 57	55 69
Arizona	_	0	2	8	45	_	0	2	32 14	12		0	2	9	13
Colorado	_	0	2	7 9	9	_	0	1 1	4 3	23	1	0	1	16	22
Idaho [§] Montana [§]	_	0	2 1	4	4	_	0	0	_	6 3	1	0	1	5 5	8 3
Nevada [§]	_	0	2	5	15	_	0	3	3	3	_	0	1	4	6
New Mexico [§] Utah	_	0 0	2 1	6 4	5 7	_	0 0	1 1	3 5	5 13	_	0 0	1 3	7 9	3 12
Wyoming§	_	0	1	3	3	_	0	0	_	_	_	0	1	2	2
Pacific Alaska	_	5 0	10 2	255 5	103 10	1	2	10 2	162 6	182 2	1	5 0	19 2	252 5	249 3
California	_	3	10	195	75	_	2	8	120	130	_	3	19	179	177
Hawaii	N	0	0	N	N	_	0	1	3	2	_	0	1	5	10
Oregon [§] Washington	_	1 0	4 4	44 11	6 12	1	0 0	2 3	4 29	18 30	1	1 0	3 5	38 25	31 28
American Samoa	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_
C.N.M.I. Guam	_			_	_	_	_			_ 1	_	_		_	_
Puerto Rico	N	0	0	N	N	_	0	1	1	3	_	0	1	3	8
U.S. Virgin Islands	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.

C.N.M.I.: Confinonwealth of Not most seed.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Nieu. Nieu.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007 (52nd week)*

			Pertussis	i			Ra	ıbies, anir	nal		F	Rocky Mo	untain sp	otted fever	<u> </u>
			vious					ious					ious		
Reporting area	Current week	Med	veeks Max	Cum 2008	Cum 2007	Current week	Med	eeks Max	Cum 2008	Cum 2007	Current week	52 w Med	Max	Cum 2008	Cum 2007
United States	75	180	849	9,499	10,454	5	102	164	4,824	5,975	3	38	195	2,247	2,221
New England	_	12	49	609	1,552	1	7	20	363	522	_	0	2	4	10
Connecticut Maine [†]	_	0	4 5	34 46	89 83	_	4 1	17 5	199 61	219 86	 N	0	0	N	N
Massachusetts	_	9	32	420	1,178	N	Ó	0	N	N		0	1	1	9
New Hampshire Rhode Island [†]	_	0 1	4 25	38 59	80 59	 N	0	3 0	35 N	53 N	_	0	1 2	1 2	1
Vermont†	_	Ö	4	12	63	1	1	6	68	164	_	0	0	_	_
Mid. Atlantic	10	19	43	1,043	1,314	2	28	63	1,530	997	_	1	5	80	85
New Jersey New York (Upstate)	3	1 7	9 24	71 424	229 549		0 9	0 20	494	<u> </u>	_	0	2 2	12 17	32 7
New York City	_	0	5	46	150	_	0	2	19	44	_	0	2	24	28
Pennsylvania E.N. Central	7	9 30	32	502	386	_	18 3	48 28	1,017 247	439	_	0 1	2 15	27 149	18 60
Illinois	12	6	189 37	1,803 497	1,495 199	_	1	26 21	103	414 113	1	i	10	103	39
Indiana Michigan	<u> </u>	1 5	15 14	112 291	68 292	_	0	2 8	10 73	13 202	_	0 0	3 1	8 3	6 4
Ohio	7	10	176	789	609	_	1	7	61	86	1	0	4	34	10
Wisconsin	_	2	7	114	327	N	0	0	N	N	_	0	1	1	1
W.N. Central lowa	<u>1</u>	17 2	142 17	1,266 174	909 150	_	3 0	12 5	195 29	276 31	_	4 0	32 2	453 7	369 17
Kansas	_	1	13	66	104	_	0	3	_	110	_	0	0	_	12
Minnesota Missouri	_	2 5	131 49	224 485	393 118	_	0 1	10 8	65 65	40 38	_	0 3	4 31	423	6 315
Nebraska†	1	2	35	273	70	_	0	0	_	_	_	0	4 0	20	14
North Dakota South Dakota	_	0	5 5	1 43	14 60	_	0 0	8 2	24 12	30 27	_	0 0	1	3	5
S. Atlantic	13	17	50	906	978	2	36	101	1,965	2,184	2	12	71	911	1,020
Delaware District of Columbia	_	0 0	3 1	18 7	11 9	_	0 0	0 0	_	_	_	0	5 2	32 8	17 3
Florida	4	5	20	306	211	_	0	77	139	128	2	0	3	20	19
Georgia Maryland [†]	1 2	1 2	6 8	83 129	37 118	_	5 8	42 17	298 410	300 431		1 1	8 7	72 71	60 63
North Carolina	_	0	38	79	330	2	9	16	450	472	_	3	55	499	665
South Carolina [†] Virginia [†]	<u> </u>	2	8 10	123 152	102 128	_	0 11	0 24	 591	46 730	_	1 2	9 15	54 148	64 123
West Virginia	_	0	2	9	32	_	1	9	77	77	_	0	1	7	6
E.S. Central Alabama [†]	_	7 1	26 5	381 56	463 91	_	3 0	7 0	165	156	_	3 1	23 8	317 90	276 96
Kentucky	_	1	11	131	33	_	0	4	45	21	_	0	1	1	5
Mississippi Tennessee [†]	_	2 2	5 14	89 105	255 84	_	0 2	1 6	2 118	3 132	_	0 2	1 19	6 220	20 155
W.S. Central	_	25	198	1.474	1,303	_	1	40	92	1.086	_	2	153	286	361
Arkansas†	_	1	18	82	173	_	0	6	48	33	_	0	14	68	122
Louisiana Oklahoma	_	1 0	7 21	77 55	21 58	_	0 0	0 32	<u>-</u>	6 78	_	0 0	1 132	5 170	4 186
Texas [†]	_	21	179	1,260	1,051	_	0	7	2	969	_	1	8	43	49
Mountain Arizona	10 2	15 4	37 10	795 196	1,137 210	N	1 0	8 0	77 N	97 N	_	1 0	3 2	43 17	37 10
Colorado	6	3	6	154	307	_	0	0	_	_	_	0	1	1	3
Idaho† Montana†	1	0	5 11	36 83	45 53	_	0 0	0 2	9	12 21	_	0 0	1	1 3	4 1
Nevada [†]	_	Ó	7	19	37	_	0	4	5	13	_	0	2	2	_
New Mexico [†] Utah	_ 1	1 4	8 27	65 226	74 387	_	0 0	3 6	25 14	15 16	_	0	1 1	2 7	6
Wyoming [†]	<u>.</u>	Ö	2	16	24	_	ő	3	24	20	_	ő	2	10	13
Pacific	29 6	22 3	303 21	1,222	1,303 89	_	3 0	13 4	190 15	243 45	 N	0	1 0	4 N	3 N
Alaska California	-	7	129	257 382	590	_	3	12	161	45 186		0	1	1 1	1
Hawaii Orogop†	_	0 3	2 10	17 164	19 123	_	0	0 4	 14	 12	<u>N</u>	0	0 1	N 3	N 2
Oregon† Washington	23	5	169	402	482	_	0	0	14 —	- IZ	N	0	0	N N	N
American Samoa	_	0	0	_	_	N	0	0	N	N	N	0	0	N	N
C.N.M.I. Guam	_			_	_	_			_	_	N			N	N
Puerto Rico	_	0	0	_	_	_	1	5	59	48	N	0	0	N	N
U.S. Virgin Islands	_	0	0			N	0	0	N	N	N	0	0	N	N

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Incidence data for reporting year 2008 are provisional.

† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007

		S	almonello	sis		Shig	a toxin-pı	oducing	E. coli (ST	EC)†			Shigellosi	s	
	_		vious veeks	_		_	Prev 52 w		_		_		vious veeks	_	
Reporting area	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007
United States	286	827	2,110	44,551	47,995	20	82	250	5,065	4,847	99	431	1,227	19,967	19,758
New England	2	19	506	1,692	2,239	_	3	47	218	315	_	2	39	157	250
Connecticut Maine§		0 2	477 8	477 148	431 138	_	0 0	44 3	44 24	71 41	_	0 0	38 6	38 21	44 14
Massachusetts	_	14	52	741	1,305	_	1	11	80	145	_	1	5	78	155
New Hampshire Rhode Island [§]	_	2 2	10 8	138 106	171 111		0 0	3 3	34 9	35 8	_	0	1	3 12	7 25
Vermont§	_	1	7	82	83	_	Ö	3	27	15	_	ő	2	5	5
Mid. Atlantic New Jersey	27	90 14	177 30	5,053 671	5,946 1,226	2	6 0	192 3	592 30	531 118	4	44 13	96 38	2,288 764	939 184
New York (Upstate)	12	26	73	1,429	1,476	2	3	188	410	208	3	11	35	570	185
New York City	2	23	53	1,246	1,296	_	1	5	61	50	_	13	35	703	283
Pennsylvania E.N. Central	13 17	27 88	78 192	1,707 4,930	1,948 5,923	_ 3	1 11	8 74	91 915	155 746	1 44	3 77	21 145	251 3,972	287 3,186
Illinois		25	72	1,299	1,966	_	1	9	109	131	_	17	33	865	781
Indiana Michigan	_ 1	9 17	53 38	597 911	675 966	_	1 2	14 43	93 233	105 128	_	10 3	83 20	591 211	296 83
Michigan Ohio	16	25	65	1,340	1,322	3	3	17	201	155	43	34	80	1,874	1,257
Wisconsin	_	15	50	783	994	_	4	20	279	227	1	8	32	431	769
W.N. Central lowa	1	49 8	151 16	2,731 416	2,877 477	1	13 2	59 21	800 200	780 175	_	16 3	39 11	896 186	1,819 109
Kansas	_	7	31	452	405	_	0	7	51	52	_	1	5	62	26
Minnesota Missouri	_	13 13	70 48	691 748	701 764	_	3 2	21 11	201 147	232 152	_	5 4	25 14	299 221	237 1,276
Nebraska [§]	1	4	13	236	275	1	2	29	149	93	_	0	3	15	28
North Dakota South Dakota	_	0 2	35 9	45 143	81 174	_	0 1	20 4	3 49	29 47	_	0 0	15 9	37 76	21 122
S. Atlantic	108	249	457	12,188	12,650	7	14	50	779	710	11	58	144	3.046	4,772
Delaware	1	2	9	144	140	_	0	2	12	16	_	0	1	11	11
District of Columbia Florida	— 73	1 100	4 174	52 5,242	64 5,022	 5	0 2	1 11	12 148	164	<u> </u>	0 15	3 34	19 796	18 2,288
Georgia	9	38	86	2,189	2,031	_	1	7	89	94	2	20	48	1,067	1,641
Maryland§ North Carolina	8	13 23	36 228	780 1,526	903 1.844	1	2 1	10 12	120 121	85 153	3	2 3	8 27	113 268	117 105
South Carolina§	_	18	55	1,088	1,166	_	1	4	40	14	_	8	32	521	220
Virginia§ West Virginia	17	18 3	49 25	1,010 157	1,249 231	1	3 0	25 3	208 29	165 19	2	4 0	13 61	235 16	200 172
E.S. Central	10	58	138	3,341	3,482	1	5	21	280	319	11	37	67	1,867	3,037
Alabama§	1	14	47	927	980	_	1	17	59	67	_	7	18	390	741
Kentucky Mississippi	3	9 13	18 57	477 1,027	574 1,048	_	1 0	7 2	100 6	123 8	_	3 5	24 20	260 288	504 1,420
Tennessee§	6	14	60	910	880	1	2	7	115	121	11	17	44	929	372
W.S. Central Arkansas§	20 4	110 11	894 40	6,035 768	6,065 847	_	6 1	27 3	318 43	300 45	6 3	93 11	748 27	4,836 566	3,117 105
Louisiana	_	16	50	983	978	_	Ó	1	2	12	_	11	25	594	493
Oklahoma Texas§	9 7	15 54	72 794	806 3,478	706 3,534	_	1 4	19 10	53 220	33 210	3	3 62	32 702	178 3,498	161 2,358
Mountain	26	58	110	3,180	2,752	2	10	38	592	589	18	19	53	1,186	983
Arizona	6	19	45	1,112	1,001	_	1	5	68	106	10	9	34	640	557
Colorado Idaho [§]	16 3	12 3	43 14	695 189	563 155	_	3 2	17 15	188 148	154 133	8	2 0	11 2	143 14	123 14
Montana [§]	_	2	10	121	121	_	0	3	35	_	_	0	1	8	27
Nevada [§] New Mexico [§]	_	3 6	9 33	174 479	263 290		0 1	2 6	10 49	31 42	_	4 1	13 10	216 119	79 108
Utah	1	6	19	359	286	_	1	9	89	100	_	1	3	39	42
Wyoming§	— 75	106	300	51 5 401	73		0 8	1	5 571	23	_	0	1	7	33
Pacific Alaska	75 1	106 1	399 4	5,401 57	6,061 87	<u>4</u>	0	49 1	571 7	557 5	5 —	28 0	82 1	1,719 1	1,655 8
California	_	77	286	3,914	4,571	_	5	39	305	293	_	26	74	1,481	1,331
Hawaii Oregon§	_	5 7	15 20	257 409	313 330	_	0 1	2 8	13 65	39 79	_	1 1	3 10	41 90	71 86
Washington	74	12	103	764	760	4	2	16	181	141	5	2	13	106	159
American Samoa C.N.M.I.	_	0	1	2	_	_	0	0	_	_	_	0	1	1	5
Guam	_	0	2	13	20	_	0	0	=	=	_	0	3	15	19
Puerto Rico	_	10	41	522	949	_	0	1	2	1	_	0	4	19	24
U.S. Virgin Islands		0	riana Islan				0	0				0	0		

U: Unavailable. — No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2008 are provisional.

† Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007 (52nd week)*

	•	Streptococcal	diseases, inv	asive, group A		Streptococc		e, invasive di Age <5 years	sease, nondru	ıg resistant [†]
	Current		ious eeks	Cum	Cum	Current	Prev 52 w		Cum	Cum
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007
United States	60	89	259	5,066	5,294	20	33	166	1,629	2,032
New England	1	6	31	324	409	_	1	14	71	141
Connecticut Maine [§]	_ 1	0 0	26 3	101 28	132 28	_	0 0	11 1	11 2	24 4
Massachusetts	<u> </u>	2	8	138	190	_	0	5	39	89
New Hampshire Rhode Island [§]	_	0 0	2 9	27 18	27 14	_	0	1 2	11 7	13 9
Vermont§	_	Ö	2	12	18	_	Ö	1	1	2
Mid. Atlantic	13	18	43	1,002	946	5	3	17	210	350
New Jersey New York (Upstate)	4	2 6	11 17	153 325	173 295	 5	1 2	4 14	63 106	75 123
New York City	_	3	10	185	226	_	0	6	41	152
Pennsylvania	9	7	16	339	252	N	0	0	N	N
E.N. Central Illinois	7	16 4	42 16	909 243	987 293	4	5 0	23 5	262 48	334 84
Indiana	_	2	11	130	128	_	0	14	35	37
Michigan	3	3	10	171	201	_	1	5	77	84
Ohio Wisconsin	4	5 1	14 10	258 107	239 126	4	1 1	5 4	65 37	69 60
W.N. Central	2	5	39	377	351	_	2	16	154	116
Iowa	_	0	0	_	_	_	0	0	_	_
Kansas Minnesota	_	0 0	5 35	36 172	32 173	_	0	3 13	19 71	3 66
Missouri	_	2	10	89	85	_	1	2	37	27
Nebraska§	2	1	3	45	25	_	0	2	9	18
North Dakota South Dakota	_	0 0	5 2	12 23	24 12	_	0 0	2 1	8 10	1 1
S. Atlantic	16	21	37	1,091	1,264	3	5	16	296	349
Delaware	_	0	2	9	10	_	0	0	_	_
District of Columbia Florida	3	0 5	4 10	23 266	17 309	<u> </u>	0 1	1 4	2 70	3 71
Georgia	5	4	14	237	259	1	i	4	67	85
Maryland [§] North Carolina	8	4 2	8 10	183 136	212 167	1 N	1 0	5 0	59 N	72 N
South Carolina§	_	1	5	73	101	_	1	4	51	58
Virginia [§]	_	3	12	131	162	_	0	6	39	52
West Virginia E.S. Central	 1	0 3	3 9	33 174	27 213	_ 1	0 2	1 11	8 102	8 119
Alabama§	Ň	0	0	N	213 N	Ň	0	0	102 N	N
Kentucky	_	1	3	41	41	N	0	0	N	N
Mississippi Tennessee [§]	N 1	0 3	0 6	N 133	N 172		0 2	3 9	20 82	13 106
W.S. Central	12	9	85	477	401	6	5	66	287	350
Arkansas [§]	_	0	2	5	19	_	0	2	7	19
Louisiana Oklahoma		0 2	2 19	16 122	16 85	_ 1	0 1	2 7	13 69	39 65
Texas§	7	6	65	334	281	5	3	58	198	227
Mountain	6	10	22	542	574	1	4	13	228	259
Arizona Colorado	1 5	3 3	9 8	192 150	208 145	1	2 1	8 4	113 58	128 52
Idaho [§]	_	0	2	15	18	_	0	1	5	2
Montana [§] Nevada [§]	<u>N</u>	0 0	0 1	N	N 2	N	0 0	1 0	4 N	1 N
New Mexico§	_	1	8	12 98	107	- N	0	3	18	1N 44
Utah	_	1	5	68	89	_	0	4	29	32
Wyoming [§]	_	0	2	7	5	_	0	1	1	_
Pacific Alaska	<u>2</u>	3 1	8 4	170 40	149 25	N	0 0	2 0	19 N	14 N
California	_	0	0	_	_	N	0	0	N	N
Hawaii Oregon [§]	2 N	2 0	8 0	130 N	124 N	N	0	2	19 N	14 N
Washington	N	0	0	N	N	N	0	0	N	N
American Samoa C.N.M.I.	_	0	12	30	4	<u>N</u>	0	0	<u>N</u>	<u>N</u>
Guam		0	0		14		0	0		
Puerto Rico	N	0 0	0 0	N	N	N N	0 0	0	N	N

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2008 are provisional.

† Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available (NNDSS event code 11717).

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007 (52nd week)*

		S	Streptococ	cus pneui	moniae, ir	vasive dis	ease, dru	g resistan	t [†]						
			All ages				Αg	ged <5 yea	ars		Sy	philis, pr	imary an	d seconda	ıry
			vious					ious					rious		
Reporting area	Current week	Med	eeks Max	Cum 2008	Cum 2007	Current week	Med	eeks Max	Cum 2008	Cum 2007	Current week	Med	eeks Max	Cum 2008	Cum 2007
United States	32	54	307	2,896	3,329	4	8	43	430	563	25	237	351	11,755	11,466
New England	1	1	49	103	156	_	0	8	13	21	1	5	13	292	279
Connecticut Maine [§]	_	0	48 2	55 17	99 13	_	0	7 1	5 2	11 3	_	0	6 2	31 10	39 9
Massachusetts	_	0	0		2	_	0	0	_	2	_	4	11	210	155
New Hampshire Rhode Island [§]	_	0	0 3	 16	 24	_	0	0 1	<u> </u>	_ 3	1	0	2 5	20 13	30 36
Vermont§	1	0	2	15	18	_	0	1	2	2	_	0	2	8	10
Mid. Atlantic	1	4	13	236	168	_	0	2	23	31	6	33	51	1,646	1,558
New Jersey New York (Upstate)	_	0 1	0 6	<u> </u>	— 58	_	0	0 2	 8	12	2 3	4 2	10 13	208 140	227 155
New York City	_	1	6	72		_	0	0	45	_	_	20	36	1,029	913
Pennsylvania E.N. Central	1 1	2 12	9 64	99 682	110 847	_	0 1	2 14	15 90	19 139	1 8	5 20	12 35	269 1,047	263 901
Illinois		0	17	71	225	_	Ö	3	14	49	_	5	15	275	464
Indiana Michigan	_	2	39 3	205 19	203 3	_	0	11 1	21 2	36 2	2 1	2 2	10 21	140 228	54 123
Ohio	1	8	17	387	416	_	i	4	53	52	5	6	15	345	194
Wisconsin W.N. Central	_	0 2	0 115	— 151	360	_	0	0 9	— 10	— 53	_	1 8	4 14	59 376	66 359
Iowa	_	0	0	_	_	_	0	0	_	_	_	0	2	15	21
Kansas Minnesota	_	0 0	5 114	59 —	90 186	_	0	1 9	4	10 35	_	0 2	5 5	30 100	28 59
Missouri	_	1	8	85	65	_	0	1	3	3	_	4	10	222	239
Nebraska [§] North Dakota	_	0	0 0	_	2	_	0 0	0 0	_	_	_	0	1 0	8	4 1
South Dakota	_	Ö	ĭ	7	17	_	ő	1	3	5	_	ő	1	1	7
S. Atlantic Delaware	25	22 0	53 1	1,251 3	1,349 11	3	4 0	12 0	219	249 2	6	51 0	215 4	2,695 15	2,784 18
District of Columbia	_	0	3	19	21	_	0	1	1	1	_	2	9	135	178
Florida Georgia	23 2	14 7	30 23	770 363	726 510	2 1	3 1	12 5	150 57	134 103	5	19 11	37 175	996 603	913 680
Maryland§	_	0	2	7	1	_	0	1	1	_	_	6	14	320	345
North Carolina South Carolina§	N —	0 0	0 0	N	N	N —	0 0	0 0	N —	N	_	6 2	19 6	278 87	323 91
Virginia§	N	0	0	N	N	N	0	0	N	N	1	5	16	259	230
West Virginia E.S. Central	 3	1 5	9 15	89 268	80 282	_	0 1	2 4	10 44	9 38	_ 2	0 21	1 37	2 1,111	6 936
Alabama§	N	0	0	N	N	N	0	0	N	N	_	8	17	448	380
Kentucky Mississippi	2	1 0	6 2	75 4	28 61	_	0	2 1	11 1	3	_	1 3	7 19	81 172	56 133
Tennessee§	1	3	13	189	193	_	0	3	32	35	2	8	19	410	367
W.S. Central Arkansas§	_	2	7 4	92 20	96 6	_	0	2 1	13 4	14 2	2 2	41 2	60 19	2,091 169	1,880 122
Louisiana	_	1	6	72	90	_	0	2	9	12	_	10	30	531	533
Oklahoma Texas [§]	N —	0	0 0	N	N	N	0 0	0 0	N	N	_	1 26	5 47	55 1,336	65 1,160
Mountain	1	2	15	111	68	1	0	4	16	15	_	8	16	415	543
Arizona Colorado	_	0	0 0	_	_	_	0	0 0	_	_	_	4 1	12 7	200 92	296 57
Idaho§	N	0	0	N	N	N	Ö	0	N	N	_	0	2	6	1
Montana [§] Nevada [§]	 N	0	1 0	1 N	N	 N	0	0 0	 N	N	_	0 1	0 6	— 73	8 111
New Mexico§	_	0	1	2	_	_	0	0	_	_	_	1	4	40	46
Utah Wyoming [§]	1	1 0	14 1	104 4	51 17	1	0 0	4 0	16 —	12 3	_	0 0	2 1	1 3	20 4
Pacific	_	0	1	2	3	_	0	1	2	3	_	44	64	2,082	2,226
Alaska California	N N	0	0 0	N N	N N	N N	0	0	N N	N N	_	0 38	1 58	1 1,877	7 2,038
Hawaii	_	Ö	1	2	3	_	Ö	Ĭ	2	3	_	0	2	20	9
Oregon [§] Washington	N N	0	0 0	N N	N N	N N	0 0	0 0	N N	N N	_	0 3	3 9	24 160	18 154
American Samoa	N	0	0	N	N	N	0	0	N	N	_	0	0	_	4
C.N.M.I.		- 0	- 0	=	_	_	- 0	-	_		_	- 0	- 0	_	
Guam Puerto Rico	=	0	0	=	_	_	0	0	_	=	_	3	11	163	169
U.S. Virgin Islands		0	0	_	_	_	0	0	_	_	_	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Max* Incidence data for reporting year 2008 are provisional.

† Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720).

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 27, 2008, and December 29, 2007 (52nd week)*

		Vario	ella (chick	ennov)			Ne	euroinvasi			irus diseas		neuroinva	sive§	
			vious	c.ipox)			Prev		¥-C			Prev		3146,	
	Current		veeks	Cum	Cum	Current	52 w		Cum	Cum	Current	52 w		Cum	Cum
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007	week	Med	Max	2008	2007
United States	194	499	1,660	26,628	40,146	_	1	76	628	1,227		1	77	694	2,403
New England	5	11	46	518	2,551	_	0	2	6	5	_	0	1	3	6
Connecticut Maine [¶]	_	0	28 1	_	1,440 357	_	0	0	5	2	_	0	1 0	3	2
Massachusetts	_	0	i	1	_	_	Ö	Ö	_	3	_	0	0	_	3
New Hampshire	_	5	13	238	374	_	0	0	_	_	_	0	0	_	_
Rhode Island [¶] Vermont¶	<u> </u>	0 5	0 17	279	380	_	0	1 0	1	_	_	0	0 0	_	1
Mid. Atlantic	55	45	81	2,253	4,680	_	0	8	46	22	_	0	5	19	11
New Jersey New York (Upstate)	N N	0	0	N N	N N	_	0	1 5	3 23	1 3	_	0	1 2	4 7	_ 1
New York (Opsiale)	N N	0	0	N N	N N	_	0	2	23 8	13	_	0	2	6	5
Pennsylvania	55	45	81	2,253	4,680	_	Ö	2	12	5	_	Ö	1	2	5
E.N. Central	49	140	336	7,004	11,309	_	0	8 4	41	113	_	0	3	20	65
Illinois Indiana	1	22 0	63 222	1,344	1,091 444	_	0 0	1	11 2	63 14	_	0 0	2 1	8 1	38 10
Michigan	18	58	116	2,807	4,187	_	0	4	11	16	_	0	2	6	1
Ohio Wisconsin	30	47 4	106 50	2,369 484	4,536 1,051	_	0	3 1	14 3	13 7	_	0	1 1	1 4	10 6
W.N. Central	_	21	145	1,269	1,733	_	0	6	43	249	_	0	22	161	739
lowa	N	0	0	N	N	_	0	2	3	12	_	0	1	3	18
Kansas Minnesota	_	6 0	40 0	444	586	_	0 0	2 2	8 2	14 44	_	0 0	4 4	30 8	26 57
Missouri	_	10	51	756	923	_	Ö	3	12	61	_	Ö	1	7	16
Nebraska [¶]	N	0	0	N	N	_	0	1	5	21	_	0	8	44	142
North Dakota South Dakota	_	0	140 5	49 20	140 84	_	0	2 5	2 11	49 48	_	0	12 6	41 28	320 160
S. Atlantic	22	88	173	4,561	5,296	_	0	3	14	43	_	0	3	14	39
Delaware	_	1	5	44	49	_	0	0	_	1	_	0	1	1	_
District of Columbia Florida	 22	0 29	3 87	23 1,708	32 1,321	_	0	0 2	_	3	_	0	0	_	_
Georgia	N	0	0	N	N	_	0	1	4	23	_	0	1	4	27
Maryland¶ North Carolina	N N	0	0	N N	N N	_	0 0	2 0	7	6 4	_	0	2 0	7	4 4
South Carolina [¶]		14	67	833	1,103	_	0	0	_	3	_	0	1	1	2
Virginia [¶]	_	21	81	1,295	1,582	_	0	0	_	3	_	0	1	1	2
West Virginia	_	12	36	658	1,209	_	0	1	1	70	_	0	0	_	_
E.S. Central Alabama [¶]	_	17 17	101 101	1,091 1,078	701 699	_	0	7 3	46 11	76 17	_	0	8 3	58 10	99 7
Kentucky	N	0	0	N	N	_	0	1	3	_4	_	0	0	-	_
Mississippi Tennessee [¶]	N	0	2 0	13 N	2 N	_	0 0	4 1	22 10	50 5	_	0 0	7 3	41 7	86 6
W.S. Central	62	113	886	7,663	10,992		0	7	56	269		0	8	58	158
Arkansas¶	_	8	38	514	808	_	0	1	7	13	_	0	1	2	7
Louisiana Oklahoma	N	1 0	10 0	70 N	123 N	_	0	2 1	9 2	27 59	_	0 0	6 1	27 5	13 48
Texas [¶]	62	108	852	7,079	10,061	_	0	6	38	170	_	Ö	4	24	90
Mountain	1	40	90	2,131	2,798	_	0	12	102	289	_	0	24	201	1,041
Arizona Colorado	1	0 14	0 43	838	1,089	_	0 0	10 4	61 17	50 99	_	0 0	8 13	50 78	47 477
Idaho¶	Ń	0	0	N	1,003 N	_	Ö	1	3	11	_	Ö	6	30	121
Montana [¶]		5	27	335	424	_	0	0	_	37	_	0	2	5	165
Nevada [¶] New Mexico [¶]	N	0 3	0 18	N 208	N 422	_	0	2	9 6	2 39	_	0	3 1	7 3	10 21
Utah	_	13	55	740	828	_	0	2	6	28	_	0	5	20	42
Wyoming [¶]	_	0	4	10	35	_	0	0		23	_	0	2	8	158
Pacific Alaska	_	2 1	8 6	138 74	86 43	_	0	38 0	274	161	_	0	24 0	160	245
California	_	0	0	_	_	_	0	38	270	154	_	0	19	146	226
Hawaii Orogon¶		1 0	6 0	64 N	43 N	_	0	0	_		_	0	0	12	10
Oregon¶ Washington	N N	0	0	N N	N N	_	0	2 1	3 1	7	_	0 0	4 1	13 1	19 —
American Samoa	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_
C.N.M.I.	_	_	17	_	_	_	_	_	_	_	_	_	_	_	_
Guam Puerto Rico	_	1 7	17 20	63 402	239 727	_	0	0 0	_	_	_	0	0 0	_	_
U.S. Virgin Islands	_	0	0	_		_	0	0	_	_	_	0	0	_	

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable.
* Incidence data for reporting year 2008 are provisional. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

[†] Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

[§] Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.

¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE III. Deaths in 122 U.S. cities.* week ending December 27, 2008 (52nd week)

		All cau	ses, by a	age (year	s)		P&I [†] Total		All causes, by age (years)					.	
Reporting area	All Ages	<u>≥</u> 65	45–64	25–44	1–24	<1		Reporting area	All Ages	≥65	45–64	25–44	1–24	<1	P&I [†] Tota
New England	374	286	64	12	6	6	36	S. Atlantic	724	455	184	45	21	19	53
Boston, MA	100	68	25	2	4	1	8	Atlanta, GA	108	61	35	7	2	3	7
Bridgeport, CT	29	24	3	2	_	_	4	Baltimore, MD	163	97	50	7	5	4	16
Cambridge, MA	10	.9	1	_	_	_	3	Charlotte, NC	90	60	17	8	2	3	9
Fall River, MA	20	15	4	1	_	_	2	Jacksonville, FL	84	55	20	3	3	3	9
Hartford, CT	35	28	5	_	_	2	5	Miami, FL	93	61	21	9	1	1	6
Lowell, MA Lvnn. MA	17 16	15 16	2	_	_	_	1	Norfolk, VA Richmond, VA	32 20	18 16	9 2	4 1	_ 1	1	1
New Bedford, MA	18	14	3	1	_	_	3	Savannah, GA	40	26	9	1	4	_	1
New Haven, CT	Ü	Ü	Ü	ΰ	U	U	Ü	St. Petersburg, FL	27	16	8		_	3	
Providence, RI	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Tampa, FL	60	40	11	5	3	1	_
Somerville, MA	7	4	1	2	_	_	_	Washington, D.C.	U	Ú	U	Ü	Ū	U	U
Springfield, MA	37	26	6	1	1	3	3	Wilmington, DE	7	5	2	_	_	_	1
Waterbury, CT	25	17	8	_	_	_	4	E.S. Central	704	463	145	61	23	12	54
Worcester, MA	60	50	6	3	1	_	3	Birmingham, AL	129	75	37	10	5	2	15
Mid. Atlantic	1,644	1,145	369	86	21	23	73	Chattanooga, TN	68	26	10	22	8	2	3
Albany, NY	57	39	14	1	_	3	1	Knoxville, TN	81	64	13	_	2	2	4
Allentown, PA	33	26	7	_	_	_	2	Lexington, KY	43	24	12	4	2	1	3
Buffalo, NY	80	55	21	2	2	_	9	Memphis, TN	171	113	36	15	4	3	18
Camden, NJ Elizabeth, NJ	32 10	23 6	8 2	1 1	1	_	1	Mobile, AL Montgomery, AL	86 41	64 34	15 5	6 1	1	_ 1	4
Erie, PA	42	32	9		1	_	1	Nashville, TN	41 85	63	5 17	3	1	1	3
Jersey City, NJ	42 U	J2 U	U	U	Ü	U	Ú	W.S. Central	758	501	174	36	21	26	42
New York City, NY	662	475	137	36	7	7	25	Austin, TX	33	24	7	1	_	1	2
Newark, NJ	23	12	6	3	1	1	_	Baton Rouge, LA	Ü	Ü	Ú	Ú	U	Ú	Ū
Paterson, NJ	17	10	5	2	_	_	_	Corpus Christi, TX	26	21	3	2	_	_	1
Philadelphia, PA	420	264	106	34	9	7	16	Dallas, TX	145	92	34	9	6	4	7
Pittsburgh, PA§	26	21	4	1	_	_	4	El Paso, TX	36	25	10	_	_	1	2
Reading, PA	19	16	3	_	_	_	2	Fort Worth, TX	104	61	30	3	3	7	9
Rochester, NY	125	93	25	2	_	5	5	Houston, TX	U	U	U	U	U	U	U
Schenectady, NY	16	12	4	_	_	_	2	Little Rock, AR	85	55	18	4	3	5	3
Scranton, PA	21	18	3	_	_	_	1	New Orleans, LA¶	U	U	U	U	U	U	U
Syracuse, NY	17	11	4	2	_	_	_	San Antonio, TX	210	145	44	10	6	5	13
Trenton, NJ	13	8	5	_	_	_	2	Shreveport, LA	37	21	11	2	1	2	1
Utica, NY	14 17	10 14	3 3	1	_	_	1 1	Tulsa, OK	82	57 524	17	5	2 22	1 11	4
Yonkers, NY E.N. Central	1,367	932	305	— 72	31	<u> </u>	89	Mountain Albuquerque, NM	828 U	524 U	209 U	62 U	22 U	U	43 U
Akron, OH	43	23	13	3	3	1	3	Boise, ID	42	33	6	2	_	1	1
Canton, OH	25	18	7	_	_		2	Colorado Springs, CO	102	61	28	10	3		6
Chicago, IL	149	100	30	12	3	4	12	Denver, CO	79	50	22	5	1	1	7
Cincinnati, OH	75	51	14	8	_	2	3	Las Vegas, NV	296	184	83	20	5	4	14
Cleveland, OH	195	148	41	_	1	5	13	Ogden, UT	16	13	2	_	1	_	1
Columbus, OH	152	99	36	8	3	6	12	Phoenix, AZ	114	68	27	10	7	2	6
Dayton, OH	93	76	13	3	1	_	6	Pueblo, CO	16	13	2	1	_	_	_
Detroit, MI	U	U	U	U	U	U	U	Salt Lake City, UT	86	52	19	11	3	1	5
Evansville, IN	42	31	8	1	2	_	4	Tucson, AZ		_50	20	.3	2	2	3
Fort Wayne, IN	47	34	11	1	1	_	3	Pacific	1,072	759	231	47	20	15	117
Gary, IN	6	2	2 6	2	_	1	_	Berkeley, CA	5 U	3 U	1 U	1 U	 U	U	U
Grand Rapids, MI	25 148	18 94	33	 10	 8	3		Fresno, CA	23	19	3	1	_	U	9
Indianapolis, IN Lansing, MI	33	94 21	33 8	3	1	_	1	Glendale, CA Honolulu, HI	23 70	52	13	3	1	1	3
Milwaukee, WI	84	48		7	1	2	12		57	37		2	3	2	8
Peoria, IL	43	30	26 9	1	3	_	7	Long Beach, CA Los Angeles, CA	221	149	13 50	15	3	4	24
Rockford, IL	55	36	12	5	2		2	Pasadena, CA	U	Ü	U	Ü	Ŭ	Ū	U
South Bend, IN	47	32	9	3	2	1	1	Portland, OR	30	20	8	1	_	1	3
Toledo, OH	64	43	15	4	_	2		Sacramento, CA	146	102	31	7	5	1	17
Youngstown, OH	41	28	12	1	_	_	2	San Diego, CA	84	56	22	3	_	3	6
W.N. Central	356	242	77	18	8	11	26	San Francisco, CA	111	86	23	2	_	_	17
Des Moines, IA	33	25	5	2	_	1	3	San Jose, CA	155	111	34	5	4	1	22
Duluth, MN	17	12	4	_	1	_	_	Santa Cruz, CA	20	13	4	2	_	1	5
Kansas City, KS	11	5	4	2	_	_	2	Seattle, WA	25	17	5	_	2	1	_
Kansas City, MO	64	49	9	5	1	_	3	Spokane, WA	40	33	6	1	_	_	1
Lincoln, NE	27	24	2	_	1	_	3	Tacoma, WA	85	61	18	4	2	_	2
Minneapolis, MN	46	27	12	3	_	4	1	Total**	7,827	5,307	1,758	439	173	150	533
Omaha, NE	45	35	8	1	_	1	8	1							
St. Louis, MO	34	10	13	4	5	2	1	I							
St. Paul, MN	33	25	7	1	_	_	3	I							
Wichita, KS	46	30	13	_	_	3	2	I							

U: Unavailable. —:No reported cases.

* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

[§] Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

¹¹ Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted.

** Total includes unknown ages.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the MMWR Series, including material to be considered for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to mmwq@cdc.gov.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in MMWR were current as of the date of publication.

☆ U.S. Government Printing Office: 2009-523-019/41147 Region IV ISSN: 0149-2195



Recommended Immunization Schedules for Persons Aged 0 Through 18 Years — United States, 2009

Weekly

January 2, 2009 / Vol. 57 / Nos. 51 & 52

The Advisory Committee on Immunization Practices (ACIP) annually publishes immunization schedules that summarize recommendations for currently licensed vaccines for children aged 18 years and younger. Changes to the previous schedule (1) are as follows:

- Recommendations for rotavirus vaccines include changes for the maximum age for the first dose (14 weeks 6 days) and the maximum age for any dose (15 months 0 days). The rotavirus footnote also indicates that if RV1 (Rotarix°) is administered at ages 2 and 4 months, a dose at 6 months is not indicated (2).
- Routine annual influenza vaccination is recommended for all children aged 6 months through 18 years. Children aged younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time during the previous season but only received 1 dose should receive 2 doses of influenza vaccine at least 4 weeks apart. Healthy nonpregnant persons aged 2 through 49 years may receive either live attenuated influenza vaccine or inactivated influenza vaccine (3).
- The minimum interval between tetanus and diphtheria toxoids (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap) for persons aged 10 through 18 years is addressed. An interval less than 5 years may be used if pertussis immunity is needed (4).
- Information about the use of *Haemophilus influenzae* type b (Hib) conjugate vaccine among persons aged 5 years and older at increased risk for invasive Hib disease has been added. Use of Hib vaccine for these persons is not contraindicated.
- Catch-up vaccination with human papillomavirus (HPV) vaccine is clarified. Routine dosing intervals should be used for series catch-up (i.e., the second and third doses should be administered 2 and 6 months after the first

used for series catch-up (i.e., the second and third doses should be administered 2 and 6 months after the first

The recommended immunization schedules for persons aged 0 through 18 years and

Suggested citation: Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years—United States, 2009. MMWR 2008;57(51&52).

the catch-up immunization schedule for 2009 have been approved by the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the

American Academy of Family Physicians.

- dose). The third dose should be given at least 24 weeks after the first dose.
- Abbreviations for rotavirus, pneumococcal polysaccharide and meningococcal polysaccharide vaccines have been changed.

The National Childhood Vaccine Injury Act requires that health-care providers provide parents or patients with copies of Vaccine Information Statements before administering each dose of the vaccines listed in the schedules. Additional information is available from state health departments and from CDC at http://www.cdc.gov/vaccines/pubs/vis/default.htm.

Detailed recommendations for using vaccines are available from ACIP statements (available at http://www.cdc.gov/vaccines/pubs/acip-list.htm), and the 2006 Red Book (6). Guidance regarding the Vaccine Adverse Event Reporting System form is available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.

References

- 1. CDC. Recommended immunization schedules for persons aged 0–18 years—United States 2008. MMWR 2008;57(1).
- 2. CDC. ACIP provisional recommendations for the prevention of rotavirus gastroenteritis among infants and children. Atlanta, GA: US Department of Health and Human Services, CDC; 2008. Available at http://www.cdc.gov/vaccines/recs/provisional/default.htm#acip.
- CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR 2008;57(No. RR-7).
- CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55 (No. RR-3).
- American Academy of Pediatrics. Active and passive immunization. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. 2006 red book: report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.

FIGURE 1. Recommended immunization schedule for persons aged 0 through 6 years — United States, 2009 (for those who fall behind or start late, see the catch-up schedule [Table])

Vaccine ▼ Age ►	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19–23 months	2–3 years	4–6 years	
Hepatitis B ¹	НерВ	He	pB	see footnote 1		He	рВ	:		•		
Rotavirus ²		* * * * * * * * * * * * * * * * * * *	RV	RV	RV ²					*		Range of recommende
Diphtheria, Tetanus, Pertussis ³		• • • • • • • • • • • • • • • • • • •	DTaP	DTaP	DTaP	see footnote3	D	ГаР		**************************************	DTaP	ages
Haemophilus influenzae type b ⁴		• • • • • • • • • • • • • • • • • • •	Hib	Hib	Hib⁴	Н	ib			**************************************		
Pneumococcal⁵		**************************************	PCV	PCV	PCV	P	CV			PF	SV	Certain high-risk
Inactivated Poliovirus		**************************************	IPV	IPV		IF	V	:		**************************************	IPV	groups
Influenza ⁶		**************************************			Influenza (Yearly)				:			
Measles, Mumps, Rubella ⁷		**************************************			**************************************	МІ	MR	s	ee footnote	7	MMR	
Varicella ⁸		**************************************			g	Vari	cella	s	ee footnote	8	Varicella	
Hepatitis A ⁹		**************************************	**************************************		**************************************		HepA	(<mark>2 doses</mark>)	НерА	Series	1
Meningococcal ¹⁰	•					:		•		M	CV	1

This schedule indicates the recommended ages for routine administration of currently licensed vaccines, as of December 17, 2008, for children aged 0 through 6 years. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. Licensed combination vaccines may be used whenever any component of the combination is indicated and other components are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult

the relevant Advisory Committee on Immunization Practices statement for detailed recommendations, including high-risk conditions: http://www.cdc.gov/vaccines/pubs/acip-list.htm. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.

1. Hepatitis B vaccine (HepB). (Minimum age: birth) At birth:

- Administer monovalent HepB to all newborns before hospital discharge.
- If mother is hepatitis B surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB within 12 hours of birth.
 Determine mother's HBsAg status as soon as possible and, if HBsAg-positive, administer HBIG (no later than age 1 week).

After the birth dose:

- The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1 or 2 months. The final dose should be administered no earlier than age 24 weeks.
- Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg (anti-HBs) after completion of at least 3 doses of the HepB series, at age 9 through 18 months (generally at the next well-child visit).

4-month dose:

 Administration of 4 doses of HepB to infants is permissible when combination vaccines containing HepB are administered after the birth dose.

2. Rotavirus vaccine (RV). (Minimum age: 6 weeks)

- Administer the first dose at age 6 through 14 weeks (maximum age: 14 weeks 6 days).
 Vaccination should not be initiated for infants aged 15 weeks or older (i.e., 15 weeks 0 days or older).
- Administer the final dose in the series by age 8 months 0 days.
- If Rotarix[®] is administered at ages 2 and 4 months, a dose at 6 months is not indicated.

3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)

- The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose.
- Administer the final dose in the series at age 4 through 6 years.
- 4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age:
 - of PRP-OMP (PedvaxHIB® or Comvax® [HepB-Hib]) is administered at ages 2 and 4 months, a dose at age 6 months is not indicated.
 - TriHiBit® (DTaP/Hib) should not be used for doses at ages 2, 4, or 6 months but can be used as the final dose in children aged 12 months or older.

Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPSV])

 PCV is recommended for all children aged younger than 5 years. Administer 1 dose of PCV to all healthy children aged 24 through 59 months who are not completely vaccinated for their age.

- Administer PPSV to children aged 2 years or older with certain underlying medical conditions (see MMWR 2000;49[No. RR-9]), including a cochlear implant.
- 6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 2 years for live, attenuated influenza vaccine [LAIV])
 - Administer annually to children aged 6 months through 18 years.
- For healthy nonpregnant persons (i.e., those who do not have underlying medical conditions that predispose them to influenza complications) aged 2 through 49 years, either LAIV or TIV may be used.
- Children receiving TIV should receive 0.25 mL if aged 6 through 35 months or 0.5 mL if aged 3 years or older.
- Administer 2 doses (separated by at least 4 weeks) to children aged younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time during the previous influenza season but only received 1 dose.

7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)

- Administer the second dose at age 4 through 6 years. However, the second dose may be administered before age 4, provided at least 28 days have elapsed since the first dose.
- 8. Varicella vaccine. (Minimum age: 12 months)
 - Administer the second dose at age 4 through 6 years. However, the second dose may be administered before age 4, provided at least 3 months have elapsed since the first dose.
 - For children aged 12 months through 12 years the minimum interval between doses is 3 months. However, if the second dose was administered at least 28 days after the first dose, it can be accepted as valid.


9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)

- Administer to all children aged 1 year (i.e., aged 12 through 23 months).
 Administer 2 doses at least 6 months apart.
- Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
- HepA also is recommended for children older than 1 year who live in areas where vaccination programs target older children or who are at increased risk of infection. See MMWR 2006;55(No. RR-7).

Meningococcal vaccine. (Minimum age: 2 years for meningococcal conjugate vaccine [MCV] and for meningococcal polysaccharide vaccine [MPSV])

- Administer MCV to children aged 2 through 10 years with terminal complement component deficiency, anatomic or functional asplenia, and certain other highrisk groups. See MMWR 2005;54(No. RR-7).
- Persons who received MPSV 3 or more years previously and who remain at increased risk for meningococcal disease should be revaccinated with MCV.

FIGURE 2. Recommended immunization schedule for persons aged 7 through 18 years — United States, 2009 (for those who fall behind or start late, see the schedule below and the catch-up schedule [Table])



This schedule indicates the recommended ages for routine administration of currently licensed vaccines, as of December 17, 2008, for children aged 7 through 18 years. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. Licensed combination vaccines may be used whenever any component of the combination is indicated and other components are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult

the relevant Advisory Committee on Immunization Practices statement for detailed recommendations, including high-risk conditions: http://www.cdc.gov/vaccines/pubs/acip-list.htm. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.

Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL®)

- Administer at age 11 or 12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoid (Td) booster dose.
- Persons aged 13 through 18 years who have not received Tdap should receive a dose.
- A 5-year interval from the last Td dose is encouraged when Tdap is used as a booster dose; however, a shorter interval may be used if pertussis immunity is needed.

2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)

- Administer the first dose to females at age 11 or 12 years.
- Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose (at least 24 weeks after the first dose).
- Administer the series to females at age 13 through 18 years if not previously vaccinated.

3. Meningococcal conjugate vaccine (MCV).

- Administer at age 11 or 12 years, or at age 13 through 18 years if not previously vaccinated
- Administer to previously unvaccinated college freshmen living in a dormitory.
- MCV is recommended for children aged 2 through 10 years with terminal complement component deficiency, anatomic or functional asplenia, and certain other groups at high risk. See MMWR 2005;54(No. RR-7).
- Persons who received MPSV 5 or more years previously and remain at increased risk for meningococcal disease should be revaccinated with MCV.

4. Influenza vaccine.

- Administer annually to children aged 6 months through 18 years.
- For healthy nonpregnant persons (i.e., those who do not have underlying medical conditions that predispose them to influenza complications) aged 2 through 49 years, either LAIV or TIV may be used.
- Administer 2 doses (separated by at least 4 weeks) to children aged younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time during the previous influenza season but only received 1 dose.

5. Pneumococcal polysaccharide vaccine (PPSV).

Administer to children with certain underlying medical conditions (see MMWR 1997;46[No. RR-8]), including a cochlear implant. A single revaccination should be administered to children with functional or anatomic asplenia or other immunocompromising condition after 5 years.

6. Hepatitis A vaccine (HepA).

- Administer 2 doses at least 6 months apart.
- HepA is recommended for children older than 1 year who live in areas where vaccination programs target older children or who are at increased risk of infection. See MMWR 2006;55(No. RR-7).

7. Hepatitis B vaccine (HepB).

- Administer the 3-dose series to those not previously vaccinated.
- \bullet A 2-dose series (separated by at least 4 months) of adult formulation Recombivax HB $^{\!8\!}$ is licensed for children aged 11 through 15 years.

8. Inactivated poliovirus vaccine (IPV).

- For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age 4 years or older.
- If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.

9. Measles, mumps, and rubella vaccine (MMR).

 If not previously vaccinated, administer 2 doses or the second dose for those who have received only 1 dose, with at least 28 days between doses.

10. Varicella vaccine.

- For persons aged 7 through 18 years without evidence of immunity (see MMWR 2007;56[No. RR-4]), administer 2 doses if not previously vaccinated or the second dose if they have received only 1 dose.
- For persons aged 7 through 12 years, the minimum interval between doses is 3 months. However, if the second dose was administered at least 28 days after the first dose, it can be accepted as valid.
- For persons aged 13 years and older, the minimum interval between doses is 28 days.

TABLE. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind — United States. 2009

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age.

		CATCH-UP SCHEDULE FOR PERS	SONS AGED 4 MONTHS THROUGH 6 YEARS									
Vaccine	Minimum Age	Minimum Interval Between Doses Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5										
Vaccine	for Dose 1	Dose 1 to Dose 2		Dose 3 to Dose 4	Dose 4 to Dose 5							
Hepatitis B ¹	Birth	4 weeks	8 weeks (and at least 16 weeks after the first dose)									
Rotavirus ²	6 wks	4 weeks	4 weeks ²		<u> </u>							
Diphtheria, Tetanus, Pertussis ³	6 wks	4 weeks	4 weeks	6 months	6 months ³							
Haemophilus influenzae type b ⁴	6 wks	4 weeks if first dose administered at younger than age 12 months 8 weeks (as final dose) if first dose administered at age 12-14 months No further doses needed if first dose administered at age 15 months or older	4 weeks ⁴ if current age is younger than 12 months 8 weeks (as final dose) ⁴ if current age is 12 months or older and second dose administered at younger than age 15 months No further doses needed if previous dose administered at age 15 months or older	8 weeks (as final dose) This dose only necessary for children aged 12 months through 59 months who received 3 doses before age 12 months								
Pneumococcal ⁵	6 wks	if first dose administered at younger than age 12 months 8 weeks (as final dose for healthy children) if first dose administered at age 12 months or older or current age 24 through 59 months No further doses needed for healthy children if first dose administered at age 24 months or older	4 weeks if current age is younger than 12 months 8 weeks (as final dose for healthy children) if current age is 12 months or older No further doses needed for healthy children if previous dose administered at age 24 months or older	8 weeks (as final dose) This dose only necessary for children aged 12 months through 59 months who received 3 doses before age 12 months or for high-risk children who received 3 doses at any age								
Inactivated Poliovirus ⁶	6 wks	4 weeks	4 weeks	4 weeks ⁶	Ì							
Measles, Mumps, Rubella ⁷	12 mos	4 weeks										
Varicella ⁸	12 mos	3 months			j							
Hepatitis A ⁹	12 mos	6 months			Ì							
		CATCH-UP SCHEDULE FOR I	PERSONS AGED 7 THROUGH 18 YEARS									
Tetanus, Diphtheria/ Tetanus, Diphtheria, Pertussis ¹⁰	7 yrs ¹⁰	4 weeks	4 weeks if first dose administered at younger than age 12 months 6 months if first dose administered at age 12 months or older	6 months if first dose administered at younger than age 12 months								
Human Papillomavirus ¹¹	9 yrs		Routine dosing intervals are recommen	ded ¹¹								
Hepatitis A ⁹	12 mos	6 months										
Hepatitis B ¹	Birth	4 weeks	8 weeks (and at least 16 weeks after first dose)									
Inactivated Poliovirus ⁶	6 wks	4 weeks	4 weeks	4 weeks ⁶								
Measles, Mumps, Rubella ⁷	12 mos	4 weeks			ĺ							
Varicella ⁸	12 mos	3 months if the person is younger than age 13 years 4 weeks if the person is aged 13 years or older										

1. Hepatitis B vaccine (HepB).

- Administer the 3-dose series to those not previously vaccinated.
- A 2-dose series (separated by at least 4 months) of adult formulation Recombivax HB[®] is licensed for children aged 11 through 15 years.

2. Rotavirus vaccine (RV).

- The maximum age for the first dose is 14 weeks 6 days. Vaccination should not be initiated for infants aged 15 weeks or older (i.e., 15 weeks 0 days or older).
- Administer the final dose in the series by age 8 months 0 days.
- If Rotarix® was administered for the first and second doses, a third dose is not indicated.

3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).

 The fifth dose is not necessary if the fourth dose was administered at age 4 years or older.

4. Haemophilus influenzae type b conjugate vaccine (Hib).

- Hib vaccine is not generally recommended for persons aged 5 years or older. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults. However, studies suggest good immunogenicity in persons who have sickle cell disease, leukemia, or HIV infection, or who have had a splenectomy; administering 1 dose of Hib vaccine to these persons is not contraindicated.
- If the first 2 doses were PRP-OMP (PedvaxHIB® or Comvax®), and administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months and at least 8 weeks after the second dose.
- If the first dose was administered at age 7 through 11 months, administer 2 doses separated by 4 weeks and a final dose at age 12 through 15 months.

5. Pneumococcal vaccine.

- Administer 1 dose of pneumococcal conjugate vaccine (PCV) to all healthy children aged 24 through 59 months who have not received at least 1 dose of PCV on or after age 12 months.
- For children aged 24 through 59 months with underlying medical conditions, administer 1 dose of PCV if 3 doses were received previously or administer 2 doses of PCV at least 8 weeks apart if fewer than 3 doses were received previously.
- Administer pneumococcal polysaccharide vaccine (PPSV) to children aged 2 years or older with certain underlying medical conditions (see MMWR 2000;49 [No. RR-9]), including a cochlear implant, at least 8 weeks after the last dose of PCV.

6. Inactivated poliovirus vaccine (IPV).

- For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age 4 years or older.
- If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.

7. Measles, mumps, and rubella vaccine (MMR).

- Administer the second dose at age 4 through 6 years. However, the second dose may be administered before age 4, provided at least 28 days have elapsed since the first dose.
- If not previously vaccinated, administer 2 doses with at least 28 days between doses.

8. Varicella vaccine.

- Administer the second dose at age 4 through 6 years. However, the second dose may be administered before age 4, provided at least 3 months have elapsed since the first dose.
- For persons aged 12 months through 12 years, the minimum interval between doses is 3 months. However, if the second dose was administered at least 28 days after the first dose, it can be accepted as valid.
- For persons aged 13 years and older, the minimum interval between doses is 28 days.

9. Hepatitis A vaccine (HepA).

- HepA is recommended for children older than 1 year who live in areas where vaccination programs target older children or who are at increased risk of infection. See MMWR 2006;55(No. RR-7).
- 10. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).
 - Doses of DTaP are counted as part of the Td/Tdap series
 - Tdap should be substituted for a single dose of Td in the catch-up series or as a booster for children aged 10 through 18 years; use Td for other doses.

11. Human papillomavirus vaccine (HPV).

- Administer the series to females at age 13 through 18 years if not previously vaccinated.
- Use recommended routine dosing intervals for series catch-up (i.e., the second and third doses should be administered at 2 and 6 months after the first dose).
 However, the minimum interval between the first and second doses is 4 weeks. The minimum interval between the second and third doses is 12 weeks, and the third dose should be given at least 24 weeks after the first dose.